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Oestrogen receptor α (ERα) positive breast cancer is the most prevalent form of breast 
cancer diagnosed. While a number of therapeutics have been developed targeting the 
dependence of these cancers on oestrogen for the transcription of genes related to cell 
growth and proliferation, a significant problem in the treatment of ERα+ breast cancers is 
the development of oestrogen independent growth. An association between poor 
antiproliferative response to aromatase inhibitors and an increased level of lymphocytic 
infiltration in ERα+ cancer has led to the suggestion that the interaction of neoplastic and 
immune cells facilitates the development of a pro-tumour microenvironment which 
supports cell growth and proliferation in the absence of oestrogen. This notion is supported 
by previous work, which has shown that three pro-inflammatory chemokine encoding 
genes, CCL5, CCL22 and CXCL16, were upregulated in oestrogen deprived MCF-7 cells. 
 
This project aimed to determine whether the expression of these three pro-inflammatory 
chemokines is modulated in response to treatment with two other classes of anti-oestrogen 
therapies; Tamoxifen and Fulvestrant, in two ER+ cell lines. In response to Tamoxifen 
treatment, MCF-7 and T47D cells expressed the three chemokines in markedly different 
patterns. CCL5 and CXCL16 expression were not modulated in response to Tamoxifen in 
MCF-7 cells, but were significantly down and upregulated in T47D respectively. The 
expression of CCL22 was greater in treated MCF-7 cells compared to controls, while down 
regulated in Tamoxifen treated T47D cells. In response to Fulvestrant treatment, CCL5 and 
CCL22 were found to be upregulated in MCF-7 cells, while CCL22 alone was modulated 




To further examine the effect of upregulated pro-inflammatory chemokines following 
Tamoxifen and Fulvestrant treatment, we examined the number of immune cells which had 
transmigrated in response to a chemotactic gradient towards treated MCF-7 cells.  
Significantly more immune cells migrated towards Fulvestrant treated cells compared to 
the control, however no significant difference in migration was observed towards 
Tamoxifen treated cells or the control.  
 
Additionally, we examined the expression of CCL5, CCL22 and CXCL16 in vivo, in 
response to the aromatase inhibitor, Letrozole or Letrozole and Celecoxib in combination. 
This was achieved using STAT1-/- tumours in immunocompetent mice, which model ERα+ 
breast cancer. We found no significant difference in the expression of the chemokines of 
interests between treatments or the controls.  
 
We also examined microarray data from ER+ breast cancers from post-menopausal women 
treated with 250mg/28 days or 500mg (on day 0,14, 278 and monthly thereafter) of 
Fulvestrant, and found five and 19 unique chemokine and chemokine receptors 
respectively, which were regulated by treatment. From our three chemokines of interest, 
CCL5 alone was found to be up-regulated in patients treated with 500mg of Fulvestrant.  
No significant alteration in expression of these chemokines was observed patients treated 
with 250mg.  
 
We suggest that the expression of pro-inflammatory chemokines is regulated in response to 
anti-oestrogen therapy in both a cell line and treatment specific manner. This study has 
highlighted the importance of considering the interactions between cancer cells, the 
immune response and the tumour microenvironment when examining the response of 
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1.1 | Breast Cancer 
 
Breast cancer is the most common cancer diagnosed in women worldwide, with an estimated 
1.67 million women diagnosed in 2012 [1]. As with other types of cancer, breast cancer is 
characterized by the acquisition of a range of biological capabilities, including sustaining 
proliferative signalling, evading growth suppressors and resisting cell death [2, 3]. While 
standard therapeutic modalities have improved the prognosis and quality of life for women 
diagnosed with this disease, breast cancer remains the second most common cause of cancer-
related deaths in women [4].  This highlights the need for new therapeutics [5].  
 
1.2 | Heterogeneity of breast cancer 
Breast cancer is a complex and heterogeneous disease associated with distinctive histological 
patterns, biological features and clinical behaviours [6].  Traditionally, invasive breast cancer 
was classified based on histological grade, histological type, lymphovascular invasion and 
lymph node metastasis [7]. With the move towards individualised therapies, the 
categorisation of breast cancers is increasingly moving away from morphological markers, 
towards gene expression profiling and molecular characterization [8, 9]. 
 
1.2.1 | Molecular heterogeneity  
Global gene expression profiling has revealed the extensive level of heterogeneity within 
breast cancer, facilitating the characterization of biologically distinct subgroups based on a 
collection of intrinsic molecular markers [10].  These principal subgroups fall into three 





common molecular subtypes have also been described [10].  The presence of these specific 
biological markers has long been recognised to differentiate between tumour subtypes and 
provide a prognostic indicator of a tumours susceptibility to targeted treatments [11]. 
 
1.2.2 | Luminal breast cancer  
A large majority of breast cancers fall within the ‘luminal’ subgroup, which is further 
classified into luminal A and luminal B tumours [12]. This subtype is characterised by the 
expression of genes regulated by the oestrogen receptor transcription factor in the luminal 
epithelium of the mammary ducts [13].  
 
  1.2.2.1 | Luminal A  
Luminal A is the more prevalent subtype, representing 50-60% of all breast cancers [13]. 
Immunohistochemically defined, luminal A tumours additionally express the progesterone 
receptor, Bcl-2 and cytokeratins CK8 and CK18 [13].  Typically, these cancers are of low 
histological grade and express a low rate of proliferation, as measured by the cell division 
marker, Ki67 [6].  Patients with luminal A breast cancer generally have a good prognosis, 
with a significantly lower relapse rate and increased survival period from the time of relapse 
as compared to other subtypes [13, 14].  
 
1.2.2.2 | Luminal B 
In comparison, luminal B tumours represent 10-20% of all breast cancers and are typically 
more aggressive than those of the luminal A subtype [13]. Presenting with higher histological 
grade and rate of proliferation, luminal B tumours may express additional 
immunohistochemical markers, such as the epidermal growth factor receptor (EGFR) and 





additional mechanisms whereby the tumour is able to grow and proliferate [14].  Patients 
with luminal B tumours have a poorer prognosis compared to those with luminal A tumours, 
but respond better to neoadjuvant chemotherapy, with a greater proportion achieving a 
pathologically complete response compared to other subtypes [13, 15].  
 
1.2.3 | HER2-positive breast cancer 
15-20% of all breast cancers are characterised by high expression of the HER2 gene and/or an 
amplification of the HER2 amplicon located at 17q12 [13]. This leads to aberrant expression 
of the growth factor receptor in malignant cells [16].  Due to the over-expression of genes 
related to cellular proliferation, these tumours are highly proliferative and present with a high 
histological grade [13]. Heterogeneity within this subtype is evident, as the IHC profile of up 
to 30% of HER2+ classified tumours do not correspond with the intrinsic feature of this 
subtype [13]. HER2+ breast cancers are aggressive, and are associated with a significantly 
decreased disease-free survival period and reduced overall survival [16].  
 
1.2.4 | Basal- like breast cancer 
Basal- like breast carcinomas are defined based on their lack of oestrogen receptor, 
progesterone receptor and HER2 expression [17]. Instead, this cancer subtype expresses 
genes characteristic of basal myoepithelial cells, as well as low levels of luminal epithelium 
genes [13].  Basal-like carcinomas clinically present as large tumours with a high histological 
grade and frequent lymph node affectation [13].  Despite initially responding well to 
chemotherapy, these tumours are associated with an increased likelihood of distant recurrence 







1.3  | Clinical relevance of oestrogen receptor-positive breast cancer 
Approximately 80% of human breast carcinomas present with an oestrogen receptor-positive 
(ER+) expression profile [10]. The dependence of ER+ breast cancers on oestrogen for cell 
growth and survival render them susceptible to pharmacological oestrogen deprivation [19]. 
Traditionally, clinicopathological features such as patient age, histological grade, tumour size 
and location have been used to evaluate prognosis and expected benefit from chemotherapy 
[20].  More recently, multi-gene assays have become clinically available to estimate the risk 
of cancer recurrence through the quantification of expression of specific tumour-associated 
genes [21].   
 
One such assay, Oncotype DX, analyses the expression of 21 pre-determined genes to 
estimate potential benefit of chemotherapy and the likelihood of distant recurrence in women 
with node-negative, ER+ breast cancer, who were scheduled to receive Tamoxifen [20, 21].  
A recurrence score is derived and a treatment plan is determined on the basis of prognosis 
[22]. Generally speaking, patients with a high risk of recurrence and poor prognosis are 
prescribed more aggressive treatment, such as adjuvant chemotherapy, whereas those with a 
low risk of recurrence and a good prognosis are treated more conservatively with endocrine 
therapy, as no additional significant benefit is derived from chemotherapy [22, 23]. 
 
1.3.1 | The oestrogen receptor 
The human oestrogen receptor (ER) is a member of the nuclear receptor super family of 
ligand-inducible transcription factors, which exists as two isoforms: ER alpha (ERα) 
(hereafter ER) and ER beta (ERβ) [24]. Both isoforms play a role in the normal physiological 
function of female reproductive organs by mediating the physiological effects of oestrogen 






Analogous to other hormone-responsive nuclear receptors, the ER is comprised of a number 
of conserved functional domains that mediate its function [27].  Of note, a weak constitutive 
activation (AF-1) and stronger oestrogen-dependent activation function (AF-2) lie within the 
N-terminal and ligand-binding domain (LBD) respectively, and are required for oestrogen 
signal transduction [28]. AF-1 is independent of ligand binding, in contrast to AF-2, which is 
strictly dependent on oestrogen for its activity [29]. The DNA-binding domain (DBD) is 
comprised of two non-equivalent zinc fingers, which function to recognize the oestrogen 
response element (ERE) and stabilize non-specific protein-DNA interactions once bound to 
the agonist, oestrogen [27, 30].  
 
In the inactivated state, the ER is sequestered by co-repressor complexes, which recruit 
histone deacetylases (HDACs) and promote chromatin condensation [31].  Upon activation, 
via oestrogen binding, the ER undergoes a conformational change and a hydrophobic patch 
on the surface of the AF-2 is formed (Figure 1.1 [A]) [28, 32]. This conformational change 
stabilizes helix 12 and facilitates interactions with a family of co-activator (CoA) proteins 
that bind histone acetyltransferases (HATs) [27].  Acetylation of  histones results in 
decondensation of the chromatin and activation of transcriptional machinery [33, 34].  
 
Oestrogen signalling has been implicated in the rapid activation of several protein kinase-
signalling pathways, including the Ras-Raf-MEK-ERK pathway, the PI3K/AKT/MTOR 
pathway and PKC signalling [35]. These pathways subsequently mediate post-translational 







1.4 | Pharmacotherapy of ER+ breast cancer  
While surgery is the primary intervention modality in the treatment of breast cancer, 
pharmacotherapy treatment is often given in combination either prior to (neoadjuvant) or post 
(adjuvant) surgical intervention [36].  In ER+ breast cancer, the dependence of tumours on 
oestrogen is pharmacologically targeted via two mechanisms; (i) impeding the transcriptional 
activity of the ER or (ii) inhibiting oestrogen synthesis [37]. These actions are commonly 
mediated by the use of selective oestrogen receptor modulators (SERMs), such as Tamoxifen, 
selective oestrogen down regulators (SERDs), such as Fulvestrant, or aromatase inhibitors 
(AI) (Figure 1.1). 
 
1.4.1 | Tamoxifen  
Selective oestrogen receptor modulators, such as Tamoxifen, have been the endocrine therapy 
of choice in the treatment of ER+ breast cancers for several decades, due to their antagonistic 
function [38].  When the active metabolites of Tamoxifen, 4-hydroxytamoxifen (OHT) and 
N-desmethyl-4-hydroxytamoxifen (Endoxifen), are bound to the ligand binding domain of 
the ER, it induces a structural rearrangement of helix 12, thereby blocking access of the 
hydrophobic patch to p160 co-activators [39-42]. In addition, OHT additionally alters the 
structure of the ER such that it preferentially interacts with co-repressors, which negatively 
regulate the transcription of oestrogen-responsive genes (Figure 1.1 [B]) [43].  While AF-2-
mediated gene expression is blocked pharmacologically by Tamoxifen treatment, ligand 
independent gene expression may still occur via the hormone-independent transactivation 
domain of the ER (AF-1) [44, 45].  This is thought to explain the mixed agonist and 






While response rates to this therapeutic modality are reported to be approximately 70%, it is 
noted that most responsive tumours will eventually develop resistance to therapy [47]. Recent 
examination of the benefit of extended adjuvant Tamoxifen treatment in early stage breast 
cancer has shown a decrease in recurrance rate in women treated with Tamoxifen for 10 years 
(21.4%) compared to those treated with the previous standard of care of five years treatment 
(25.1%) [48]. However, given the large number of women diagnosed with this disease, 21.4% 
represents a significant number of women that will relapse despite this extended treatment 
[48]. 
 
Although generally well tolerated by patients, Tamoxifen treatment is associated with a 
significant increase in the incidence of endometrial cancer and thrombo-embolic disease [49]. 
In addition, Tamoxifen use is associated with a significant loss of bone mineral density in 
premenopausal women [50].  These agonist activities have been postulated to be responsible 
for a proportion of disease relapses, and consequently, has increased interest in agents that 
inhibit oestrogen synthesis, and therefore lack oestrogenic activity [46].  
 
1.4.2 | Aromatase inhibitors  
Aromatase inhibitors (AIs) are potent selective inhibitors of aromatase activity, and are 
increasingly becoming the first line therapeutic in both the neoadjuvant and adjuvant setting 
[37].  The clinical efficacy of AI has been found to be superior to that of selective oestrogen 
receptor modulators, and the absence of known agonistic effects makes them an attractive 
therapeutic agent [51, 52]. 
 
The mode of action of this class of drugs is to inhibit the aromatisation of androgens to 





for the synthesis of androstenedione and testosterone to oestrogen  [54]. Prior to menopause, 
ovarian aromatase is primarily responsible for the production of circulating oestrogen [55].  
Succeeding menopause, aromatase in fat and muscle tissue is likely to be responsible [55]. By 
inhibiting aromatase activity, AIs directly block the synthesis of oestrogen, which negatively 
regulates the transcription of oestrogen-responsive genes (Figure 1.1 [C]) [43].   
 
AIs can be classified into two groups; (i) irreversible steroidal activators, or (ii) reversible 
non-steroidal imidazole-based inhibitors [56]. Although both agents interfere with the rate-
limiting step of oestrogen biosynthesis, they do so by vastly different mechanisms [56].  
Structurally similar to androgens, steroidal activators compete with the endogenous 
aromatase substrate, androstenedione [57]. By irreversibly binding to the catalytic site of the 
enzyme, the agent causes a loss of enzymatic activity [56, 57].  In contrast, non-steroidal 
imidazole agents interact with the cytochrome P450 moiety of the enzyme in a reversible 
manner, and require continued presence of the agent to exert interference with oestrogen 
biosynthesis [58, 59].  In both scenarios, transcription of ER target genes is impeded by a 
reduction in the level of endogenous oestrogen [60].  
 
Third generation AIs, including Anastrozole, Exemestane and Letrozole, have been shown to 
reduce endogenous aromatase activity by approximately 98% [61]. Clinical trials examining 
the response to AIs compared to other anti-oestrogen therapies in hormone-receptor-positive 
patients have shown that Anastrozole has increased disease-free survival, time to recurrence 
and time to distant recurrence compared to Tamoxifen [62, 63]. The profile of adverse effects 
associated with AIs differs to that of Tamoxifen, in that there is no observed increase in the 
incidence of endometrial cancer and thrombo-embolic disease [49, 55]. It is noted however, 





menopausal women, AIs have a limited ability to reduce circulating oestrogen in this 
situation [55, 64]. In addition, ovarian aromatase promoters are highly sensitive to 
endogenous gonadotropins, which increase significantly following administration of AIs [64]. 
For this reason, AIs are generally not administered to pre-menopausal women without 
additional medication to suppress gonadotropin levels [55]. 
 
1.4.3 | Fulvestrant  
Fulvestrant (ICI 182,780), a selective oestrogen down regulator (SERD), acts as a pure 
antagonist of the ER devoid of agonist activity in oestrogen target tissues [65]. The potency 
of Fulvestrant is a result of a 7α side chain substitute, which, when the compound is bound to 
the LBD of the receptor, induces a distinct receptor conformation change [66]. This 
destabilises the association between the transactivation helix (H12) and the LBD by 
physically preventing H12 from adopting its agonist or AF-2 antagonist orientation [66]. 
Consequently, Fulvestrant exerts anti-proliferative effects by inhibiting receptor dimerization 
and impeding the transcriptional activity of the ER (Figure 1.1 [D]) [67]. By inhibiting both 
of the ER’s transactivation functions (AF-1 and AF-2), Fulvestrant is without demonstrable 
agonist activity, in contrast to SERMs (such as Tamoxifen) which fail to inhibit AF1 [66, 68].   
 
Modulation of the level of functional receptors is a major control mechanism whereby gene 
transcription is regulated [69].  Steroidal hormones regulate the intracellular levels of their 
cognate receptor by altering receptor gene transcription of mRNA and protein degradation 
rates in response to changing cellular conditions [70]. The effects of both Fulvestrant and 
Tamoxifen on ER-protein, ER-mRNA and oestrogen regulated gene expression have been 
examined using primary ER positive human breast cancers treated with either 6mg/day or 





treatment ER-mRNA levels were found to be similar to that of the control, contrasting the 
significantly supressed ER-protein expression compared to controls in Fulvestrant treated 
patients. This reduction in ER-protein expression was not observed in Tamoxifen treated 
patients, and occurs without a concurrent reduction in mRNA expression [71].  
 
Previous studies have shown that Fulvestrant induces specific nuclear matrix protein-ER 
interactions which mediate receptor cellular localisation and subsequent degradation [45, 65]. 
Of note, Fulvestrant has been shown to interact with two nuclear matrix-intermediate 
filament proteins, cytokeratin 8 and 18 (CK8 and CK18) [65]. As proteasomes are primarily 
associated with intermediate filaments, it is thought that the rapid degradation of the ER is a 
result of CK8 and CK18 bringing the ER in close proximity to proteasome degradation 
machinery [65, 72]. Up-regulation of CK8 and CK18 expression has been associated with 
good prognosis (decreased mortality rate) in primary breast tumours, with their down-
regulation associated with poor clinical outcome [73, 74].  
 
The clinical efficacy of Fulvestrant has been examined in both the first-line and second-line 
endocrine therapy setting. Low dose Fulvestrant (250mg/month) has been shown to provide 
comparable time to progression (TTP) to oral Anastrozole (1mg/day) in a second-line setting, 
where patient’s disease has progressed on previous endocrine therapy (HR 0.98; 95.14% CI, 
0.80 to 1.21; P = 0.84) [75, 76]. Additionally, clinical benefit rates (complete response + 
partial response + stable disease for equal to or greater than 24 weeks) and tolerability were 
found to be similar in these two treatment modalities (clinical benefit rates: Fulvestrant = 
44.6%, Anastrozole = 45.0%) [75].  Thus, Fulvestrant was deemed to fulfil the criteria for 






The efficacy and tolerability of Fulvestrant (250mg/month) in comparison to Tamoxifen 
(20mg/day) was assessed in postmenopausal women with either metastatic or locally advance 
breast cancer, who were previously untreated with endocrine therapy [77]. No significant 
difference in time to progression was observed between the treatments (TTP: Fulvestrant = 
6.8 months, Tamoxifen = 8.3 months, HR 1.18; 95% CI, 0.98 to 1.44; P = 0.088), nor was 
there significant difference in tumour response rate to treatment [77]. However, the clinical 
benefit rate was found to be significantly greater (P = 0.026) in Tamoxifen treated patients 
(62.0%) compared to Fulvestrant treated patients (54.3%) [77]. While both Fulvestrant and 
Tamoxifen are generally well tolerated, Fulvestrant does not appear to have any additional 
benefits over Tamoxifen in the first-line setting, and is consequently utilised in the second-









Figure 1.1: Modes of action of Tamoxifen, Aromatase Inhibitors and Fulvestrant. [A] Oestrogen binds to the oestrogen receptor (ER), which promotes receptor dimerization. ER receptor 
dimers bind to oestrogen response elements and drive expression of ER target genes. [B] Tamoxifen competes with oestrogen for ER binding, blocking AF-2 mediated oestrogen responsive 
gene expression. [C] Aromatase inhibitors inhibit the aromatisation of androgens to oestrogens. Consequently, oestrogen is not available for binding to the ER and transcription of oestrogen-
responsive genes is blocked. [D] Fulvestrant inhibits the function of both the AF-1 and AF-2 transactivation domains, inhibits receptor dimerization, alters DNA binding and degrades the ER 














1.5.  | Resistance to endocrine therapy 
Whilst endocrine therapy remains the most effective therapy for early-stage ER+ breast 
cancers, a significant fraction (~20%) of tumours are found to recur within 10 years of AI 
therapy [78, 79].  Additionally, up to 40% of women treated with adjuvant Tamoxifen relapse 
within 5 years [80]. Response and resistance to endocrine therapy in oestrogen receptor 
positive breast cancer is poorly understood [10].  Two proposed mechanisms by which breast 
cancers are able to resist the anti-oestrogenic effect of Tamoxifen, AIs and Fulvestrant are: (i) 
de novo resistance and (ii) acquired resistance. 
 
1.5.1. | De novo resistance  
By definition, de novo resistance in ER+ breast cancer is a result of intrinsic properties of the 
tumour, whereby the tumour is initially unresponsive to endocrine therapies [81].  It is 
important to note that heterogeneity within an individual tumour is often significantly greater 
than the assigned subtype would imply [11].  For example, oestrogen-receptor positive status 
is assigned to tumours in which the number of cells exhibiting this receptor exceed a 1% 
threshold [11]. This low threshold value implies that in a number of cases, the majority of 
cells present in a tumour display molecular features inconsistent with the overall status 
appointed [11]. Clinically, patients with higher ER level receive greater therapeutic benefit 
from 5 years of Tamoxifen than patients with ER-poor tumours [11, 82]. By virtue of the 
treatment, ER-poor tumours will not be responsive to anti-oestrogenic therapies [11]. 
 
Mutations affecting the ER have been proposed as a possible mechanism of resistance in ER+ 
breast cancer [83]. Structural changes are thought, however, to not account for de novo 





resistant carcinomas [84, 85]. In addition, ESR1 mutations were found to be infrequent in 
primary breast cancer [86, 87].  
 
Additionally, it has been reported that polymorphism of the CYP2D6 gene may reduce a 
breast cancers response to Tamoxifen [88]. The pharmacological activity of Tamoxifen is 
dependent on the conversion of Tamoxifen to its active metabolite, endoxifen [89]. 
Therefore, patients with reduced CYP2D6 activity produce little endoxifen and derive 
reduced therapeutic benefit from the anti-oestrogen [88].  
  
1.5.2 | Acquired resistance  
In vitro studies of acquired resistance to oestrogen deprivation in breast cancer lines has 
revealed several putative methods by which growth is sustained following endocrine therapy 
[90]. Recent studies have elucidated that although ESR1 mutations are rare in primary ER+ 
breast carcinomas, in metastatic tumours approximately 22% of tumours present with ESR1 
mutations following AI therapy [86, 87]. These mutations cluster in the ESR1 region 
encoding the LBD, driving constitutive, oestrogen-independent receptor activity [86]. 
Additionally, the equilibrium between co-activators and co-repressors associated with the ER 
has the ability to be displaced and influence the ligand-independent activity of the receptor 
[31].  
 
Increased activation of ER co-activators, such as nuclear co-activator 3 (NCOA3), drive 
constitutive expression of genes regulated by the ER [31].  Analysis of approximately 1,200 
primary breast carcinomas has revealed that amplification of this activator is present in ~5% 





Tamoxifen [91, 92]. Conversely, down regulation of ER co-repressors are associated with in 
vitro resistance to Tamoxifen [93].  
 
The activation of growth factor- related signal transduction pathways are thought to be 
largely involved in propagating oestrogen- independent carcinoma growth and survival [31, 
94].  This includes epidermal growth factor (EGF) activation of the MAP kinase pathway, 
and insulin- like growth factor-I (IGF-1) activation of receptor tyrosine kinases [95]. There is, 
however, little clinical evidence support this hypothesis [53]. 
 
While the molecular characteristics of the neoplastic cells have traditionally been emphasized 
as potential mechanisms of resistance, increasing in vivo evidence suggests that the influence 
of non-neoplastic stromal cells on cancer is as, if not more, important to the growth and 
invasiveness of breast carcinomas [53, 96].  Molecular profiling of AI treated post-
menopausal women with ER+ breast cancers has revealed a differential gene expression 
pattern correlated with therapeutic outcome [53]. A 45-gene immune response signature was 
found to be the strongest correlate of poor anti-proliferative response and that tumours with 
higher levels of lymphocyte infiltration were more likely to respond poorly to AI therapy [10, 
53]. Thus, it is suggested that higher baseline expression of this gene signature, and the 
presence of immune cells in ER+ breast cancer may confer resistance to AI therapy [53].   
 
Interestingly, this is contradictory to studies of lymphocytic infiltration following cytotoxic 
chemotherapy, which have shown that the expression of immune related genes is a good 
clinical prognostic indicator of response to chemotherapy [97, 98]. This paradox is possibly 
explained by the effect of chemotherapy on the immune system, destroying both immune and 





1.6. | Cancer immunology  
It is now recognised that the immune system plays a dual role in carcinogenesis; acting to 
both supress tumour growth by eliminating cancerous cells or inhibiting their out-growth, and 
promoting tumour progression by selecting for cells that are able to survive in an immuno-
compromised host, or by establishing a microenvironment which assists outgrowth [100]. 
This dual role is unified into a conceptual framework termed ‘cancer immuno-editing’. 
 
1.6.1. | Cancer immuno-editing 
It is postulated that immuno-editing is a three-step, directional process that results in the 
tumour cells acquiring the ability to circumvent immune recognition, resulting in tumour 
metastasis [100].  The three distinct phases are termed;  (i) elimination, (ii) equilibrium, and 
(iii) escape (Figure 1.2) [100]. 
 
(i) Elimination:  
In the elimination phase, both the innate and adaptive immune system play a role in 
eliminating malignant cells and protecting the host from clinically-apparent tumours [100]. 
Whilst the precise mechanisms by which the immune system detects a developing tumour are 
not yet elucidated, it is postulated that dendritic cells activated by cytokines, such as Type I 
IFN, promote the induction of adaptive immune responses [100]. Damage-associated 
molecular pattern molecules (DAMPs) and stress ligands, such as RAE-1, are thought to also 
play a role in this phase [100]. If this response is effective, the cancerous cell does not 








(ii) Equilibrium:  
In the equilibrium phase, rare tumour cell variants that have circumvented the elimination 
phase create a subset of cells that are maintained in a state of dormancy by the immune 
system [100].  
 
(iii)  Escape:  
In the escape phase, the population of dormant tumourigenic cells emerge as proliferating 
carcinomas [100].  This transition can occur due to changes in the tumour cell populations in 
response to the immune system’s editing function and/or due to the establishment of a cancer-









Figure 1.2: Cancer immunoediting.  Cancer immunoediting consists of three sequential phases: elimination, equilibrium and escape. In the elimination phase, the innate and adaptive immune system work 
together to suppress tumour growth (green cell = malignant cell, blue hexagram = immune system). However, if a rare cancer cell variant (as indicated by the purple cell) is not destroyed in the elimination 
phase, it may enter the equilibrium phase, whereby its outgrowth is prevented by immunological mechanisms. From the tumour cells held in equilibrium, tumour cell variants may emerge that are no longer 
recognized by adaptive immunity, or have become insensitive to immune effector mechanisms. These tumour cells may then enter the escape phase, in which their outgrowth is no longer blocked by immunity 



















1.6.2 | The tumour microenvironment  
The dynamic role of the tumour microenvironment is increasingly being appreciated with 
respect to its function in cancer progression [101].  Recent studies have demonstrated that the 
course of disease is not solely linked to intrinsic features of the tumour, but that features of 
the stroma can significantly influence disease outcome [102, 103]. In healthy tissue, the 
stroma functions as a barrier against tumourigenesis [104]. However, cancerous cells that 
have escaped the equilibrium phase initiate changes in the tumour microenvironment that 
support tumour progression [101]. These changes involve the co-evolution of the neoplastic 
cells, tumour vasculature, extracellular matrix and immune cells to successfully outgrow and 
metastasise [101].  
 
Cells involved in the innate immune system act to repair damaged tissue and support tissue 
remodelling [105]. By secreting pro-inflammatory cytokines, these cells may enhance tumour 
growth and progression, rather than inhibit this process [105].  Primary sources of these 
cytokines are macrophages, which are categorised as type 1 (M1) or type 2 (M2) [106].  M1 
macrophages act to generate a cytotoxic effect against tumour cells by activating T-helper 1 
(Th1) adaptive immunity and CD8+ T cells [106].  In opposition, M2 macrophages secrete 
immunosuppressive cytokines, promoting tumour growth [105]. When associated with 
tumours, M2 macrophages (TAMs) contribute to tumour progression and invasion, and 
infiltration of these cells have been shown to be an independent predictor of poor prognosis 
in a number of malignancies [107, 108].  
 
Chronic inflammatory states block the differentiation of immature myeloid precursors into 
mature myeloid cells [105]. This elicits myeloid-derived suppressor cells (MDSCs), which 





CD4+ T regulatory cells (Treg) [109]. The balance between cytotoxic CD8+ cells and CD4+ 
cells has been shown to be of prognostic significance [5]. High CD8+ infiltration and 
concurrent low CD4+ infiltration have been shown to increase relapse-free survival compared 
to patients with high CD4+ and low CD8+ infiltration [5]. It should be noted that the 
topography of the tumour microenvironment can vary dramatically, even within the same 
lesion [101].  The distribution of immune cell infiltration has differential prognostic 
significance, indicating the crucial nature of intra-tumoural localisation [110].  
 
1.7 | Chemokines and their role in the immune response and cancer   
Chemokines are chemotactic cytokines that regulate the migration of effector leukocytes in 
response to inflammatory cytokines, pathogenic stimuli and secreted growth factors [111, 
112]. These small, inducible cytokines direct the migration of cells expressing their cognate 
receptor towards locations of high chemokine concentration [113]. Defined based on the 
presence of a conserved tetra-cysteine motif, the two major subclasses of chemokines are 
differentiated by the relative position of the first two consensus cysteines: either two 
subsequent cysteines (CC) or a separation of these cysteines by a non-conserved amino acid 
(CXC) [111, 114]. 
 
The biological effect of chemokines is mediated by a subset of the G protein-coupled 
receptor superfamily, the seven-transmembrane-domain receptors [115]. It is important to 
note that there is a level of functional redundancy in this system, whereby a chemokine may 
bind to several receptors and a single chemokine receptor may transduce a signalling cascade 
for several chemokines [111, 116].  Additionally, effector cells may express a number of 
different chemokine receptors [117].  The signal of chemokine-receptor binding is attenuated 





and phosphatidylinositol 3-kinase (PI3K), NF-κB, RAS and the RHO family of GTPases 
[112, 118]. These signalling events promote the trafficking and positioning of immune cells 
in both homeostatic and inflammatory conditions [119].  
 
Inflammatory chemokines have broad target-cell selectivity, and act on cells associated with 
both the innate and adaptive immune system [116]. The expression of these chemokines is 
induced in response to inflammatory stimuli such as IL-1, LPS and TNF-α expression [119]. 
These stimuli are often produced by epithelial tumour cells, which recruit leukocytes to the 
malignancy [113]. Chronic exposure of leukocytes to high concentrations of TH2 chemokines 
(e.g. IL-4, IL-5 and IL-13) in the tumour microenvironment can activate M2 macrophages, 
which in turn release immunosuppressive cytokines (IL-10 and TGF-β) [120]. Additionally, 
the expression of CCL2, CCL3 and CCL5 have been implicated in the induction of matrix 
metalloproteinases (MMPs), which degrade the extracellular matrix and facilitate leukocyte 
penetration of the stroma [121, 122]. Thus, autocrine and paracrine networks are established, 
and a pro-tumour microenvironment is established where growth factors, protease and 
immunosuppressive cytokines aid in the growth and survival of the malignancy [119]. For 
this reason, inflammatory chemokines and their receptors are often correlated with the 
progression of the disease [123-125]. 
 
1.8 | The effect of oestrogen deprivation on chemokine immunosignalling  
As previously mentioned, high baseline expression of an inflammatory signature is associated 
with poor anti-proliferative response in ER+ breast carcinoma [53].  Furthermore, an up-
regulation of genes encoding chemokines associated with lymphocyte infiltration was noted 
[53].  Unpublished in vitro work has examined the chemokine expression in an invasive 





Chemokine (C-C motif) ligand (CCL) 5, CCL22 and chemokine (C-X-C motif) ligand 16 
were found to be up-regulated in oestrogen deprived MCF-7 cells [126]. Furthermore, 
following five days of oestrogen deprivation, increased immune cell migration towards the 
cancerous cells was observed [126]. This suggests a role for the above-mentioned 
chemokines in attracting immune cells to the tumour microenvironment of oestrogen 
deprived cells, and is consistent with in vivo studies [53, 126]. However, it is not known 
whether the chemokine expression pattern observed in MCF-7 cells occurs in all ER+ve 
breast cancer cells lines, and whether oestrogen deprivation by Tamoxifen treatment, elicits 
the same response as simulated AI treatment. It is also unknown by which pathway oestrogen 
deprivation leads to chemokine up-regulation and increased immune infiltration.  
 
1.9 | Murine models of ER+ve breast cancer  
Despite the number of advances in the treatment of luminal breast cancers, failure to 
recapitulate the hormonal responsiveness and biology of human ERα+ breast cancers in 
murine models has hampered efforts to develop models of tumorigenesis and response to 
treatment [127].  
 
Classically defined as a Th1 pro-immune and anti-tumour transcription factor, STAT1 is 
known to play a critical role in IFN signalling and has been implicated in the maintenance of 
basal caspase expression, up-regulation of p27Kip1 and p53 and BRCA1 interactions in vitro 
[128-130]. However, a number of observations have suggested a paradoxical role, whereby 
STAT1 can facilitate tumour progression and acquisition of resistance in human breast 
cancers, with the down-regulation of the STAT1 pathway showing association with 






The association between decreased STAT1 expression and breast cancer progression led to 
the investigation of a causal role of this transcription factor in mammary tumorigenesis [127]. 
This was achieved by monitoring both STAT1-/- mice (129S6/SvEvTac-Stat1tm1Rds) and WT 
129S6/SvEv mice for tumour development [127]. 65% of STAT1 deficient mice were found 
to spontaneously develop breast cancer, compared to the absence of disease in WT mice 
[127]. Immunohistochemical staining of the resultant neoplastic tissue revealed that 90% of 
the cells present were ERα positive and that none of the primary tumours were positive for 
HER2 [127]. 
 
To characterize these spontaneous STAT1-/- mammary (SSM) carcinomas, three tumour cell 
lines were established (SSM1, SSM2 and SSM3). In contrast to SSM1, which expressed very 
low levels of ERα and PR, SSM2 and SSM3 cells lines expressed nuclear ERα similar to that 
of the ERα positive breast cancer cell line, MFC-7, as well as both isoforms of the PR [127]. 
This suggests functionality of the ER in SSM2 and SSM3 cells, which was confirmed by 
assessing the metabolic activity of the cells in the presence and absence of oestrogen [127].  
Both SSM2 and SSM3 cells were found to require the presence of oestrogen to proliferate in 
vitro compared to SSM1 cells, whose metabolic activity was unchanged between the 
conditions, thus demonstrating that not all STAT1-/- breast cancers are hormone dependent  
[127]. 
 
When SSM1, SSM2 or SSM3 were injected into the fat pad of ovariectomized or sham-
operated WT or STAT1-/- mice, SSM2 and SSM3 tumours grew only in the presence of 
oestrogen (either sham-operated mice or ovariectomized mice receiving subcutaneous 
oestrogen pellet implants), illustrating their ovarian hormone dependency in vivo [127]. 





cells or established SSM3 tumour fragments and treated with ovarian ablation 
(ovariectomized or sham-operated at a tumour diameter of 5mm), hormone deprived 
(ovariectomized mice) tumours failed to progress in size, compared to hormone intact mice 
(sham-treated) [127]. Thus, it was determined that STAT1-/- ERα mammary tumour cells are 
reliant upon ovarian hormones for both establishment of tumour growth and maintenance of 
tumour progression [127]. 
 
In addition to receptor expression and hormone dependency reflective of luminal breast 
cancers, further investigation of STAT1-/- mammary tumours has elucidated that biomarkers 
classically expressed by luminal epithelial cells (in particular CK19 and CK8/18) are strongly 
present in primary STAT1-/- tumours [127]. Furthermore, the molecular signature of STAT1-/- 
tumours was found to closely resemble that of luminal breast cancers (namely upregulation of 
genes such as GATA3, MYB and FOXA1), a characteristic unique to STAT1-/- tumours, 
compared to the 13 pre-existing mouse breast cancer models [127, 133]. Thus, transplanting 
SSM3 cells into wild-type mice presents a unique opportunity to study the effect of anti-
oestrogen treatment in ER positive mice with an intact immune system [127].  
 
1.10  | Aims  
A significant problem in the treatment of oestrogen dependent breast carcinomas is the 
development of oestrogen independent growth, which occurs in 20-40% of patients following 
anti-oestrogen therapy and typically leads to clinical relapse [78, 80, 90]. Thus, 
understanding the mechanisms of resistance to current therapeutics and improving the 






Due to the correlation of poor anti-proliferative response and higher levels of lymphocytic 
infiltration in ER positive breast cancers, it is hypothesised that the tumour 
microenvironment, namely immune cells, plays a significant role in facilitating the 
progression of tumours [53]. It is suggested that this is achieved via the secretion of pro-
inflammatory cytokines, which facilitate the co-evolution of neoplastic cells, immune cells 
and the tumour microenvironment and push tumorigenic cells from the equilibrium phase 
into the escape phase in the absence of oestrogen stimulation.  
 
Previous work from our group has elucidated that three inflammatory chemokines, CCL5, 
CCL22 and CXCL16, are up-regulated in response to oestrogen deprivation (simulated 
aromatase inhibitor treatment) in MCF-7 cells [126]. In addition, increased migration of 
immune cells was observed in AI treated MCF-7 cells compared to the control [126]. This 
project sought to investigate the expression of CCL5, CCL22 and CXCL16 in MCF-7 cells in 
response to treatment with two different anti-oestrogenic agents, Tamoxifen and Fulvestrant, 
and compare this to the expression in oestrogen deprived cells. Furthermore, we aimed to 
investigate whether modulation of chemokine expression following Tamoxifen or Fulvestrant 
treatment was associated with increased immune cell migration. We hypothesize that due to 
the different mechanisms of action of these treatment modalities, both regulation of these 
pro-inflammatory chemokines and immune cell migration may differ between treatments. 
 
In addition to MCF-7 cells, we aimed to elucidate the chemokine response to Tamoxifen and 
Fulvestrant in T47D cells. Although both MCF-7 and T47D cells are derived from ER+ 
breast cancers, T47D cells express the ERβ isoform of the oestrogen receptor at a higher level 
than that of MCF-7 cells, as well as several proteins involved in cell growth and anti-





up-regulation of these chemokines is a trait unique to MCF-7 cells alone, or whether they are 
more broadly applicable to ER positive breast cancers as a whole. 
 
A concurrent study from the Dunbier laboratory has made STAT1-/- tumours resulting from 
SSM3 cells transplanted into immunocompetent mice available for investigation. We sought 
to investigate the effect of Letrozole or Letrozole and Celecoxib in combination, following 
ovarian hormone depletion or sham-surgery, on CCL5, CCL22 and CXCL16 expression. In 
vivo analysis of the expression of these chemokines in the presence of an aromatase inhibitor 
and a non-steroidal anti-inflammatory drug has the potential to strengthen in vitro 
observations from this laboratory, as well as investigating the effect of anti-inflammatory 
drugs on the inflammatory response in an ER positive murine model setting. 
 
To further investigate the effect of Fulvestrant in vivo, we examined a publically available 
microarray dataset to observe the effect Fulvestrant treatment on human ERα+ breast cancers.  
Using matched pre- and on-treatment microarray data for patients treated with 250mg and 
500mg Fulvestrant, we hoped to elucidate the effect of Fulvestrant on expression on 
chemokine and chemokine receptor expression. We hypothesised that genes involved in 
immune cell recruitment would be differentially expressed in response to treatment with 











2: MATERIALS AND METHODS 
 
 
2.1   | Materials 
2.1.1  | Reagents 
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) – Sigma Aldrich, 
USA. 
17β-Oestradiol – Sigma-Aldrich, USA. 
alamarBlue® - Thermo Fisher Scientific, USA. 
b-mercaptoethanol– Sigma Aldrich, USA. 
Charcoal, dextran coated – Sigma-Aldrich, USA. 
Dimethyl sulfoxide (DMSO) – Sigma-Aldrich, USA. 
DMEM/F12– Sigma-Aldrich, USA. 
Ethanol (EtOH) – Lab supplies, NZ. 
Fetal bovine serum (FBS) – Invitrogen, USA. 
Ficoll-Plaque PLUS- GE Healthcare, USA. 
Formaldehyde – Scharlau, Spain. 
Fulvestrant – Sigma Aldrich, USA. 
Gentamicin (50mg/mL) – Life Technologies, USA. 
 
HycloneTM Trypan Blue Stain – Thermo Fisher Scientific, USA. 
Hydrocortosone – Sigma Aldrich, USA. 
 
Hydroxyurea – Life Technologies, USA. 
 
Insulin (Actrapid® Penfill® 100IU/mL) –Novo Nordisk®, Denmark. 
L-glutamine - Life Technologies, USA. 





Michigan Cancer Foundation – 7 (MCF-7) cell line – American Type Culture Collection, 
USA.  
Milli-Q - EMD Millipore, USA.  
NIH/3T3 cell line – American Type Culture Collection, USA. 
Phosphate Buffered Saline - Thermo Fisher Scientific, USA. 
Phytohaemagglutinin – Kindly donated by Associated Professor Alexander McLellan 
(University of Otago, NZ). 
Penicillin Streptomycin (10,000 U/mL) – Life Technologies, USA. 
PrimeScriptTM RT reagent Kit (Perfect Real Time) – Takara Bio Inc., Japan. 
Primetime standard qPCR assay CCL5 Hs.PT.58.40305992 – Integrated DNA Technologies, 
Inc., USA. 
Primetime standard qPCR assay CCL5 Mm.PT.58.43548565 – 
Integrated DNA Technologies, Inc., USA. 
Primetime standard qPCR assay CCL22 CCL22.exon2/3 – Integrated DNA Technologies, 
Inc., USA. 
Primetime standard qPCR assay CCL22 Mm.PT.58.15758573 – Integrated DNA 
Technologies, Inc., USA. 
Primetime standard qPCR assay CXCL16 Hs.PT.58.28311933.gs – Integrated DNA 
Technologies, Inc., USA. 
Primetime standard qPCR assay CXCL16 Mm.PT.56a.42520449 – Integrated DNA 
Technologies, Inc., USA. 
Primetime standard qPCR assay FKBP15 Hs.PT.49a.2552313 – Integrated DNA 
Technologies, Inc., USA. 
Primetime standard qPCR assay FKBP15 Mm.PT.58.17505976 – Integrated DNA 





Primetime standard qPCR assay PUM1 Hs.PT.56a.1997572 – Integrated DNA 
Technologies, Inc., USA. 
Primetime standard qPCR assay PUM1 Mm.PT.58.8963208 – Integrated DNA Technologies, 
Inc., USA. 
Qubit® RNA HS Assay Kit – Life Technologies, USA. 
Quick RNA miniprep kit – Zymo Research, USA. 
RMPI [+] 2-Glutamine media – Gibco by Life Technologies, USA. 
Sodium Dodecyl Sulfate (SDS) – VWR, USA. 
SSM3 cell line – Kindly donated by Professor Robert Schreiber (Washington University of 
Medicine, USA) and Professor Mark Smyth (Peter MacCallum Cancer Centre, Australia). 
T47D cell line – American Type Culture Collection, USA. 
Tamoxifen – Sigma Aldrich, USA. 
TaqMan® Gene Expression Master Mix – Applied Biosystems, USA. 
Thermal seal, Real-time PCR Optical plastic sheet – Interlab Ltd, NZ. 
Transferrin – Sigma Aldrich, USA. 
Trypsin/EDTA – Invitrogen, USA 
Superscript® III Reverse transcriptase – Life Technologies, USA. 
 
 
2.1.2  | Equipment 
1.7mL microfuge tube – SorensonTM BioScience, Inc. USA.  
15mL and 50mL tubes – Greiner Bio-one, Switzerland. 
25 cm2 and 75cm2 Cellstar cell culture flasks – Greiner Bio-one, Switzerland. 
6-well and 96-well Cellstar cell culture plates – Greiner Bio-one, Switzerland. 
384-well optical plate – Applied Biosystems, USA. 





ABI Prism 7900 HT – Applied Biosystems, USA.  
Agilent 2100 Bioanalyzer – Agilent Technologies, USA. 
C1000™ ThermoCycler – Bio-rad, USA. 
Corning® 1L Filter System – Corning, USA. 
Corning® Cell Lifter – Corning, USA. 
Costar® Transwell® plate (6.5mm Diameter Inserts, 8.0μM Pore Size) – Corning, USA. 
Epoch Microplate Reader – Biotek, China. 
Heracell™ 150i CO2 Incubator – Thermo Fisher Scientific, USA. 
IEC Centra-4 x Centrifuge – International Equipment Company, USA. 
Kimble® Kontes Disposable Pellet pestles – Sigma Aldrich, USA. 
Nanodrop – Nanodrop Technologies, USA. 
Olympus DP71 camera – Olympus, Japan. 
Olympus IX7I microscope – Olympus, Japan. 
POLARstar OPTIMA Multidetection Microplate Reader – BMG LABTECH, Germany. 
QUBIT® 2.0 Flurometer – Invitrogen by Life Technologies – USA. 
 
2.1.3  | Software 
javaGSEA Desktop Application – Broad Institute, USA. 
Microsoft Excel for Mac 2011 – Microsoft, USA. 
Prism 6.0 – GraphPad Software, Inc, USA. 
RStudio – RStudio, Inc. USA. 













2.2 | General Methods  
 
2.2.1 | Cell culture  
All cell culture was performed under sterile conditions in a Class II Tissue Culture Hood.  
 
2.2.1.1 | MCF-7 Complete growth medium 
For routine cell passage and maintenance, MCF-7 cells were cultured in complete growth 
medium, which consisted of phenol-red free RMPI [+] 2-Glutamine media supplemented 
with 10% foetal bovine serum (FBS) (herein termed ‘MCF-7 complete media/medium’).   
 
2.2.1.2 | T47D Complete growth medium  
For routine cell passage and maintenance, T47D cells were cultured in complete growth 
medium, which consisted of phenol-red free RMPI [+] 2-Glutamine media supplemented 
with 10% FBS and 0.02% insulin (herein termed ‘T47D complete media/medium’).   
 
 2.2.1.3 | SSM3 Complete growth medium 
SSM3 cells were maintained in Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 
(DMEM/F12) supplemented with 10% FBS, 1% L-glutamine, 1% penicillin streptomycin, 
0.05M β-mercaptoethanol, 0.3μM hydrocortisone, 10ng/mL transferrin and 5μg/mL insulin 
(herein termed ‘SSM3 complete media/medium’).  
 
 2.2.1.4 | NIH/3T3 Complete growth medium  
For routine cell passage and maintenance, NIH/3T3 cells were cultured in complete growth 
medium, which consisted of phenol-red free RMPI [+] 2-Glutamine media supplemented 






2.2.2 | Stripping Fetal bovine serum  
Fetal bovine serum (FBS) was stripped of non-polar material by incubating 500mL of FBS 
with 2.5g of charcoal and 0.25g of dextran, at 55°C for 30 minutes. The FBS was then 
decanted into 50mL falcons and centrifuged at 10,000 rpm for 10 minutes. The clarified FBS 
was further decanted and incubated with 2.5g of charcoal and 0.25g of dextran, at 55°C for 
30 minutes. The serum was then centrifuged at 10,000 rpm for 10 minutes and filtered 
through a 0.45μM Corning filter unit. Following an additional filtration with a 0.25μM filter 
unit, the serum (herein termed ‘dextran coated charcoal stripped FBS’ or ‘DCC-FBS’) was 
then aliquoted into 50mL sterile falcons and stored at -20°C indefinitely.  
 
2.2.3 | Experimental media 
2.2.3.1 | MCF-7 Oestrogen supplemented DCC medium 
Media for the MCF-7 Tamoxifen treatment study consisted of phenol-red free RMPI [+] 2-
Glutamine media supplemented with 10% DCC-FBS and 1nM of oestrogen (herein referred 
to as ‘MCF-7 washout media/ medium’). 
 
2.2.3.2 | T47D Oestrogen supplemented DCC medium  
Media for the T47D Tamoxifen treatment study consisted of phenol-red free RMPI [+] 2-
Glutamine media supplemented with 10% DCC-FBS, 0.02% insulin and 1nM of oestrogen 
(E2) (herein referred to as ‘T47D washout media/ medium’). 
 
2.2.4 | Thawing frozen cells 
Frozen cells were removed from liquid nitrogen and thawed in a 37°C water bath. 10mL of 





cell suspension was centrifuged for 5 minutes at 500rpm and the supernatant removed. Cells 
were resuspended in 5mL of complete media and transferred to a 25cm2 Cellstar® cell 
culture flask. Cell morphology was examined under an Olympus CK2 Microscope and 
compared to ATCC® documented characteristics (ATCC® HTB-122, ATCC® HTB-133 and 
ATCC® CRL-1658). Cells were incubated in a humidified incubator at 37°C and 5% CO2.  
Media was removed and replaced with fresh complete media daily until cells reached 80% 
confluency.  
 
2.2.5 | Cell culture maintenance  
Cells were grown in complete medium in a humidified incubator at 37°C and 5% CO2.  
When 80% confluency was reached (approximately every 3-4 days), cells were passaged.  
Medium was removed from the 25cm2 Cellstar® cell culture flasks and replaced with 1mL of 
pre-warmed phosphate-buffered saline (PBS). The PBS was then aspirated from the flask and 
replaced with 1mL of pre-warmed 0.05% trypsin. The cell culture flask was then returned to 
the humidified incubator for 5-7 minutes to detach adherent cells. 2mL of complete media 
was then added to the cell culture flask to dilute the trypsin and resuspend the cells. The cell 
suspension was transferred to a 15mL Falcon tube and centrifuged at 500rpm for five 
minutes. The supernatant was removed and the cell pellet was resuspended in 2mL of 
complete media. Cells were then seeded at a ratio of 1:5 in a new 25cm2 flask with 4mL of 
fresh complete media and returned to the incubator.  
 
To prevent genetic drift, cells were passaged to total of no more than 30 times. After this, 
cells were discarded and a new vial of cells was thawed from liquid nitrogen as per the 







2.2.6 | Manual cell counts  
Cell numbers were calculated based on manual cell counts using a haemocytometer and an 
Olympus BX51 microscope.  Medium was removed from adherent cells and replaced with 
1mL of pre-warmed PBS. The PBS was then aspirated and 1mL of pre-warmed 0.05% 
trypsin was added to the cell culture flask. Cells were incubated for 5-7 minutes in the 
humidified incubator until adherent cells had detached from the flask.  2mL of complete 
media was added to the flask to resuspend the cells, before transferring the suspension to a 
15mL Falcon tube. Cells were pelleted by centrifugation at 500rpm for five minutes. The 
supernatant was aspirated and cells were resuspended in 1mL of complete media.  
 
A 20μL aliquot of cell suspension was added to 20μL of 0.4% Trypan Blue stain and mixed 
thoroughly.  The cover-slip was affixed to the haemocytometer and 10μL of the cell/Trypan 
blue mix was pipetted at the edge of the cover-slip and allowed to run under the cover-slip. 
The haemocytometer grid was visualized under the microscope at 10X magnification. Viable 
cells (those that excluded the Trypan blue stain) were counted in all four of the large corner 
squares. This was repeated on the second half of the haemocytometer to calculate two cell 
concentration values for each sample.  Cell concentration per mL was calculated using:  
 
           Average of the 4 large corner squares x dilution factor x 104 
 
Note that the dilution factor was 2 (1:1 dilution with Trypan blue) except for cases where the 
number of cells exceeded 200 per large corner square. In this scenario, the cell suspension 







2.2.7 | RNA Extraction  
RNA was extracted using the Zymo Research Quick-RNATM MiniPrep Kit and accompanying 
protocol. Adherent cells were lysed by removing liquid medium and adding RNA Lysis 
Buffer to the monolayer. Cells were removed from the culture surface using a Costar® Cell 
Lifter. In preparing RNA samples, two wells of a 6-well plate were combined and centrifuged 
in the Spin-Away™ Filter.  The optional In-column DNase I Treatment was performed to 
purify RNA yield. Following extraction, the Zymo-Spin™ IIICG Column was transferred to 
a clean 1.5mL Eppendorf tube and RNA was eluted in 35μL of DNase/RNase Free Water. 
Samples were then placed on ice.  
 
2.2.7.1 | RNA Quantification  
The Nanodrop 1000 was used to measure the quantity and quality of extracted RNA.  1μL of 
the DNase/RNase Free Water used to elute the RNA sample was used as the blank 
measurement. Following quantification, samples were stored at -80°C indefinitely. 
 
2.2.8 | cDNA synthesis 
cDNA was synthesized from extracted RNA using the PrimeScript™ RT Reagent Kit.  
 
2.2.8.1 | Sample cDNA synthesis 
Each reaction of sample RNA cDNA synthesis consisted of 3.5μL of master mix (Table 2.1) 
and 6.5μL of RNA. A total of 500ng of RNA was added to each reaction, except when 
samples yielded low RNA concentrations. In these cases, 400ng of total RNA was added to 







2.2.8.2 | Standard cDNA synthesis 
Standard cDNA was synthesized using an equimolar mix of Day 5 treated and Vehicle RNA 
samples to a total of 2000ng.  5μL of master mix and 5μL of standard RNA was added to 
each reaction. Six reactions of standard cDNA were performed to synthesize standard cDNA 
for each of the genes investigated.  
 
2.2.8.3 | No reverse transcriptase (RT) control  
A no RT control was synthesized with a master mix lacking the PrimeScript RT Enzyme Mix 
I, consisting instead of 3μL of master mix, 2μL of MQH2O and 5μLof Day 3 Vehicle RNA 
(with the same amount of RNA used in the congruent sample RNA cDNA reaction).  
 
Following the addition of all components, the PCR tubes were centrifuged and placed in the 
C1000™ Thermal Cycler. The reaction mixture was incubated for 15 minutes at 37°C (for 
reverse transcription to take place) and then heated to 87°C for 5 seconds (to inactivate the 
reverse transcriptase).  Samples were then kept at -80°C indefinitely.  
 
 
 Table 2.1: Components of Master Mix (one cDNA synthesis reaction) for cDNA 
synthesis. 
 




No RT control 
(μL) 
5X PrimeScript Buffer 2 2 2 
PrimeScript RT Enzyme Mix I 0.5 0.5 - 
Oligo dT Primer (50μM) 0.5 0.5 0.5 
Random 6 mers (100μM) 0.5 3 0.5 
RNA 6.5 (500ng) 5 5 








2.2.9 | Quantitative Real-Time Polymerase Chain Reaction (qPCR) 
Assuming 100% efficiency of the cDNA synthesis, cDNA samples were diluted with 
MQH2O to 4.44ng/μL. A master mix constituted of 5μL of Taqman Gene Expression Master 
Mix and 0.5μL PrimeTime® qPCR Assay (sequences detailed in Table 2.3), was made. 
5.5μL of this master mix and 4.5μL of the diluted cDNA was added to each well on a 
MicroAmp® Optical 384-Well Reaction Plate.  Sample cDNA was plated in triplicate for 
technical replicates.  
 
A standard curve was created using the standard cDNA serially diluted to 100ng, 20ng, 2ng, 
0.2ng and 0.02ng, plated in triplicates. The diluted no RT control and a blank control were 
also plated in triplicate.  
 
The 384- well plate was sealed with an Interlab Real Time PCR Thermal Seal and 
centrifuged at 2000rpm for five minutes. The plate was then loaded into the ABI 7900HT 




Table 2.2: Cycle temperature and time for qPCR. 
 
Stage Temperature  
(°C) 
Time 
 (minute: second) 
Number of cycles 
1 50 2:00 1 
2 95 10:00 1 
3 95 0:15 40 
60 1:00 










2.2.9.1 | qPCR analysis  
qPCR analysis was performed using SDS 2.4 software. The Minimum Information for 
Publication of Quantitative Real-Time PCR Experiments Guidelines (MIQE guidelines) were 
adhered to [136]. 
 
The threshold was manually set in the linear phase and relative RNA was quantified for each 
gene of interest.  Quantification cycle (Cq) values were compared against the generated 
standard curve to quantify RNA transcript levels for each chemokine of interest (CCL5, 
CCL22 and CXCL16). Data was normalised using the GEOmean of the reference genes 
FKBP15 and PUM1.  
 
 
 2.2.9.2 | Statistical analysis of qPCR 
Normalised chemokine expression was plotted using PRISM 6.0 and displayed with 
plus/minus the standard error of the mean. Data was analysed using an unpaired T test with 
equal standard distribution. The average expression for each replicate was used to centre the 














2.3  | MCF-7 Tamoxifen treatment Study  
 
2.3.1 | MCF-7 Tamoxifen treatment growth curve – MTT assay 
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assays were 
performed to assess MCF-7 cells response to Tamoxifen. Following a three-day washout 
period (three days of daily media changes with MCF-7 washout media (Section 2.2.3.1), two 
96-well cell culture plates were seeded with 3000 MCF-7 cells per well, in MCF-7 washout 
media. 24 hours later 10μL of MTT was added to each well on one of the 96-well plates. This 
plate was incubated in the humidified incubator for four hours, after which 100μL of MTT 
solubilisation buffer (40g of sodium dodecyl sulfate (SDS), 100mL 37% formaldehyde and 
100 mL of MQH2O) was added to each well. The cell culture plate was then protected from 
the light and kept at room temperature overnight. Absorbance was measured at 560nM and 
670nM on the Epoch micro-plate reader, and MTT values were calculated by subtracting the 
670nM reading from the 560nM reading. The MTT values were examined to ensure equal 
seeding across the 96-well plate.  
 
To the second plate, media was aspirated and serial dilutions of Tamoxifen in MCF-7 
washout media were added at the 24-hour time point. Equal dilutions of the vehicle (DMSO) 
were also assessed (Stock solutions of Tamoxifen were prepared in dimethyl sulfoxide 
(DMSO) at 10mM). The cell culture plate was incubated at 37°C and 5% CO2 for three days. 
Three days after initial treatment, media was replaced with serial dilutions of Tamoxifen in 
MCF-7 washout media. Cells were further incubated for 48 hours. Standard MTT protocols 
were then performed, as outlined above. A concentration of 10µM of Tamoxifen was chosen 







2.3.2 | Cell density optimization 
To ensure sufficient RNA yield from treated cells, yet avoid confluency in Vehicle wells, cell 
density was optimized. Adherent MCF-7 cells were passaged as per Section 2.2.5, and seeded 
in four Cellstar® 6-well plates at densities of 60,000, 80,000 and 100,000 cells per well. 24 
hours after seeding (Day 0) RNA was extracted from two 6-well plates, combining two wells 
of corresponding densities in one Spin-Away™ Filter.   
 
The media on the remaining two 6-well plates was aspirated and replaced with either 10µM 
of Tamoxifen (in MCF-7 washout media) or a 0.05% DMSO control.  Plates were returned to 
the incubator for five days, with a media change after three days. On Day 5, plates were 
inspected for confluency under the Olympus CK2 microscope (10X objective) and 
photographs were taken. A cell density of 80,000 was chosen for RNA yield at Day 0 and due 
to confluency of each of the Vehicle wells at Day 5, the experiment was designed to finish at 
Day 3.  
 
2.3.3 | Experimental protocol 
For the MCF-7 Tamoxifen treatment study, MCF-7 cells were maintained in MCF-7 
complete growth medium (Section 2.2.1.1) and passaged when 80% confluency was reached. 
A total of four Cellstar® 75cm2 cell culture flasks were maintained for cell numbers. Twenty-
four  hours after passaging, the media was removed from the cells and 10mL of MCF-7 
washout media (Section 2.2.3.1) was added to each cell culture flask. Cells were then 
returned to the humidified incubator (37°C and 5% CO2). This was repeated for two 







Following the three-day washout period, the media of each cell culture flask was aspirated 
and cells were washed with 3mL of pre-warmed PBS. The PBS was then aspirated from the 
flask and replaced with 3mL of pre-warmed 0.05% trypsin. The cell culture flasks were then 
returned to the humidified incubator for 4-5 minutes to detach adherent cells. 4mL of MCF-7 
washout media was then added to each cell culture flask to dilute the trypsin and resuspend 
the cells. The cell suspension of two flasks were combined and transferred to a 15mL Falcon 
tube and centrifuged at 500rpm for five minutes. The supernatant was removed and the cell 
pellet was resuspended in 2mL of MCF-7 washout media. Cells were then manually counted 
as described in Section 2.2.6.  
 
Figure 2.1: MCF-7 Tamoxifen treatment experimental timeline. MCF-7 cells were split into MCF-7 complete media 
when 80% confluency was reached. 24 hours later, media was removed and replaced with MCF-7 washout media for three 
days of oestrogen deprivation (DCC). Following this period, cells were seeded in 6-well cell culture plates in MCF-7 
washout media. On Day 0, media was replaced with either Vehicle (0.05% DMSO in MCF-7 washout media) or Treatment 
(10μM Tamoxifen in MCF-7 washout media). Cells were then cultured for 3 days, with RNA harvested and cells counts on 





Twelve Cellstar® 6-well plates were labelled such that the three time points (Day 0, Day 1 
and Day 3) had a ‘Vehicle’ plate (0.05% dimethyl sulfoxide (DMSO) in MCF-7 washout 
media), a ‘Treatment’ plate (10μM of Tamoxifen in MCF-7 washout media), and a plate for 
cell counting. A solution of cells at 160,000 cells/mL in MCF-7 washout media was made, 
and 0.5mL of cell suspension was added to each well. 1.5mL of MCF-7 washout media was 
then added to each well. Twenty-four hours later (Day 0 time point), media was aspirated 
from the Day 1 and Day 3 plates and replaced with either 0.05% DMSO vehicle or 10µM of 
Tamoxifen (as determined by the MCF-7 Tamoxifen treatment growth curve) in MCF-7 
washout media.  Cells from the Day 0 plate were counted using a haemocytometer (as 
described in Section 2.2.6) and RNA was extracted and quantified (as described in Sections 
2.2.7). Cell counts and RNA extractions were repeated 24 hours later on the Day 1 plate, and 
on the Day 3 plate three days post treatment.  
 
cDNA synthesis and qPCR was performed using the collected RNA (Section 2.2.8). Vehicle 
RNA collected at Day 3 was used to make a no RT control. Standard cDNA was made from 
an equimolar mix of Day 3 treated (10µM Tamoxifen) and Vehicle (0.05% DMSO) RNA. 













2.4  | T47D Tamoxifen treatment study  
2.4.1 | T47D Tamoxifen treatment growth curve – MTT assay  
An MTT assay (as described in Section 2.3.1) was performed using 3000 T47D cells per 
well, following a three-day washout period using T47D washout media. The first 96-well 
plate was examined 24 hours post seeding to ensure equal seeding density across the plate.  
 
With the second plate, media was aspirated and a number of dilutions of Tamoxifen in T47D 
washout media were assessed at the 24-hour time point. Equivalent dilutions of the vehicle 
(DMSO) were also assessed. The cell culture plate was incubated at 37°C and 5% CO2.  72 
hours after initial treatment, media was replaced with corresponding Tamoxifen dilutions in 
T47D washout media or the Vehicle control (in T47D washout media). Cells were further 
incubated for 48 hours and standard MTT protocols performed (Section 2.3.1). A 
concentration of 5μM of Tamoxifen (0.025% DMSO) was chosen for further investigation.   
 
2.4.2 | Cell density optimization  
Cell density optimization for the Tamoxifen treatment study was similar to that of the MCF-7 
Tamoxifen treatment study (described in Section 2.3.2). 6-well plates were seeded at 
densities of 100,000, 150,000 and 200,000 cells per well. Twenty-four hours after seeding 
(Day 0), RNA was extracted from two 6-well plates, combining two wells of corresponding 
densities in one Spin-Away™ Filter.   
 
The media on the remaining two 6-well plates was aspirated and replaced with either 
‘Vehicle’ (0.025% DMSO in T47D washout media) or ‘Treatment’ (5μM of Tamoxifen in 
T47D washout media).  Plates were returned to the incubator for 120 hours (Day 5), with a 





Olympus CK2 microscope (10X objective) and photographs were taken. A cell density of 
100,000 was chosen as the best RNA yield at Day 0 and confluency percentage at Day 5.  
 
2.4.3 | Experimental protocol 
For the Tamoxifen treatment study, T47D cells were maintained in T47D complete growth 
medium and passaged when 80% confluency was reached. A total of four Cellstar® 75cm2 
cell culture flasks were maintained for cell numbers. Twenty-four hours after passaging, the 
media was removed from the cells and 10mL of T47D washout media (Section 2.2.3.3) was 
added to each cell culture flask. Cells were then returned to the humidified incubator (37°C 
and 5% CO2). Cells were cultured in this media for a total of three days (experimental 
protocol illustrated in Figure 2.2).  
 
The experimental procedure of the T47D Tamoxifen treatment study was similar to that of 
the MCF-7 Tamoxifen treatment (as described in Section 2.3.3) subject to the following 
modifications.  Following the washout period, cells were seeded at a density of 100,000 cells 
per well in T47D washout media. Twelve Cellstar® 6-well plates were labelled such that the 
four time points (Day 0, Day 1, Day 3 and Day 5) had a ‘Vehicle’ plate (0.025% DMSO in 
T47D Washout media), a ‘Treatment’ plate (5μM of Tamoxifen in T47D washout media), 
and a plate for cell counting. Cells were treated with the aforementioned medium 24 hours 
post seeding. Cell counts and RNA extractions were performed at each of the time points and 
medium was changed 72 hours post treatment.  
 
cDNA synthesis and qPCR was performed using the harvested RNA (Sections 2.2.8). Vehicle 





an equimolar mix of Day 5 Treatment and Vehicle RNA. Results were analysed using SDS 
2.4 and plotted using PRISM 6.0 (as described in Section 2.3.1).  
 
 
Figure 2.2: T47D Tamoxifen treatment experimental timeline. T47D cells were split into T47D complete media when 
80% confluency was reached. 24 hours later, media was removed and replaced with T47D washout media for three days of 
oestrogen deprivation (DCC). Following this period, cells were seeded in 6-well cell culture plates in T47D washout media. 
On Day 0, media was replaced with either Vehicle (0.025% DMSO in T47D washout media) or Treatment (5μM Tamoxifen 
in T47D washout media). Cells were then cultured for 3 days, with RNA harvested and cells counts on Day 0, Day 1, Day 3 











2.5  | CCL22 Baseline expression  
Baseline CCL22 expression was determined from a 25cm2 flask of cells in T47D complete 
media at ~80% confluency.  Cells were then seeded into 6-well plates at a density 
approximately equal to that of a 25cm2 flask, in T47D complete media (see Figure 2.3 for 
illustrated timeline). Twenty-four hours later RNA extractions were performed (Washout Day 
1) on one 6-well plate. The remaining 6-well plates underwent the three-day washout period 
(daily media changes with T47D washout media). To examine the effect of trypsination on 
CCL22 expression, RNA extractions were performed on cells with (After trypsination) and 
without (Before trypsination) this process. Cells were then seeded again at 100,000 cells/well 
into 6-well plates, to simulate the seeding protocol described in Section 2.4.3.  Twelve hours 
post seeding, RNA extractions were performed with (12hrs +PBS Wash) and without (12hrs 
no PBS Wash) the PBS wash step found in the Zymo Research Quick-RNATM MiniPrep Kit 
protocol, to examine whether this was affecting CCL22 expression levels. RNA extractions 
were also performed at 24, 36 and 48 hours post seeding, with a media change (T47D 


























Figure 2.3: CCL22 Baseline expression experimental timeline. At ~80% confluency, T47D cells were seeded such that three 6-well plates and two 25cm2 flasks were approximately the same density, in 
T47D complete media. RNA extractions are illustrated by red arrow heads. 24hrs after seeding, on Washout 1, RNA was extracted from one of the 6-well plates. The remaining 6-well plates and the flasks 
underwent the three day washout period. On Washout 3, RNA extractions were performed with (“After”) and without (“Before”) trypsinisation on the remaining 6-well plates. The 25cm2 flasks were used 
to seed 6-well plates at 100,000 cells per well, in T47D washout media. RNA was extracted 12 hours post seeding, with and without the PBS wash step. RNA was additionally extracted at 24, 36 and 48 





2.6  | MCF-7 Fulvestrant treatment study 
2.6.1 | MCF-7 Fulvestrant treatment dose response – MTT assay   
Similar to the protocol outlined in Section 2.3.1, 1000 MCF-7 cells per well were seeded into 
two 96-well cell culture plates, in MCF-7 complete media. Twenty-four hours later, 10µL of 
MTT was added to each well on one of the 96-well plates. Following four hours of incubation 
at 37°C, 100µL of MTT solubilisation buffer was added to the plate containing MTT. The 
plate was protected from the light and kept at room temperature overnight. Absorbance was 
measured and calculated as described in Section 2.3.1. 
 
To the second 96-well plate, media was removed 24 hours after seeding and replaced with 
various dilutions of Fulvestrant in MCF-7 complete media. Dilutions of the vehicle (DMSO) 
were also assessed. The cell culture plate was then incubated at 37°C and 5% CO2 for three 
days. Three days after initial treatment, media was removed, and fresh media (containing 
diluted Fulvestrant or DMSO) was added. Cells were then incubated for a further 48 hours. 
Standard MTT protocols were then performed (as described above). A concentration of 
0.1µM of Fulvestrant was chosen for further investigation.  
 
2.6.2 | Cell density optimization  
As described in Section 2.3.2, MCF-7 cells were seeded at densities of 60,000, 80,000 and 
100,000 cells per well in a 6-well plate. RNA yield at Day 0 was assessed by combining two 
wells of corresponding densities in one Spin-Away™ Filter, 24 hours after seeding.  
 
The media on the remaining wells were removed and replaced with either 0.1µM of 
Fulvestrant or 0.0005% DMSO in MCF-7 complete media (Vehicle control). Plates were 





Day 5, plates were inspected for confluency under an Olympus CK2 microscope (10X 
objective). Given the RNA yield at Day 0 and the confluency of each density at Day 5, it was 
decided to modify the experimental protocol (described in Section 2.6.3 and illustrated in 
Figure 2.4) and use 80,000 cells per well.  
 
2.6.3 | Experimental protocol 
For the MCF-7 Fulvestrant treatment study, MCF-7 cells were maintained in MCF-7 
complete growth medium (Section 2.2.1.1) and passaged when 80% confluency was reached. 
Cells were passaged such that four Cellstar ® 75cm2 cell culture flasks (two for Treatment, 
two for Vehicle) and five 6-well plates (seeded at a density of 80,000 cells per well) were 
seeded in MCF-7 complete media (See Figure 2.4 for illustration). Twenty-four hours after 
passaging, media on the Cellstar ® 75cm2 cell culture flasks were removed. The media on 
two flasks were replaced with MCF-7 complete media supplemented with 0.1µM of 
Fulvestrant, while the other two flasks were treated with 0.0005% DMSO in MCF-7 
complete media. One 6-well plate was treated with 2mL of 0.1µM Fulvestrant in MCF-7 
complete media, while another 6-well plate was treated with 2mL of the Vehicle. A third 6-
well plate was treated so that three wells contained the Treatment and three wells contained 
the Vehicle (See Figure 2.4). These three 6-well plates were labelled ‘Day 2’ and were used 
to count cell numbers and harvest RNA two days after treatment. The remaining two 6-well 
plates were untreated and used to count cell numbers (Section 2.2.6) and harvest RNA 
(Section 2.2.7) on Day 0.  
 
Two days after treatment, the flasks were used to seed 6-well plates at 80,000 cells per well. 
Nine Cellstar® 6-well plates were labelled such that the three additional time points (Day 3, 





‘Treatment’ plate (0. 1µM of Fulvestrant in MCF-7 complete media), and a plate for cell 
counting. Each condition was kept in its respective media (0.1µM of Fulvestrant or 0.0005% 
DMSO) at all times. Cell numbers were determined using the ‘Day 2’ plate and RNA was 
harvested.  This was repeated on Day 3, Day 4 and Day 5. cDNA synthesis and qPCR was 
performed as described in Section 2.2.8. Results were analysed using SDS 2.4 and plotted 
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Figure 2.4: MCF-7 Fulvestrant treatment experimental timeline. When MCF-7 cells reached 80% confluency, cells were seeded into 6-well cell culture plates in MCF-7 complete 
media. Concurrently, 75cm2 cell culture flasks were also seeded at a ratio of 1:10. 24 hours later, on Day 0, media was removed on the Day 2 plate and cell culture flasks, and replaced 
with either Vehicle (0.0005% DMSO in MCF-7 complete media) or Treatment (0.1μM Fulvestrant in MCF-7 complete media) media. Day 0 plates were used for cell counts and RNA 
harvest. On Day 2, cells in the cell culture flasks were used to seed additional 6-well cell culture plates for Day 3, Day 4 and Day 5. Cells were kept in their respective media (Vehicle 






2.7  | T47D Fulvestrant treatment study  
2.7.1 | T47D Fulvestrant treatment growth curve  
The effect of Fulvestrant on T47D cells was examined similar to the protocol outlined in 
Section 2.3.1. 3000 T47D cells were seeded per well of a black walled 96-well cell culture 
plate in T47D complete media. Twenty-four hours later, the media was replaced with serial 
dilutions of Fulvestrant or equivalent percentages of DMSO (in T47D complete media).  
Cells were cultured in the same manner as described in Section 2.5.1. 
 
AlamarBlue® was used to assess the metabolic activity of the cells. 20μL of alamarBlue® 
was added to each well on Day 5, before cells were returned to the humidified incubator for a 
four hour incubation period. After this time, fluorescence was measured using the 
POLARstar OPTIMA at 560nm and 590nm. The average fluorescence value of the media 
only (no Fulvestrant, no DMSO) control was subtracted from all fluorescence values of 
experimental wells. Fluorescence was then plotted against the concentration of Fulvestrant. A 
concentration of 0.01μM of Fulvestrant (0.00005% DMSO) was chosen for further 
investigation.   
 
2.7.2 | Cell density optimization 
As described in Section 2.3.2, T47D cells were seeded in triplicate at densities of 80,000, 
100,000 and 120,000 cells per well in Cellstar® 6-well plates (in T47D complete media) for 
Day 0 and Day 2 time points. Additional plates for RNA harvest were also seeded. 
Concurrently, two 25cm2 Cellstar® cell culture flasks were passaged at a ratio of 1:5 in T47D 
complete media. Twenty-four hours later, media on both the 6-well plates and 25cm2 flasks 
was replaced with either ‘Treatment’ (0.01μM Fulvestrant in T47D complete media) or 





numbers determined using the Day 0 plates (see Section 2.2.7). On Day 2, cell numbers were 
determined (using the Day 2 plates) and the 25cm2 flasks were seeded, in their respective 
medias, at densities of 80,000, 100,000 and 120,000 cells per well for Day 3 and Day 5 time 
points. At Day 3, RNA yield was determined and confluency was examined at Day 5. To 
facilitate downstream assays, 120,000 cells per well was chosen as the seeding density for the 
T47D Fulvestrant treatment study.   
 
2.7.3 | Experimental protocol 
The experimental procedure of the T47D Fulvestrant treatment study was similar to that of 
the MCF-7 Fulvestrant treatment study (as described in Section 2.5.3 and illustrated in Figure 
2.4) subject to the following modifications. 120,000 T47D cells were seeded per well of a 6-
well cell culture plate, in addition to six 75cm2 flasks passaged at a ratio of 1:5. Twenty-four 
hours later (Day 0), media on both the 6-well plates and 75cm2 flasks was replaced with 
either ‘Treatment’ (0.01μM Fulvestrant in T47D complete media) or ‘Vehicle’ (0.00005% 
DMSO in T47D complete media) media. Cell numbers were determined (Section 2.2.6) and 
RNA harvested on Day 0 and Day 2. Additionally, on Day 2, the 75cm2 flasks were used to 
seed further 6-well plates at 120,000 cells per well to facilitate Day 3, Day 4 and Day 5 cell 
counts and RNA harvest. Treated cells were kept in their respective media at all times. cDNA 
synthesis and qPCR was performed as described in Section 2.2.8. Results were analysed 










2.8        | MCF-7 Fulvestrant treated PBMC migration assay  
 2.8.1 | Cell density optimization  
To ensure that any observed effect of the treatment on human peripheral blood mononuclear 
cell (PBMC) migration was not due to differing number of MCF-7 cells, cell density 
following five days of treatment were optimized such that the number of cells at 120 hours 
post treatment (equivalent to Day 5 in MCF-7 Fulvestrant treatment study) was comparable 
in both the Vehicle and Treatment conditions (time course illustrated in Figure 2.5). MCF-7 
cells were maintained in MCF-7 complete media until 80% confluency was reached. Cells 
were then split 1:10 into two 25cm2 cell culture flasks in MCF-7 complete media and returned 
to the humidified incubator. Twenty-four hours later, media was removed and replaced with 
either 0.1µM of Fulvestrant or 0.0005% DMSO in MCF-7 complete media. Forty-eight hours 
post treatment, cells were seeded at a variety of densities in Cellstar™ 24-well plates. Each 




Figure 2.5: MCF-7 PBMC Migration assay timeline. At 80% confluency, MCF-7 cells were split 1:10 in two 25cm2 cell 
culture flasks in MCF-7 complete media. 24hours later, on Day 0, media was removed from each of the flasks and replaced 
with either 0.0005% DMSO in MCF-7 complete media (Vehicle) or 0.1μM Fulvestrant in MCF-7 complete media 
(Treatment). On Day 2, cells were seeded into the wells of a Transwell plate and were kept in their respective media at all 












120 hours post treatment (72 hours post seeding), cell numbers were determined using a 
haemocytometer (Section 2.2.6).  20,000 Vehicle cells and 60,000 Treatment cells were 
determined to be comparable 120 hours post treatment, and were used for further 
investigation.  
 
 2.8.2 | PBMC migration assay  
 2.8.2.1 | Cell culture 
MCF-7 cells were maintained in MCF-7 complete media until 80% confluency was reached. 
Cells were then split into two 25cm2 cell culture flasks in MCF-7 complete media and 
returned to the humidified incubator for 24 hours. Media was then removed and replaced with 
either 0.1µM of Fulvestrant or 0.0005% DMSO in MCF-7 complete media. Forty-eight hours 
post treatment, three wells of treatment cells were seeded at 60,000 cells per well in a 
Costar® Transwell® Permeable Support 24-well plate, and three wells of vehicle cells were 
seeded at 20,000 cells per well. A second 24-well plate (Cellstar®) was seeded in the same 
manner for cell counting. Each condition was kept in its respective media at all times.  Plates 
were then returned to the humidified incubator for 72 hours.  
 
  2.8.2.2 | Migration assay  
120 hours post treatment, a PBMC migration assay was performed (equivalent to Day 5 in 
MCF-7 Fulvestrant treatment study). Approximately 20mL of human blood was collected 
from healthy adult participants, selected from a Univeristy population. Approval for the study 
was obtained from the University of Otago Human Ethics Committee, as well as written 
consent from each participant. Blood was diluted 1:1 with sterile PBS and layered upon 
15mL of Ficol-Paque PLUS in a 50mL falcon. Care was taken not to mix the Ficol-Paque 





temperature (settings: Acceleration = 3 and Brake = 0). Following centrifugation, the buffy 
coat fraction was removed from the gradient and placed in a sterile 50mL falcon. The white 
blood cells and platelets were then washed three times with 1:3 sterile PBS (centrifugation at 
300G for 15 mins at 20°C. Settings: Acceleration = 9 and Brake = 9). Cells were then 
resuspended in 1mL of MCF-7 complete media and a 10μL aliquot was taken for counting on 
a haemocytometer (1:20 dilution). Cells were then diluted to 10,000,000 cells/mL in MCF-7 
complete media.  
 
Media was removed from the cells on the Transwell® plate and the Transwell® inserts were 
placed in the wells over the cells. 100μL of PBMC stock (1,000,000 cells) was added into the 
insert, and 600μL of respective media (0.1µM of Fulvestrant or 0.0005% DMSO in MCF-7 
complete media) was added to the well. As a negative control, three wells that contained no 
MCF-7 cells had the Transwell® inserts placed in them and PBMCs added. 0.0005% DMSO 
in MCF-7 complete media was added to these wells for the ‘Media only’ control.  As a 
positive control, phytohaemagglutinin (PHA) was used as a chemoattractant for PBMC 
migration (PHA stimulation described in Section 2.8.2.3.) PHA was diluted 1:4 with MCF-7 
complete media and added to three empty wells on the Transwell® plate (See Figure 2.6). 
The Transwell® insert was placed in the well and PBMCs added. The Transwell® plate was 
then returned to the humidified incubator for four hours.  
 
After four hours of incubation, the Transwell® inserts were removed from the Transwell® 
plate and the PBMCs were resuspended in the 600μL of media they were in. PBMCs were 
then counted on a haemocytometer (described in Section 2.2.6) and the number of PBMCs 
per well was calculated. To ensure that the number of MCF-7 cells per condition was 
comparable, the number of Vehicle and Treatment cells following 120 hours of treatment was 





PBMC counts were plotted plus/minus the standard error of the mean using PRISM 6.0. Data 




Figure 2.6: PBMC migration assay conditions. On Day 5, the PBMC migration assay was performed by removing the 
media on the Treatment and Vehicle treated MCF-7 cells and inserting the Transwell inserts. 10 million PBMCs in MCF-7 
complete media were added to each of the Transwell inserts. Treatment media and Vehicle media was added to their 
respective cells. Vehicle media was added below a Transwell insert as a negative control, and PHA stimulated media was 
added below a Transwell insert as a positive control. 
 
 
  2.8.2.3 | PBMC PHA stimulation  
As a positive control for the PBMC migration assay, phytohaemagglutinin (PHA) was used to 
promote migration of the PBMCs through the Transwell® insert. Density gradient 
centrifugation was performed (as described in Section 2.7.2.2) and PBMCs were diluted to 
10,000,000 cells/mL in MCF-7 complete media supplemented with 50mg/mL Gentamicin, 
50mM Hydroxyurea, 3M Lithium chloride and 5µg/mL PHA. PBMCs were then cultured in 
Cellstar® 6-well plates for three days. After three days, the media was removed from the 
wells and spun at 500G for 5 minutes. Media was then filtered with a 0.22μM Corning filter 








2.9         | MCF-7 Tamoxifen treated PBMC migration assay  
 2.9.1 | Cell density optimization  
Similar to the cell density optimization methods described for Fulvestrant treated MCF-7 
cells (Section 2.8.1), the number of cells in the Treatment (10μM Tamoxifen in MCF-7 
complete media) and Vehicle (0.05% DMSO in MCF-7 complete media) wells were 
optimized so that the number of MCF-7 cells at Day 5 were comparable between treatments.  
 
MCF-7 cells were cultured, passaged and treated on the same schedule described in the MCF-
7 Fulvestrant treatment PBMC migration assay methods (Section 2.8.2.1). Treatment 
consisted of 10μM Tamoxifen (in MCF-7 complete media), while the Vehicle consisted of 
0.05% DMSO (in MCF-7 complete media). Each condition was kept in its respective media 
at all times.  
 
120 hours post treatment, cell numbers were determined using a haemocytometer (Section 
2.2.6). 20,000 Vehicle cells and 70,000 Treatment cells were determined to be comparable at 
this time point, and were used for further investigation.  
 
 2.9.2 | PBMC migration assay  
MCF-7 cells were cultured in either Treatment (10μM Tamoxifen in MCF-7 complete media) 
or Vehicle (0.05% DMSO in MCF-7 complete media) media for 48 hours prior to seeding at 
70,000 Treatment treated cells per well and 20,000 Vehicle treated cells per well in a Costar® 
Transwell® Permeable Support 24-well plate. Triplicates of each condition were also seeded 
in a Cellstar® 24-well cell culture plate for MCF-7 cell counts at 120 hours post treatment 






The migration assay was performed as described in Section 2.8.2.2, using 10μM Tamoxifen 
(in MCF-7 complete media) as ‘Treatment’ media and 0.05% DMSO (in MCF-7 complete 
media) as the ‘Vehicle’ media. 0.05% DMSO in MCF-7 complete media was used as the 
‘Media only’ control. 
 
PBMC counts were plotted plus/minus the standard error of the mean using PRISM 6.0. Data 
was analysed using an unpaired T test with equal standard distribution. 
 
2.10     | Mouse model of ER+ve tumours  
2.10.1| Experimental model  
To examine immune cell recruitment in vivo, murine modelling of oestrogen receptor positive 
breast cancer was achieved using SSM3 cells (generated from a primary tumour in a Stat1 -/- 
mouse) injected into the mammary fat pad of 129S6/SvEv mice. Tumour size was measured 
twice weekly until a size of 49mm2 was reached. A pre-treatment biopsy was then taken and 
mice commenced treatment with either: 
1) Letrozole (1mg/kg/day) + Celecoxib Vehicle  
2) Ethanol Vehicle + Celecoxib Vehicle 
3) Letrozole (1mg/kg/day) + Celecoxib (25mg/kg/day) 
4) Ethanol Vehicle + Celecoxib (25mg/kg/day). 
To achieve sufficient plasma oestradiol level reduction, ovariectomies (on Letrozole treated 
mice) or sham ovariectomies (on Vehicle treated mice) were performed at this time-point. 
Mice were treated for 25 days or until ethical reasons warranted euthanasia. A post-treatment 






SSM3 cell injection, biopsy, treatment and ovariectomies were performed by Jody Hazlett 
(Assistant Research Fellow– Dunbier Lab).  
 
2.10.2 | RNA extraction  
Remaining tumour stored in LN2 was removed from LN2 and a match head sized piece was 
cut away using a scalpel. All work with whole tumour was done on dry ice. The small piece 
of tumour was then transferred to a 1.5mL Eppendorf where 400μL of lysis buffer (Quick-
RNA™ MiniPrep Lysis Buffer) was added. Tumours were homogenized using a pellet pestle 
for 30 seconds. Samples were then vortexed for 5 seconds and centrifuged for 1 minute at 
13000rpm. Following centrifugation, the sample was transferred to a Spin-Away™ Filter and 
prepared as per the Zymo Research Quick-RNA™ MiniPrep Kit directions. The optional In-
column DNase I Treatment was performed to purify RNA yield. Following extraction, the 
Zymo-Spin™ IIICG Column was transferred to a clean 1.5mL Eppendorf tube and RNA was 
eluted in 35μL of DNase/RNase Free Water. 
 
2.10.3 | RNA quantification and quality control 
Extracted RNA was quantified using the Qubit® RNA HS (High Sensitivity) Assay Kit and 
accompanying protocol. Research Fellow from Otago Genomics Ltd, Dr Aaron Jeffs, 
assessed RNA quality using the Agilent 2100 Bioanalyzer and accompanying User’s Guide. 
The output, an RNA Integrity Number (RIN), indicates the amount of RNA degradation that 
has occurred in a given sample [137]. Intact RNA is indicated by a high RIN value, whereas 
degraded RNA has a low RIN value [137]. RIN values ≥ 5 are suitable for RT-qPCR, and 







2.10.4 | Standard cDNA synthesis 
 
Sample cDNA and No RT control synthesis was performed as described in Section 2.2.8.1 
and Section 2.2.8.3 respectively. Standard cDNA was synthesized using RNA harvested from 
SSM3 cells, NIH/3T3 cells and tumour tissues. SSM3 cells and NIH/3T3 cells were cultured 
(in SSM3 complete media and MCF-7 complete media respectively) in 75cm2 cell culture 
flasks until 80% confluency was reached. Cells were then lysed and RNA harvested as 
described in Section 2.2.7. Standard cDNA synthesis was performed as per Section 2.2.8.2. 
 
2.10.5 | Analysis 
Mouse tumour qPCR was analysed as described in Section 2.2.9.1. Normalised chemokine 
expression was displayed as a box plot using RStudio. Error bars are indicative of the 
minimum and maximum values of chemokine expression. Statistical significance was 
determined using the Analysis of Variance (ANOVA) test. 
 
2.11  | Bioinformatics 
To investigate the effects of Fulvestrant treatment on human ERα + breast cancer gene 
expression, differential expression analysis was performed on a publically available dataset 
(see Table 2.4).  Microarray data was sourced from the Gene Expression Omnibus (GEO) 
database, and analysed in RStudio using the R statistical software [139-141]. Differential 
expression analysis was performed in consultation with Associate Professor Michael Black. 
 
Analysis utilized the ‘illuminaHumanv3.db’ annotation and ‘limma’ packages  available from 
Bioconductor [141-143]. Additional standardisation was applied using the 
‘normalizeBetweenArrays’ function from the ‘limma’ package. Data was stratified by 





treatment and on-treatment biopsies to generate a list of differentially expressed genes with 
False Discovery Rate adjusted P-values < 0.05 [144].  














- 250mg Fulvestrant/ 28 days 
- 500mg Fulvestrant (day 
0,14,28 and monthly 
thereafter)  

























3. GENE EXPRESSION ANALYSIS OF TAMOXIFEN 
TREATED ERα+ve CELLS 
 
 
3.1 | Study rationale  
While AIs are the current ‘gold standard’ in the care of postmenopausal women with ER 
positive breast cancer, Tamoxifen remains an important treatment modality in premenopausal 
women and some postmenopausal cases [37, 145]. In comparison to the inhibition of 
oestrogen synthesis elicited by AIs, Tamoxifen competitively binds to the oestrogen receptor 
and halts the transcription of ER-responsive genes [42, 43]. Although these therapies have a 
similar effect overall, oestrogen suppression via AI treatment may result in better tumour 
responses than Tamoxifen due to the absence of antagonistic properties [51]. 
 
To investigate the mechanisms underlying the correlation between poor anti-proliferative 
response and higher levels of lymphocytic infiltration in ER positive breast cancers, the 
Dunbier group has previously  investigated the role of oestrogen deprivation in the expression 
of immune related chemokines [53]. Hazlett et al. (2013) showed that modelling of aromatase 
inhibitor therapy in oestrogen deprived MCF-7 cells results in increased expression of CCL5, 
CCL22 and CXCL16 – chemokines which are all chemotaxic for immune cells [126].  
 
Given the similarity of overall effect on oestrogen-responsive gene expression elicited by AIs 
and Tamoxifen, this study aimed to investigate whether these two treatment modalities have 
similar effects on immune signalling [51]. To examine whether the chemokine expression 
pattern observed in AI treatment of MCF-7 cells is replicated in Tamoxifen treated cells, the 
expression of CCL5, CCL22 and CXCL16 in MCF-7 cells following Tamoxifen treatment 





ER+ve breast cancer cell lines, the expression of these chemokines in T47D cells following 
Tamoxifen treatment was also investigated.  
 
3.2 | MCF-7 Tamoxifen Treatment Study  
3.2.1 | MCF-7 growth response to Tamoxifen  
To directly examine the antagonist effect of Tamoxifen, the medium in this study was 
supplemented with DCC-FBS and physiological levels of oestrogen to remove the effect of 
other hormones in serum. The growth of MCF-7 cells, as measured by total response to 
Tamoxifen, was assessed and compared to published literature. An MTT assay was used to 
measure the metabolic activity of the cells following five days of Tamoxifen treatment to 
determine an appropriate concentration of Tamoxifen for our time course. DMSO control 
dilutions (DMSO in MCF-7 washout media) were also examined to ensure that the vehicle 
was not having a cytotoxic effect on the cells (refer to Section 2.3.1). The absorbance was 
read at 560-670 nm to represent the reduction of the tetrazolium to formazan, which once 
solubilized, equated to the metabolic activity of the cell [146]. 
 
Figure 3.1 shows the metabolic activity of MCF-7 cells in dilutions of Tamoxifen and its 
Vehicle, DMSO. Evidence of decreased proliferation with treatment without significantly 
reducing cell number following five days of treatment was required for future experiments. 
An approximate 50% reduction in metabolic activity from baseline was observed at a dose of 
10μM of Tamoxifen. No significant reduction in metabolic activity was observed in the 
DMSO control. This was found to be consistent with published literature, and thus a 
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Figure 3.1: MTT assay of MCF-7 cells grown in stripped serum supplemented with physiological levels of oestrogen 
for three days, then treated with either Tamoxifen or DMSO for five days. MCF-7 cells were grown in grown for three 
days in phenol-red free RPMI [+] 2-Glutamine media supplemented with 10% DCC-FBS and 1nM of oestrogen. Cells were 
seeded at 3 x 103 cells per well in a 96-well plate. Cells were then treated with doses of Tamoxifen ranging from 1μM to 
10μM in oestrogen supplemented DCC media, or equivalent dilutions of the vehicle (DMSO). Media was changed after 72 
hours, and growth response was measured after 120 hours post seeding. Absorbance was measured at 560-670 nm to 
represent the metabolic activity of cells. Each data point represents the average of three replicates, with error bars displaying 




3.2.2 | MCF-7 Tamoxifen treatment seeding density optimization 
To ensure sufficient RNA yield from cells treated with 10µM of Tamoxifen for downstream 
applications, yet avoid confluency and subsequent stress of the cells in the Vehicle condition, 
the density of MCF-7 cells under these conditions were optimized. Based on previous cell 
numbers used by Hazlett et al. (2013), 60,000, 80,000 and 100,000 cells per well were chosen 
for investigation, using either 10µM of Tamoxifen or 0.05% DMSO (see Figure 2.1 and 
Section 2.3.2 for further information). RNA was extracted from untreated cells at each 
density on Day 0 to investigate whether RNA yield would be sufficient for downstream 
analysis. After the five-day treatment, Treatment and Vehicle wells were examined by eye for 
confluency (representative photographs found in Appendix 1).  From this, a seeding density 
of 80,000 cells per well was chosen as it produced sufficient RNA yield at Day 0 and an 
appropriate confluency level at Day 5.  
 





3.2.3 | MCF-7 Tamoxifen treatment cell counts 
To investigate the effect of Tamoxifen, compared to the Vehicle, on cell number over the 
time course, the number of cells per well was determined using a haemocytometer at Day 0, 
1, 3 and 5 (see Section 2.2.6). From these cell counts, it was determined that the number of 
cells in the Vehicle wells at Day 5 was much higher than anticipated, given the appearance of 
the well by eye (photographs found in Appendix 1).  As high levels of confluency may cause 
a stress response, altering chemokine expression, and the RNA yield of 60,000 Tamoxifen 
treated cells/well was too low for downstream applications on Day 5, this experiment was 
conducted for three days, rather than five. High levels of cell growth at Day 5 was thought to 
be due to the presence of oestrogen in the MCF-7 washout media compared to the media used 
in Hazlett et al. (2013), resulting in higher proliferation rates. 
 
 Figure 3.2 shows the number of cells per well under each condition over the time course in 
three biological replicates of the MCF-7 Tamoxifen treatment study (individual replicates can 
be found in Appendix 2). Characteristic of the three biological replicates, no significant 
difference in cell number was observed between the treatment and control conditions at Day 
0 and Day 1. At Day 3, the number of cells in the Tamoxifen treated wells was significantly 
less than the number of cells in the Vehicle wells (p<0.0001). While Vehicle treated cells 
continued to proliferate between days 1 and 3, the number of Tamoxifen treated cells 
stagnated at approximately 280,000 cells/well. Any intra-replicate variability observed at Day 









Figure 3.2: Cell counts from three biological replicates of the MCF-7 Tamoxifen treatment study. MCF-7 cells were 
grown for three days in phenol-red free RPMI [+] 2-Glutamine media supplemented with 10% DCC-FBS and 1nM of 
oestrogen. Cells were then seeded at 80,000 cells per well in 6-well plates. 24 hours later, cells were treated with either 
10μM of Tamoxifen or a 0.05% DMSO control for 3 days. Cell counts were performed on the haemocytometer at Day 0, 1 
and 3. Each point represents the average of three biological replicates, with error bars displaying the standard error of the 
mean. Cell counts that are significantly different between the Treatment and Vehicle conditions are indicated on the graph 




3.2.4 | qPCR analysis of gene expression 
 
Quantitative real-time polymerase chain reaction (qPCR) was used to compare the relative 
expression levels of the three chemokines found to be up-regulated in oestrogen deprived 
MCF-7 cells; CCL5, CCL22 and CXCL16, in MCF-7 cells treated with either 10µM of 
Tamoxifen or a 0.05% DMSO control (methodology described in Section 2.3.3 and Figure 
2.1). RNA was extracted and quantified on Day 0, Day 1 and Day 3, and reverse transcribed 
to cDNA (see Section 2.2.8).  
 
The Minimum Information for Publication of Quantitative Real-Time PCR Experiments 
(MIQE) guidelines were adhered to in the interpretation of qPCR results [136]. RNA 
transcripts were quantified using a standard curve (representative standard curves can be 
found in Appendix 3) and the expression levels of the genes of interest (CCL5, CCL22 and 





corresponding samples. These two reference genes have been shown to be stably expressed in 
breast cancers, and to remain consistently expressed in response to changes in oestrogen 
levels [149]. Figure 3.3 represents normalised and centred data from three biological 
replicates (individual replicates can be found in Appendix 4). 
 
Some variation in expression of CCL22 (Figure 3.3B) was observed at Day 0. Expression is 
seen to decrease approximately 2-fold between Day 0 and Day 1 in both experimental 
conditions. At Day 3, the expression of CCL22 in the treatment group was 1.2-fold higher 
compared to the Vehicle (p <0.0212). Neither CCL5 (Figure 3.3A) nor CXCL16 (Figure 
















Figure 3.3: CCL5 (A), CCL22 (B) and CXCL16 (C) gene expression in MCF-7 cells treated with either 10µM 
Tamoxifen or a 0.05% DMSO control. Following a three-day washout period (DCC media supplemented with 1nM 
oestrogen), MCF-7 cells were seeded in 6-well plates and treated with either 10µM of Tamoxifen or a 0.05% DMSO control 
for 3 days. Each point represents the average of nine replicates collected over three biological replicates. Values from each 
biological replicate were Normalised using the reference genes FKBP15 and PUM1 and then centred. Differential expression 
between the treatment and control groups was analysed using an unpaired t test, assuming both populations have the same 
standard deviations and were plotted with error bars indicating the standard error of the mean. Expression values for the 


























































































3.3     | T47D Tamoxifen Treatment Study  
3.3.1 | T47D growth response to Tamoxifen  
 
The metabolic activity of T47D cells in response to a series of Tamoxifen doses was assessed 
using an MTT assay (Section 2.4.1) to determine an appropriate concentration of Tamoxifen 
to treat T47D cells with over the time course. Equivalent dilutions of the vehicle (DMSO) in 
T47D washout media were also examined to ensure that the vehicle was not having a 
cytotoxic effect on the cells.  
 
Figure 3.4 shows the metabolic activity of T47D cells in response to dilutions of Tamoxifen 
and its vehicle, DMSO. While previous literature investigating metabolic activity following a 
similar experimental protocol in T47D cells was not available, it has been reported that the 
ER is blocked by Tamoxifen at a dose of 1μM [150]. An approximate 50% reduction in 
metabolic activity from baseline is observed at a dose of 5μM of Tamoxifen, with no 
significant reduction in metabolic activity elicited by the Vehicle treatment. Thus, the 
concentration of 5μM was chosen to treat T47D cells for future experiments. 
 
3.3.2 | T47D Tamoxifen treatment seeding density optimization 
Based on previous experiments, cell densities of 100,000, 150,000 and 200,000 cells per well 
were chosen for investigation of the effect of 5μM of Tamoxifen or 0.025% DMSO on RNA 
yield and well confluency (Section 2.4.2). RNA was extracted on Day 0 to investigate 
whether yield would be sufficient for downstream analysis and Treatment and Vehicle wells 
were examined for confluency on Day 5 (representative photographs found in Appendix 5).  







































Figure 3.4: MTT assay of T47D cells grown in stripped serum supplemented with physiological levels of oestrogen for 
three days, then treated with either Tamoxifen or DMSO for five days. T47D cells were grown for three days in phenol-
red free RPMI [+] 2-Glutamine media supplemented with 10% DCC-FBS, 0.02% insulin and 1nM of oestrogen. Cells were 
seeded at 3 x 103 cells per well in a 96-well plate. Cells were then treated with doses of Tamoxifen ranging from 1μM to 
10μM in oestrogen and insulin supplemented DCC media, or equivalent dilutions of the Vehicle (DMSO). Media was 
changed after 72 hours, and growth response was measured after 120 hours post seeding. Absorbance was measured at 560-
670 nm to represent the metabolic activity of cells. Each data point represents the average of three  




3.3.3 | T47D Tamoxifen treatment cell counts 
To investigate the effect of Tamoxifen, compared to the Vehicle, on cell number over the 
time course, cell counts were performed at Day 0, 1, 3 and 5, in parallel with the 6-well plates 
for RNA extractions (Figure 2.2).  
 
Figure 3.5 shows the number of cells per well over the time course in three biological 
replicates of the T47D Tamoxifen treatment study (individual replicate can be found in 
Appendix 6). Characteristic of each biological replicate, no significant difference in cell 
number was observed between the Treatment and Vehicle conditions at Day 0 and Day 1 of 
the time course. At both Day 3 and Day 5, the number of cells in the Tamoxifen treatment 
wells was significantly less than the number of cells in the Vehicle wells (p <0.0057 and p 























Figure 3.5: Cell counts from three biological replicates of the T47D Tamoxifen treatment study.  T47D cells were 
grown for three days in phenol-red free RMPI [+] 2-Glutamine media supplemented with 10% DCC-FBS, 0.02% insulin and 
1nM of oestrogen (T47D washout media). Cells were then seeded at 100,000 cells per well in 6-well plates. 24 hours later, 
cells were treated with either 5μM of Tamoxifen or a 0.025% DMSO control for 5 days, with a media change 72 hours post 
seeding. Cell counts were performed on a haemocytometer at Day 0, 1, 3 and 5. Each point represents the average of three 
biological replicates, with error bars displaying the standard error of the mean. Cell counts that are significantly different 





3.3.4 | q PCR analysis of gene expression  
qPCR was used to compare the relative expression levels of CCL5, CCL22 and CXCL16, in 
T47D cells treated with either 5μM of Tamoxifen or a 0.05% DMSO control. Figure 3.6 
represents Normalised data from three biological replicates (representative standard curves 
and individual replicates can be found in Appendix 7 and 8). 
 
Expression levels of CCL5 (Figure 3.6A) were seen to remain unchanged between the 
Treatment and Vehicle group at days 0, 1 and 3. Expression of the gene is seen to 
significantly increase in the Vehicle group between Day 3 and Day 5, compared to the 
relatively constant expression in Tamoxifen treated cells. At Day 5, expression of CCL5 is 
significantly increased in the Vehicle group compared to the Tamoxifen treatment, with a 





CXCL16 expression (Figure 3.6C) on Day 0 and Day 1 did not significantly differ between 
the Tamoxifen treated and Vehicle conditions. While expression levels in Vehicle treated 
cells remained constant over the time course, cells treated with Tamoxifen expressed 
significantly greater levels of CXCL16 at both Day 3 (p <0.0109) and Day 5 (p <0.0033).  
Fold changes were 1.1 and 1.2 respectively. 
 
Compared to the expression of both CCL5 and CXCL16, the expression of CCL22 over the 
five-day time course shows a high degree of variability. The expression of CCL22 (Figure 
3.6B) was found to decrease approximately 4-fold in both the Vehicle and Treatment groups 
between Day 0 and Day 1. Twenty-four hours after treatment (Day1), CCL22 expression was 
significantly increased in the treatment condition compared to the Vehicle (p <0.0459).  At 
Day 3, this observation had reversed; with expression in the Vehicle group remaining fairly 
constant, and CCL22 expression in Tamoxifen treated cells significantly decreasing (p 
<0.0212). This trend continued to Day 5, with a 1.18-fold decrease in expression in Treated 











Figure 3.6: CCL5 (A), CCL22 (B) and CXCL16 (C) gene expression in T47D cells exposed to 5µM Tamoxifen 
treatment or a 0.025% DMSO control. Following a three-day washout period (DCC Media supplemented with 0.02% 
insulin and 1nM of oestrogen), T47D cells were seeded in 6-well plates and treated with either 5μM of Tamoxifen or a 
0.025% DMSO control for 5 days. Each point represents the average of nine replicates collected over three biological 
replicates. Values from each biological replicate were Normalised using the reference genes FKBP15 and PUM1. 
Differential expression between the two groups was analysed using an unpaired t test, assuming both populations have the 
same standard deviation, and were plotted with error bars indicating the standard error of the mean. Expression values for the 
treatment group significantly different to the vehicle are indicated on the graph with summarized P values: * <0.05, ** 
























































































































3.3.5 | CCL22 baseline expression   
To investigate the relatively high expression of CCL22 at Day 0, and the subsequent, 
approximate 4-fold decrease in expression at Day 1 (Figure 3.3B and Figure 3.6B) 
consistently observed over biological replicates, a time course experiment was designed 
(methodology described in Section 2.5 and Figure 2.3). 
 
Baseline CCL22 expression was determined from a 25cm2 flask of cells in T47D complete 
media at ~80% confluency.  Cells were then seeded into 6-well plates at a density 
approximately equal to that of a 25cm2 flask, in T47D complete media. 24 hours later RNA 
extractions were performed (“Washout Day 1”). To examine the effect of trypsination on 
CCL22 expression, RNA extractions were performed on cells with (“After trypsination”) and 
without (“Before trypsination”) following the three-day washout process. Twelve hours post 
seeding, RNA extractions were performed with (“12hrs +PBS Wash”) and without (“12hrs no 
PBS Wash”) the PBS wash step to examine whether this was affecting CCL22 expression 
levels. RNA extractions were also performed at 24, 36 and 48 hours post seeding, with a 
media change (T47D washout media supplemented with 0.05% DMSO) at the 24-hour mark 
(corresponding to Day 0). The expression levels for each time point (Figure 3.7) represents 
triplicate samples from one biological replicate, normalised to the reference genes, FKBP15 
and PUM1.  
 
Twenty-four hours post seeding (“Washout Day 1”) significantly up-regulated CCL22 
compared to the “Baseline” expression is observed (p <0.0007). After the three-day wash out 
period, this up-regulation returns to baseline expression, as there is no significant different 





significant difference in expression is seen between cells that have, and have not, undergone 
the trypsination process.  
 
Twelve hours post seeding, there is a significant up-regulation of CCL22 in both the “12hr + 
PBS Wash” and “12hr no PBS Wash” conditions, compared to the “After Trypsination” 
condition (p <0.0025 and p <0.0001 respectively). No significant difference in expression 
was observed between cells that had, and had not, undergone the PBS wash.  
 
At 24 hours post seeding (equivalent to Day 0), CCL22 expression was still significantly up-
regulated compared to the “After Trypsination” time point (p <0.0274). It was, however, 
significantly decreased compared to both the 12-hour time points (p <0.0021 (+ PBS) and p 
<0.0013 (no PBS) for both conditions, not shown on graph). At 48 hours post seeding 
(equivalent to Day1), although CCL22 expression was significantly decreased compared to 
the 24-hour time point (p <0.0064), this investigation failed to recapitulate the approximate 4-
fold reduction previously seen (Figures 3.3B and 3.6B).  Instead, there is an approximate 2-




































































































Figure 3.7: Normalised CCL22 expression in T47D cells over a time course. Baseline expression was determined from a 
flask of T47D cells in T47D complete media at ~80% confluency. 24 hours post splitting; RNA extractions were performed 
(termed Washout Day 1).  Following a three-day washout period (daily media changes with phenol-red free RPMI [+] 2-
Glutamine media supplemented with 10% DCC-FBS, 0.02% insulin and 1nM of oestrogen), RNA was extracted from cells 
pre and post trypsination (Before and After Trypsination). Washed out cells were then seeded into 6-well plates at a density 
of 100,000 cells per well. 12hours post seeding, RNA extractions were performed with or without the PBS wash listed in the 
Zymo Research Quick-RNATM MiniPrep Kit protocol. Cells were treated with 0.05% DMSO in T47D washout media at 24 
hours post seeding. RNA extractions were then performed at the 24, 36 and 48-hour time points. Each data point is 
representative of three extractions. CCL22 expression was Normalised using the reference genes FKBP15 and PUM1. Error 
bars are representative of the standard error of the mean. Expression values significantly different to other time points are 




3.4 | Discussion  
Secretion of pro-inflammatory cytokines is recognized as a mechanism whereby the innate 
immune system responds to inflammatory and pathogenic stimuli and secreted growth factors 
[111, 112]. This response also appears to act to enhance tumour progression and growth 
[151]. Higher baseline expression of an inflammatory signature is associated with poor 
response to aromatase inhibitor treatment in patients with oestrogen receptor positive breasts 
cancers exemplifying the potential tumour promoting role of these signals [53]. In 
comparison to the mechanism of action elicited by aromatase inhibitors, the selective 





disrupting oestrogen binding and downstream response effects [43]. The effect of these 
different treatment modalities on the inflammatory signature is partially unknown. In this 
study, we compare the expression of three proinflammatory chemokines (CCL5, CCL22 and 
CXCL16) following aromatase inhibitor treatment or Tamoxifen treatment of MCF-7 cells.   
 
Hazlett et al. (2013) reported increased expression of the three chemokines of interest in 
MCF-7 cells following five days of oestrogen deprivation (in vitro modelling of aromatase 
inhibitor treatment) [126]. Here, we observed increased expression of CCL22 in response to 
three days of Tamoxifen treatment (p <0.0212), and no difference in expression of CCL5 and 
CXCL16.   
 
While minimally expressed in normal breast epithelial tissue, CCL5 has been found to be 
highly expressed by cancerous cells at primary tumour sites [152]. This chemokine plays an 
active role in the recruitment of leukocytes to sites of inflammation, and can, in conjunction 
with a number of cytokines released by T cells, induce the activation and proliferation of 
natural killer cells [152]. In MCF-7 cells, CCL5 has been shown to enhance proliferation via 
mTOR-dependent mRNA translation [153]. Hence, up-regulation of CCL5 in AI treated 
MCF-7 cells could potentially contribute to oestrogen-independent proliferation. In 
comparison, no significant difference was observed between Tamoxifen treated MCF-7 cells 
and the Vehicle control (Figure 3.3[A]). A clear difference between the AI-treated and 
Tamoxifen treated MCF-7 cells was apparent in the shortened time course. The AI treated 
MCF-7 cells were deprived for a total of eight days (a three-day washout period prior to a 
five-day time course), whereas the Tamoxifen treated MCF-7 cells were supplemented with 
physiological oestrogen for three days prior to three days of treatment. The significant 





treatment and continued to strengthen over the five-day time course. Therefore, the AI treated 
MCF-7 cells had, in total, undergone four days of oestrogen deprivation at this time point.  It 
is suggested, therefore, that for an effect of this treatment on CCL5 expression to be 
observed, a longer time course may have been required.  Further investigation over a longer 
time course may elucidate differential expression of this chemokine between Tamoxifen 
treated and Vehicle conditions in MCF-7 cells.  
 
While some variability in CCL22 expression between conditions is observed at Day 0 (Figure 
3.3[B]), as the cells have not undergone any treatment at this time point, it is likely that this 
variability is due to chance. Furthermore, on Day 1, relative expression of CCL22 between 
the Treatment and Vehicle conditions is reversed, with no significant difference between the 
conditions at either time point. For this reason, the observed 1.24-fold increase in expression 
of this chemokine in Tamoxifen treated MCF-7 cells is not affected by the variability 
observed at Day 0.  
 
 The chemokine CCL22 has been shown to be abundantly expressed in a number of human 
cancers [108, 154, 155].  Its cognate receptor, CCR4, is expressed predominately by 
regulatory T cells (Treg), which have been shown to be recruited to cancerous tissues in 
response to up-regulation of CCL22 ex vivo [108]. In breast cancer, the presence of 
significant numbers of FOXP3-positive Treg cells is positively associated with higher 
Nottingham grade, and subsequently, higher death hazard and reduced overall survival [108, 
156]. Thus, the up-regulation of CCL22 observed in both AI treated and Tamoxifen treated 
MCF-7 cells suggests that this may be a mechanism by which anti-oestrogen treated ER+ 






While both pro-metastatic and anti-tumorigenic functions have been described in different 
malignancies, in breast cancer, down regulation of CXCL16 has been associated with 
increased cell migration and invasiveness in vitro [157, 158]. Additionally, overexpression in 
vivo was found to inhibit tumorigenesis [157]. Hazlett et al. found an up-regulation of 
CXCL16 in AI treated MCF-7 cells and an increased immune cell migration towards 
malignant cells [126]. When treating MCF-7 cells with Tamoxifen, no significant difference 
in CXCL16 expression was observed over the three-day time course (Figure 3.3 [C]). While 
the error bars on Day 1 in the Vehicle condition are relatively large, no significant difference 
is observed between the two conditions at Day 3. This suggests that, while the expression of 
CXCL16 is more variable in the Vehicle condition at Day 1, this variability does not have an 
effect on overall CXCL16 expression. Up-regulation of CXCL16 in MCF-7 cells following AI 
treatment was observed after 1 day of treatment, suggesting that the shortened time course is 
not the reasoning behind this difference in CXCL16 expression between AI treated and 
Tamoxifen treated cells. Instead, it suggests that CXCL16 expression is not modulated by 
treatment with Tamoxifen. 
 
The differences in chemokine expression between AI treated and Tamoxifen treated MCF-7 
cells are most likely a result of the agonist properties of the latter. The near-complete 
withdrawal of oestrogen achieved via aromatase inhibitor treatment markedly lessens the 
cascade of oestrogen signalling, leading to decreased transcription of oestrogen responsive 
genes [159]. Additionally, the non-genomic action of the ER is repressed by the absence of 
oestrogen [160]. Thus, AI treated MCF-7 cells must rely upon other mechanisms to facilitate 
oestrogen independent growth and survival. It is suggested that AI treated MCF-7 cells are 
more reliant upon the secretion of proinflammatory cytokines to mediate the co-evolution of 





equilibrium phase and enhancement of tumour growth. This would support the observation 
that CCL5, CCL22 and CXCL16 are up-regulated in response to this treatment. In contrast, 
treatment with Tamoxifen results in incomplete antagonism; whereby genes dependent on 
AF-2 signalling are repressed and genes dependent on AF-1 are promoted [159]. 
Transcriptional profiling has revealed that the agonist properties of Tamoxifen induce 
transcription factors and genes that promote cell cycle progression, such as MYC, FOS and 
CCNE1 and CCNA2 [161].  This suggests that, in response to Tamoxifen treatment, MCF-7 
cells are less reliant on tumour microenvironment modulation as the agonistic properties of 
the treatment facilitate oestrogen independent growth. As a result, the expression of immune 
related chemokines in response to Tamoxifen does not mirror chemokine expression in 
response to AI treatment over the time course examined.  
 
By examining the expression of CCL5, CCL22 and CXCL16 in Tamoxifen treated T47D 
cells, we observed disparities between the expression of these chemokines following 
Tamoxifen treatment in two ER positive cells lines. Compared to MCF-7 cells, the ERα/ERβ 
ratio in T47D cells is much lower [162]. While Tamoxifen exerts partial agonistic function on 
ERα, it has been found to exert a complete antagonist function on ERβ [163, 164]. Thus, it is 
possible that differences in response between these two cell lines may be due to reduced 
agonist activity in T47D cells.  
 
CCL5 expression was found to be significantly decreased in T47D cells treated with 
Tamoxifen for five days (Figure 3.6 [A]), while no difference between the Vehicle and 
Treatment was observed in MCF-7 cells. Given the very low RNA yield at Day 5 at lower 
seeding densities, we were unable to extend the MCF-7 Tamoxifen treatment time course 





MCF-7 time course extended to five days, as seen in the T47D time course, expression of 
CCL5 may have decreased in the Treatment as no significant difference was observed 
between the treatments in either cell line at Day 3. Consequently, this difference limits the 
comparison between AI treated and Tamoxifen treated MCF-7 cells and the generalizability 
of CCL5 expression in response to Tamoxifen in ER positive cell lines.  
 
While the expression of CCL22 was found to be significantly up-regulated in Tamoxifen 
treated MCF-7 cells, the expression of this chemokine was significantly decreased compared 
to the Vehicle in T47D cells (Figure 3.6 [B]). This highlights a key difference between MCF-
7 and T47D cells in response to Tamoxifen treatment. Spontaneous secretion of this 
chemokine by breast cancer cell lines has been found to be low to undetectable, suggesting a 
mechanism of regulation and a role for the tumour microenvironment in secretory levels of 
this chemokine [165]. Although the up-regulation of CCL22 observed in MCF-7 cells 
suggests that this may be a mechanism by which MCF-7 cells recruit Treg cells to suppress 
tumour-specific T cell immunity, downregulation of the chemokine by tumour cells seems 
contradictory to this notion [108]. Thus, further investigation of the role of this chemokine in 
ER+ breast cancer is warranted to elucidate a purpose for this differential expression between 
cell lines. The difference in expression between these cells lines does however suggest that 
extrapolating observations in any one ER+ cell line to ER+ breast cancer as a whole is over 
simplification of the molecular processes behind this malignancy.  
 
To investigate the approximately 4-fold decrease in CCL22 expression at Day 1, we 
examined CCL22 expression at a number of points during the experimental protocol (Figure 
3.7). By looking at the baseline expression of CCL22 in T47D cells growing at approximately 





splitting/seeding (‘Washout Day 1’) (p<0.005). This is replicated in an analogous setting 
(‘After Trypsinisaton and 12hrs +/- the PBS wash). Expression of this chemokine is seen to 
significantly decrease between 24hrs (Day 0) and 48hrs (Day 1) (p< 0.05). Thus, it was 
concluded that expression of CCL22 is high at Day 0 of the Tamoxifen treatment studies due 
to the effect of splitting/seeding the cells, and returns to approximately baseline expression 
24hrs later.   
 
While no significant difference in CXCL16 expression between Treatment and Vehicle was 
observed in MCF-7 cells, the expression of this chemokine in Tamoxifen treated T47D cells 
was significantly higher than the Vehicle at both Day 3 and Day 5. This is consistent with the 
observed up-regulation of CXCL16 in AI-treated MCF-7 cells. As expression of cellular 
CXCL16 has been negatively correlated with cell invasiveness and migration in breast cancer 
in vitro, this suggests that Tamoxifen treated T47D cells and AI treated MCF-7 cells are less 
invasive then their Vehicle counterparts [157].  In other malignancies, however, CXCL16 
expression is correlated with the induction of migration and proliferation [166, 167]. Our 
observation supports the larger body of evidence, despite the difference in malignancy. As 
few publications investigate the effect of oestrogen deprivation, via any method, on CXCL16 
expression in breast cancer, further investigation is necessary to support either conclusion.  
 
It is known that Tamoxifen is metabolised both in vitro and in vivo to a number of 
metabolites of varying anti-oestrogen activity and potency [168]. Of note, the two clinically 
active metabolites, Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) and 4-OH-Tam (4-
hydroxy-tamoxifen), have been shown to exert comparable anti-oestrogenic effects, 30-100 
fold more potent compared to the parental drug [39-41]. Tamoxifen metabolism and 





isoforms, CYP2D6 and CYP3A4, and genetic polymorphisms in these genes have been 
proposed to contribute to the clinical variability in response to Tamoxifen [168, 169]. A large 
number of in vitro studies have used 4-OH-Tam, rather than Tamoxifen to model the effect of 
the drug in vivo [41]. Further investigation into the expression of pro-inflammatory 
chemokines in response to this modality could examine expression following treatment with 
4-OH-Tam or Endoxifen. 
  
3.5 | Conclusions 
Gene expression analysis of MCF-7 in response to Tamoxifen treatment has shown increased 
expression of CCL22 and no differential expression of CCL5 and CXCL16. This is in contrast 
to the reported up-regulation of all three chemokines in response to AI treatment [126]. It is 
suggested that this is a result of the incomplete antagonism function of Tamoxifen and a 
reduced requirement of proinflammatory cytokines to mediate the co-evolution of neoplastic 
cells, the tumour micro environment and immune cells to facilitate oestrogen independent 
growth.  
 
Furthermore, gene expression analysis of T47D cells treated with Tamoxifen has revealed 
different expression patterns to MCF-7 cells. Thus, further analysis of additional cell lines is 











4. GENE EXPRESSION ANALYSIS OF 
FULVESTRANT TREATED ERα+ve CELLS 
 
 
4.1      | Study rationale  
Similar to the mechanism of action of Tamoxifen, Fulvestrant exerts its anti-proliferative 
effect by competitively inhibiting the binding of oestradiol to the ER [75, 170]. In addition, 
however, Fulvestrant-ER binding impairs receptor dimerization and induces specific nuclear 
matrix protein-ER interactions which mediate receptor cellular localisation and subsequent 
degradation [45, 65]. By inhibiting both of the ER’s transactivation functions (AF-1 and AF-
2), Fulvestrant is without demonstrable agonist activity, in contrast to SERMs (such as 
Tamoxifen) which fail to inhibit AF1 [66, 68]. 
 
The benefits of Fulvestrant as an alternative, combination, or sequential therapy in women 
who have relapsed following other anti-oestrogen therapeutics has been reported in a number 
of clinical trials [37, 75-77]. However, the molecular mechanisms underpinning the complex, 
multifactorial action and efficacy of Fulvestrant remain unclear [171]. Notably, the effect of 
Fulvestrant treatment on the regulation of pro-inflammatory chemokines, and the immune 
response as a whole, is a significant gap in the literature.   
 
In this study, we aimed to investigate whether the three inflammatory chemokines found to 
be upregulated in AI treated MCF-7 cells (CCL5, CCL22 and CXCL16) were also regulated 
in response to treatment with Fulvestrant [126]. We hypothesise that, given the additional 
inactivation of non-genomic signalling pathways by this modality, regulation of the immune 





sought to examine whether the effect of Fulvestrant treatment on MCF-7 cells is mirrored in 
other ER+ cell lines, such as T47D.  
 
4.2      | MCF-7 Fulvestrant Treatment Study  
            4.2.1 | MCF-7 growth response to Fulvestrant  
The growth of MCF-7 cells in response to Fulvestrant treatment was measured using the 
MTT assay (refer to Section 2.6.1). Figure 4.1 illustrates the metabolic activity of MCF-7 
cells in dilutions of Fulvestrant and its Vehicle, DMSO. An approximate 50% reduction in 
metabolic activity from baseline was observed at a dose of 0.01μM of Fulvestrant. No 
significant reduction in metabolic activity was observed in the DMSO control. Published 
literature has used 0.1µM of Fulvestrant for investigation with MCF-7 cells [172]. As we 
found no significant difference in metabolic activity between these two concentrations 
(0.1µM and 0.025µM), we followed published literature and used 0.1μM of Fulvestrant for 
the MCF-7 Fulvestrant treatment study. 
 
 
Figure 4.1: MTT assay of MCF-7 cells treated with either Fulvestrant or DMSO for five days. At ~80% confluency, 
MCF-7 cells were seeded at 1 x 103 cells per well in a 96-well plate. Cells were then treated with doses of Fulvestrant 
ranging from 0.001μM to 10μM in MCF-7 complete media, or equivalent dilutions of the vehicle (DMSO). Media was 
changed after 72 hours, and growth response was measured after 120 hours post seeding. Absorbance was measured at 560-
670 nm to represent the metabolic activity of cells. Each data point represents the average of three replicates, with error bars 





            4.2.2 | MCF-7 Fulvestrant treatment seeding density optimisation 
 
To ensure sufficient RNA yield from cells treated with 0.1µM of Fulvestrant for downstream 
applications, yet avoid over-confluency in the faster growing Vehicle condition (0.0005% 
DMSO in MCF-7 complete media), the density of MCF-7 cells under these conditions were 
optimised (refer to Section 2.6.2). 
 
Sixty thousand, eighty thousand and one hundred thousand MCF-7 cells were chosen for 
investigation, grown in either 0.1µM Fulvestrant or 0.0005% DMSO in MCF-7 complete 
media for five days. After examining wells on Day 5, it was determined that the number of 
cells in the Vehicle wells was too high and had the potential to stress the cells and indirectly 
lead to chemokine expression in the Vehicle group (representative photos found in Appendix 
9). Additionally, the RNA of yield of lower cell numbers was found to be insufficient for 
downstream applications. Thus, the experimental protocol was modified (described in Section 
2.6.3 and illustrated in Figure 2.4) and given RNA yield and calculated cells numbers from 
the original seeding density optimisation, 80,000 cells per well was chosen as the seeding 
density (representative photos at Day 5 with the MCF-7 Fulvestrant treatment study protocol 
and 80,000 seeded cells found in Appendix 10). 
 
       4.2.3 | MCF-7 Fulvestrant treatment cell counts 
 
Given the significant effect of Fulvestrant treatment on cell number, the protocol used for 
both AI treated and Tamoxifen treated MCF-7 cells was altered such that Day 0 and Day 2 
cells were seeded in 6-well plates, while concurrent 75cm2 flasks were treated with either 
Fulvestrant or the Vehicle for two days prior to seeding on Day 2 (refer to Section 2.6.3 and 





per well at both Day 0 and Day 3, as they both represent 24 hours post seeding at a density of 
80,000 cells per well.  
 
In the cell counts performed on Day 0, no significant difference between the Treatment 
(0.1µM Fulvestrant in MCF-7 complete media) and Vehicle (0.0005% DMSO in MCF-7 
complete media) was detected in any of the three biological replicates (Figure 4.2. Individual 
replicates can be found in Appendix 11). By Day 2, there were significantly more cells in the 
Vehicle treated wells compared to the Fulvestrant treated wells (p <0.0001). On this day, 
cells in 75cm2 flasks which had been treated (Treatment or Vehicle) for two days were seeded 
into 6-well plates at 80,000 cells per well. 24 hours later, on Day 3 of the treatment, no 
significant difference in the number of cells was observed between the Treatment and 
Vehicle. On Day 4 and Day 5 the number of Treatment cells per well was significantly less 
than the number of Vehicle cells (p = 0.0011 and p <0.0001 respectively).  
 
 
Figure 4.2: Cell counts from three biological replicates of the MCF-7 Fulvestrant treatment study. At ~80% 
confluency, MCF-7 cells were seeded at 80,000 cells per well in 6-well plates (Day 0 and Day 2 counts), in addition to 
75cm2 cell culture flasks. 24 hours later, 6-well plates and 75cm2 flasks were treated with either 0.1µM of Fulvestrant or a 
0.0005% DMSO control. On Day 2, treated 75cm2 flasks were used to seed 6-well plates at 80,000 cells per well for Day 3, 4 
and 5 counts (indicated by black arrow). Cell counts were performed on the haemocytometer at Day 0, 2, 3, 4 and 5. Each 
data point represents the average of three biological replicates, with error bars displaying the standard error of the mean. Cell 
counts that are significantly different between the Treatment and Vehicle conditions are indicated on the graph with 








       4.2.4 | qPCR analysis of gene expression  
Quantitative real-time polymerase chain reaction (qPCR) was used to compare the relative 
expression levels of CCL5, CCL22 and CXCL16 in response to treatment with either 0.1µM 
Fulvestrant or 0.0005% DMSO control.  RNA transcripts were quantified using a standard 
curve, and MIQE guidelines were adhered to in the interpretation of qPCR results 
(representative standard curves can be found in Appendix 12).  The expression levels of the 
genes of interest (CCL5, CCL22 and CXCL16) were normalised to the expression of the 
reference genes (FKBP15 and PUM1) in corresponding samples.  Figure 4.3 represents 
normalised and centred data from three biological replicates (individual replicates can be 
found in Appendix 13).  
 
The expression of CCL5 on Day 0 differed significantly between the Treatment and Vehicle 
conditions (p = 0.0362) (Figure 4.3A). However, as the magnitude of this difference is small, 
and as the cells are untreated at this point, this difference is due to chance and is biological 
‘noise’. In addition, it appears that the upregulation of CCL5 observed at Day 0 in the Vehicle 
condition does not contribute significantly to the subsequent time points, as CCL5 is 
significantly up-regulated in the Treatment condition at Day 2 (p <0.0001).  This 
upregulation in the Treatment condition is sustained through Days 3, 4 and 5 (p = 0.0002, 
0.0390 and 0.0052 respectively).  
 
No significant difference in CCL22 expression is observed at Day 0 or Day 2 (Figure 4.3B). 
At Day 3, the expression of CCL22 is significantly increased in the Fulvestrant treated 
condition compared to the DMSO vehicle control (p = 0.0008). This trend is continued at 





The expression of CXCL16 was not found to differ significantly between the Vehicle and 
Treatment at any time point over the time course (Figure 4.3C).  
 
 
Figure 4.3 CCL5 (A), CCL22 (B) and CXCL16 (C) gene expression in MCF-7 cells treated with 0.1µM Fulvestrant 
treatment or 0.0005% DMSO control. At ~80% confluency, MCF-7 cells were seeded at 80,000 cells per well in 6-well 
plates (Day 0 and Day 2 counts), in addition to 75cm2 cell culture flasks. 24 hours later, 6-well plates and 75cm2 flasks were 
treated with either 0.1µM of Fulvestrant or a 0.0005% DMSO control. On Day 2, treated 75cm2 flasks were used to seed 6-
well plates at 80,000 cells per well for Day 3, 4 and 5 RNA harvest. Each data point represents the average of nine replicates 
collected over three biological replicates. Values from each biological replicate were Normalised using the reference genes 
FKBP15 and PUM1. Error bars are representative of the standard error of the mean. Differential expression between the two 
groups was analysed using an unpaired t test, assuming both populations have the same standard deviation, and were plotted 
with error bars indicating the standard error of the mean. Expression values for the treatment group significantly different to 































Unpaired t test with equal SD 
Day 0 p = 0.0362 *
Day 2 p =  < 0.0001 ****
Day 3 p = 0.0002 ***
Day 4 p = 0.0390 *
































Unpaired t test with equal SD 
Day 0 p = 0.6351
Day 2 p = 0.0769
Day 3 p = 0.0008 ***
Day 4 p = 0.0007 ***
































Unpaired t test with equal SD 
Day 0 p = 0.6307
Day 2 p = 0.3897
Day 3 p = 0.3924
Day 4 p = 0.1466









4.3      | T47D Fulvestrant Treatment study 
       4.3.1 | T47D growth response to Fulvestrant 
The growth of T47D cells in response to Fulvestrant treatment was measured using an 
alamarBlue® cell viability assay (refer to Section 2.7.1). Like MTT, the alamarBlue® assay 
relies upon an oxidation reduction indicator reflective of cellular metabolic reduction. This 
differed to other investigations into the growth of our cell lines in response to treatment due 
to the availability of this reagent and its superior sensitivity compared to MTT [173].   
 
Figure 4.4 illustrates the cell viability of T47D cells following five days of treatment with 
either serial dilutions of Fulvestrant or its Vehicle, DMSO (in T47D complete media). An 
approximate 50% reduction in cell viability from baseline was observed at a dose of 0.01μM 
of Fulvestrant. No significant reduction in metabolic activity was observed in the DMSO 
control. Most published literature reports use 0.1µM of Fulvestrant for investigation [172, 
174, 175]. However, we found no significant difference in cell viability between the two 
concentrations (0.1µM and 0.01µM). This observation had previously been published, thus 









Figure 4.4: alamarBlue® assay of T47D cells treated with either Fulvestrant or DMSO for five days. At ~80% 
confluency, T47D cells were seeded at 3 x 103 cells per well in a 96-well plate. Cells were then treated with doses of 
Fulvestrant ranging from 0.000001μM to 10μM in T47D complete media, or equivalent dilutions of the vehicle (DMSO). 
Media was changed after 72 hours, and growth response was measured 120 hours post seeding. Fluorescence was measured 




       4.3.2 | T47D Fulvestrant treatment seeding density optimisation 
The density of T47D cells under Treatment (0.01µM Fulvestrant) and Vehicle 
(0.00005%DMSO) conditions were optimised for percentage confluency and RNA yield 
(refer to Section 2.6.2). Eighty thousand, 100,000 and 120,000 T47D cells were chosen for 
investigation and grown in either 0.01µM Fulvestrant or 0.00005% DMSO in T47D complete 
media for five days, as per the protocol described in Section 2.7.2. After examining wells for 
confluency on Day 5 (representation photos in Appendix 14), it was determined that 120,000 
T47D cells per well would satisfy the required criteria.  
 
       4.3.3 | T47D Fulvestrant treatment cell counts 
The effect of Fulvestrant on cell number is illustrated in Figure 4.5. On Day 0, no significant 





Vehicle (0.00005% DMSO in T47D complete media) was observed in any of the three 
biological replicates (individual replicates can be found in Appendix 15). On Day 2, there 
were significantly more cells in the Vehicle treated wells compared to the Fulvestrant treated 
wells (p = 0.0012). On this day, cells in 75cm2 flasks which had been treated (Treatment or 
Vehicle) for two days were seeded into 6-well plates at 120,000 cells per well to give rise to 
Day 3, Day 4 and Day 5 samples. Thus, we expect to see a decline in the number of cells per 
well at Day 3 (24 hours post this secondary seeding event). On Day 3, the number of Vehicle 
treated cells per well was significantly higher that the Treatment wells (p = 0.004). This trend 
continued on Day 4 and Day 5 (both time points p <0.0001), as the number of Fulvestrant 
treated T47D cells remained stagnant at around 120,000 cell per well compared to the 
exponential growth observed in the Vehicle wells. 
  
 






















Plotted +/-  SEM
Unpaired t test with equal SD
Day 0 p = 0.9776
Day 2 p = 0.0012 **
Day 3 p = 0.0004 ***
Day 4 p = <0.0001 ****






Figure 4.5: Cell counts from three biological replicates of the T47D Fulvestrant treatment study. At ~80% confluency, 
T47D cells were seeded at 120,000 cells per well in 6-well plates (Day 0 and Day 2 counts), in addition to 75cm2 cell culture 
flasks. 24 hours later, 6-well plates and 75cm2 flasks were treated with either 0.01μM of Fulvestrant or a 0.00005% DMSO 
control. On Day 2, treated 75cm2 flasks were used to seed 6-well plates at 120,000 cells per well for Day 3, 4 and 5 counts 
(indicated with black arrow). Cell counts were performed on a haemocytometer at Day 0, 2, 3, 4 and 5. Each data point 
represents the average of three biological replicates, with error bars displaying the standard error of the mean. Cell counts 
that are significantly different between the Treatment and Vehicle conditions are indicated on the graph with summarized P 









4.3.4 | qPCR analysis of gene expression  
The expression of CCL5, CCL22 and CXCL16 in response to treatment with either 0.01µM 
Fulvestrant or 0.00005% DMSO is illustrated in Figure 4.6 (representative standard curves 
found in Appendix 16). Over three biological replicates, no difference in CCL5 expression is 
observed between the two treatment groups (individual replicates found in Appendix 17). 
While a large amount of variability in expression was observed at Day 0, illustrated by the 
relatively large error bars, no difference is observed between the conditions at this time. 
Furthermore, this variability has no effect on the relative expression between the conditions at 
later time points.  
 
CCL22 expression was found to be unchanged between the Treatment and Vehicle conditions 
at both Day 0 and Day 2 (Figure 4.6[B]). On Day 3, expression of this chemokine was 
significantly upregulated by Fulvestrant treated cells compared to the control (p = 0.0098).  
While expression significantly decreased in both conditions between Day 3 and Day 4, 
CCL22 remained significantly higher in the Treatment condition at both Day 4 and Day 5 
compared to the control (p = 0.0355 and 0.0002 respectively).  
 
No significant difference in expression of CXCL16 between Fulvestrant treated and DMSO 
control cells was observed over the time course. On Day 4, a large amount of variability in 
expression is observed in the Treatment condition. A trend towards significance between the 






Figure 4.6: CCL5 (A), CCL22 (B) and CXCL16 (C) gene expression in T47D cells treated with 0.01μM Fulvestrant treatment or 
0.00005% DMSO control. At ~80% confluency, T47D cells were seeded at 120,000 cells per well in 6-well plates (Day 0 and Day 2 
counts), in addition to 75cm2 cell culture flasks. 24 hours later, 6-well plates and 75cm2 flasks were treated with either 0.01μM of 
Fulvestrant or a 0.00005% DMSO control. On Day 2, treated 75cm2 flasks were used to seed 6-well plates at 120,000 cells per well for 
Day 3, 4 and 5 RNA harvest. Each data point represents the average of nine replicates collected over three biological replicates. Values 
from each biological replicate were Normalised using the reference genes FKBP15 and PUM1. Error bars are representative of the 
standard error of the mean. Differential expression between the two groups was analysed using an unpaired t test, assuming both 
populations have the same standard deviation. Expression values for the treatment group significantly different to the vehicle are 




























Plotted +/- SEM 
Unpaired t test with equal SD 
Day 0 p = 0.8101
Day 2 p = 0.4495
Day 3 p = 0.8244
Day 4 p = 0.3208
Day 5 p = 0.1070
 
B: 























Plotted +/- SEM 
Unpaired t test with equal SD 
Day 0 p = 0.6836
Day 2 p = 0.2431
Day 3 p = 0.0098 **
Day 4 p = 0.0355 *




























Plotted +/- SEM 
Unpaired t test with equal SD 
Day 0 p = 0.7341
D y 2 p = 0.6969
Day 3 p = 0.4668
Day 4 p = 0.4359












4.4        | Discussion  
A considerable amount of the literature surrounding Fulvestrant as an anti-oestrogen therapy 
has investigated the benefits of Fulvestrant as an alternative, combination, or sequential 
therapy in women who have relapsed following other anti-oestrogen therapeutics [37, 76, 77]. 
While the therapeutic mechanism of Fulvestrant is classically thought to be a result of ERα 
inactivation and degradation, leading to subsequent reduction in oestrogen-regulated gene 
expression, there is little understanding of the interaction of tumourigenic cells and immune 
cells in the tumour microenvironment following this treatment modality [177].  
 
Given the upregulation of three proinflammatory chemokines in oestrogen deprived 
(mimicking AI treatment) MCF-7 cells, this study sought to investigate whether oestrogen 
deprivation via Fulvestrant treatment elicited a similar proinflammatory response in MCF-7 
and T47D cells. We observed a significant upregulation of both CCL5 and CCL22 in 
Fulvestrant treated MCF-7 cells, and no difference in the expression of CXCL16 between the 
two conditions. Furthermore, in T47D cells, the expression of CCL22 was increased in the 
Treatment condition compared to the Vehicle, while no difference in CCL5 and CXCL16 
expression was observed.  
 
CCL5 is known to regulate signals mediated by the stress-responsive stress-activated protein 
kinase/c-Jun NH2-terminal kinase 1 pathway, and plays an essential role in cellular functions 
such as proliferation and differentiation [178, 179]. Analysis of gene expression following 
ER activation by Fulvestrant in MDA-MB-231 cells stably transfected with wtER has shown 
up-regulation of CCL5 [179]. Furthermore,  in MCF-7 cells, CCL5 expression has been 
shown to enhance proliferation via mTOR-dependent mRNA translation, as well as recruit 





chemokine may be a mechanism whereby Fulvestrant treated cells may continue to 
proliferate in the absence of oestrogen. 
 
This expression pattern, however, was not replicated in T47D cells. Microarray analysis of 
genes regulated by Fulvestrant treatment has shown that the number of genes induced or 
supressed by Fulvestrant in MCF-7 cells is twice that of T47D cells [176]. Additionally, 
hierarchical clustering analysis of genes deregulated by Fulvestrant failed to cluster T47Ds 
with its ER+/HER2- counterpart, MCF-7s. It is, therefore, possible that MCF-7 cells are 
highly responsive to Fulvestrant treatment compared to T47D cells, and that these unique 
gene changes may impact intracellular signalling to prevent the emergence of Fulvestrant 
resistant growth in T47D cells [176]. Thus, the dissimilarity in expression patterns may 
illustrate a genomic change exclusive to MCF-7 cells. This is supported by the observation 
that T47Ds treated with Fulvestrant were found to express similar levels of CCL5 compared 
to the Vehicle condition over the time course. 
 
Upregulation of CCL22 in response to Fulvestrant treatment was a trend observed in both of 
the ER positive cell lines examined (Figure 4.3 (B) and Figure 4.6 (B). In both MCF-7 and 
T47D cells, no significant difference in expression was observed for the first two days of the 
time course. Cells treated for two days in 75cm2 flasks, seeded on Day 2 and harvested on 
Day 3 showed significant upregulation of CCL22 in the Treatment condition compared the 
controls. Given the approximately 2-fold decrease in expression 24 hours later (Day 4) in 
both conditions, this suggests that the expression of CCL22 could be affected by confluency. 
This is congruent with the expression of this chemokine in Tamoxifen/Vehicle treated cells 






The upregulation of CCL22 in Fulvestrant treated MCF-7 and T47D cells observed here is the 
first time modulation of this chemokine in response to Fulvestrant has been described. Given 
the association between increased CCL22 expression and the presence of regulatory T cells 
ex vivo in ovarian cancer, and the negative association between Treg cells and prognosis in 
breast cancer, it has been suggested that increased tumour secretion of CCL22 is a 
mechanism whereby ER+ breast cancer cells activate intratumoural Treg infiltration, promoting 
immune cell proximity to neoplastic cells [108, 156, 180].  Treg cells have previously been 
shown to reduce NK cell cytotoxicity, suggesting that CCL22 expression by tumour cells 
might lead to suppression of the local immune response and favour tumour survival and 
growth [180, 181]. To more broadly, and definitively apply this observation to ER+ breast 
cancers as a whole, the use of other ER+ cell lines is warranted. Additionally, investigation 
into the expression of this chemokine in cell lines that express low, or no, ER would 
strengthen this observation.  
 
Despite a trend towards significance in T47D cells (p = 0.0505) at Day 5, a significant effect 
of Fulvestrant on CXCL16 expression is absent, as the expression of this remained unchanged 
between the Vehicle and Treatment conditions in both cell lines. This is the first time the 
effect of Fulvestrant treatment on CXCL16 expression has been reported. Previous literature 
associating oestrogen deprivation (via AI treatment) and increased CXCL16 expression has 
shown decreased cell migration and invasiveness in vitro [157]. Furthermore, overexpression 
in vivo inhibited tumorigenesis [157]. However, in MCF-7 and T47D cells deprived of 
oestrogen via Fulvestrant treatment, CXCL16 is not differentially expressed. CXCL16  has 
previously been associated with both pro-metastatic and anti-tumorigenic functions in 






4.5  | Conclusions   
Gene expression analysis of MCF-7 and T47D cells treated with Fulvestrant has revealed that 
these two oestrogen receptor positive cell lines differentially express the three inflammatory 
chemokines of interest: CCL5, CCL22 and CXCL16. While CCL5 and CCL22 expression 
increased in response to treatment with Fulvestrant in MCF-7 cells, CCL22 was the only 
chemokine found to increase in the Treatment condition in T47D cells. CXCL16 expression 
did not differ between the Treatment and Vehicle conditions in either cell line. Here we 
present the first direct analysis of the regulation of both CCL22 and CXCL16 in response to 
Fulvestrant treatment and suggest that immune related chemokines may be induced by anti-

























5. PBMC MIGRATION IN RESPONSE TO 
TAMOXIFEN AND FULVESTRANT  
TREATED MCF-7 CELLS 
 
 
5.1 | Study rationale  
Recent studies into the molecular and cellular mechanisms underlying tumourigenesis have 
demonstrated that the course of disease is not solely linked to intrinsic features of the tumour, 
but that features of the stroma can significantly influence disease outcome [102, 103].  
 
Molecular profiling of aromatase inhibitor treated postmenopausal breast cancer has revealed 
that, in addition to an inflammatory gene expression signature associated with poor 
antiproliferative response, tumours with detectable lymphocytic infiltration were more likely 
to respond poorly to AI therapy [53]. Given the upregulation of the expression of immune-
related chemokines in response to AI treatment observed by Hazlett et al. and the correlation 
between lymphocytic infiltration and poor response to AI treatment, previous work from the 
Dunbier group has examined the migratory response of peripheral blood mononuclear cells 
(PBMCs) toward AI treated MCF-7 cells. Quantitative assessment of immune cell migration 
revealed increased cell migration towards AI-treated MCF-7 cells compared to controls 
[126].  
 
In Chapter 3, we reported an increase in CCL22 expression in MCF-7 cells treated with 
Tamoxifen compared to Vehicle controls. Additionally, in Chapter 4, we show that both 
CCL5 and CCL22 are up-regulated in response to Fulvestrant treatment. Given the up-
regulation of these pro-inflammatory chemokines, this study aimed to investigate the effect of 





whether treatment with either of these modalities promoted spatial proximity of immune cells 
and neoplastic cells, and hypothesized that increased migration of PBMCs towards treated 
MCF-7 cells would facilitate interactions between neoplastic cells, immune cells and the 
tumour microenvironment, which may play a role in the equilibrium-to-escape transition.  
 
5.2  | PBMC Migration in response to Tamoxifen 
To assess the effect of Tamoxifen on PBMC migration toward treated MCF-7 cells, the 
number of MCF-7 cells per well was optimized, such that the number of cells in the 
Treatment and Vehicle wells were approximately equal on Day 5. This was done to ensure 
that the observed effect was due to increased chemokine production per cell, rather than a 
differing numbers of cells in the two conditions. The concentration of Tamoxifen used for the 
MCF-7 Tamoxifen treatment study (Section 3.2) was used to correlate the observed effect of 
our chemokines of interest and PBMC migration. 
 
Figure 5.1 illustrates the number of PBMC cells that had migrated through the Transwell 
insert towards the treated MCF-7 cells in three biological replicates (individual replicates can 
be found in Appendix 18). Both the PHA control (positive control) and the Media only 
(negative control) did not have MCF-7 cells at the bottom of the Transwell plate (see Figure 
2.5).  No significant difference in the number of PBMC cells migrating through the Transwell 
towards the treated MCF-7 cells was observed between the Vehicle and Treatment 
conditions. There were significantly more migrated PBMCs in the PHA control compared to 
either the Vehicle or Treatment (p<0.0056 and p<0.0076 respectively), and significantly less 









Figure 5.1: Migration of PBMC cells towards Tamoxifen treated MCF-7 cells. MCF-7 cells treated with 10µM 
Tamoxifen or a 0.05% DMSO Vehicle for five days. Media was removed from the cells and the Transwell inserts were 
placed over the cells. 106 PBMCs were added to each insert, and corresponding media was added to each well. Cells were 
then incubated for four hours at 37°C and 5% CO2. The number of migrated PBMCs was then determined using a 
haemocytometer. Each point represents the number of PBMCs migrated collected over three biological replicates. 
Differences in the number of migrated PBMCs between the Treatment and Vehicle groups was analysed using an unpaired t 
test, assuming both populations have the same standard deviations, and were plotted with error bars indicating the standard 




5.3  | PBMC Migration in response to Fulvestrant  
The concentration of Fulvestrant used for the MCF-7 Fulvestrant treatment study (Section 
2.6) was used to correlate the observed effect of our chemokines of interest and PBMC 
migration. Figure 5.2 illustrates the number of PBMCs that had migrated through the 
Transwell insert towards Fulvestrant (Treatment) or Vehicle treated MCF-7 cells, as well as 
the PHA and Media only controls in three biological replicates (individual replicates can be 
found in Appendix 19). Significantly more PBMCs migrated towards the Fulvestrant treated 





number of PBMCs migrated towards the PHA control media was significantly more than the 
number of PBMCs that had migrated towards the Vehicle (p = 0.0008). No significant 
difference between the Media only and Vehicle controls were observed. The two outliers in 
the Media only control are due to a high level of migration in this condition in one of the 
biological replicates. However, as there are no MCF-7 cells at the bottom of the apparatus in 
this condition (see Figure 2.5), this is thought not to be due to a chemotactic response. 
Additionally, the effect of the Treatment compared to the Vehicle is maintained in this 














Figure 5.2: Migration of PBMC cells towards Fulvestrant treated MCF-7 cells. MCF-7 cells treated with 0.1µM  
Fulvestrant or a 0.0005% DMSO Vehicle for five days. Media was removed from the cells and the Transwell inserts were 
placed over the cells. 106 PBMCs were added to each insert, and corresponding media was added to each well. Cells were 
then incubated for four hours at 37°C and 5% CO2. The number of migrated PBMCs was then determined using a 
haemocytometer. Each point represents the number of PBMCs migrated collected over three biological replicates. 
Differences in the number of migrated PBMCs between the Treatment and Vehicle groups was analysed using an unpaired t 
test, assuming both populations have the same standard deviations, and were plotted with error bars indicating the standard 
error of the mean. The number of migrated cells in the Treatment group found to be significantly different to the Vehicle are 








5.4  | Discussion  
The dual role of the immune response in tumorigenesis is increasingly being recognised [100, 
101]. The association between neoplastic cells, tumour vasculature, extracellular matrix and 
immune cells is thought to either supress tumour growth by eliminating cancerous cells, or 
contribute to a pro-tumour microenvironment by establishing a treatment resistant 
subpopulation or microenvironment which assists outgrowth [120, 182]. Investigations into 
the relationship between prognosis and the frequency of tumour-associated immune cell 
infiltration have generally elucidated a positive trend with post treatment recurrence or 
metastasis in a number of malignancies, however molecular profiling of aromatase inhibitor 
treated postmenopausal breast cancers has associated lymphocytic infiltration and poor 
response to treatment [53, 183-185]. This was supported by Hazlett et al., who described 
increased inflammatory chemokine expression and immune cell migration towards AI-treated 
MCF-7 cells compared to controls [126]. Taken together, this suggests that the infiltration of 
immune cells via the upregulation of immune-related chemokines modulates the tumour 
microenvironment, reducing the efficacy of AI treatment and selecting for cells able to evade 
therapy. 
 
In previous Chapters, we reported an up-regulation of CCL22 in MCF-7 cells treated with 
Tamoxifen, and increased expression of both CCL5 and CCL22 in MCF-7 cells treated with 
Fulvestrant. Here, we investigated the chemotactic effect of chemokines secreted by MCF-7 
cells treated with either Tamoxifen or Fulvestrant to examine whether either of these anti-
oestrogen modalities promoted spatial proximity of immune cell and cancer cells. We 
hypothesised that increased migration towards MCF-7 cells may facilitate the interaction of 






Following five days of Tamoxifen treatment, we observed no difference in the number of 
immune cells that had migrated towards the treated or Vehicle MCF-7 cells (Figure 5.1). This 
is in contrast to the significantly greater number of immune cells that had migrated towards 
the Fulvestrant treated MCF-7 cells, compared to the control (p <0.0001) (Figure 5.2). Thus, 
the effect of Fulvestrant treatment on MCF-7 cells is similar to the immune response elicited 
by treatment with AIs, and these modalities elicit a markedly difference response to MCF-7 
cells treated with Tamoxifen.   
 
Given the attenuation of ERα-mediated genomic gene regulation and non-genomic signalling 
in response to treatment with Fulvestrant, malignant cells must find alternative pathways to 
facilitate their survival and outgrowth [171]. It is possible that modulation of the immune 
response and creation of a pro-tumour environment is a method whereby Fulvestrant treated 
MCF-7 cells are able to evade therapy. The secretion of chemokines and growth factors by 
stromal and tumour cells has been shown to recruit circulating leukocytes to the tumour 
microenvironment and contribute to the differentiation of macrophages [186]. Chronic 
exposure of leukocytes to high concentrations of tumour-derived cytokines such as IL-4, IL-
10, TGF-β or prostaglandin E2 promotes the polarization of innate macrophages to the M2 
phenotype [187]. M2 macrophages, in turn, release immunosuppressive cytokines, suppress 
Th1 mediated inflammation and promote the digestion of the extracellular matrix [186, 188]. 
These macrophages also produce a number of other chemokines, such as CCL17, CCL22 and 
CCL24, which are associated with the recruitment of Th2 cells, eosinophils and basophils, 
thus creating autocrine and paracrine feedback loops which create a pro-tumour 
microenvironment [189, 190]. Chronic exposure to Fulvestrant has been shown to induce the 
production of hepatocyte growth factor, a cytokine secreted by stromal cells, which activates 





192]. Furthermore, expression of nuclear factor κB (NKκB), which is upregulated in response 
to TNFα and IL-1 signalling is strongly implicated in acquired Fulvestrant resistance [193, 
194] .  It is proposed, therefore, that the increased immune cell migration towards Fulvestrant 
treated MCF-7 cells is a result of increased secretion of proinflammatory chemokines which 
facilitates spatial proximity of malignant and immune cells and support their co-evolution. 
Thus, populations of neoplastic cells which are no longer dependent on oestrogen for survival 
are created, and enables tumour growth and proliferation.  
 
In contrast to increased immune cell migration following Fulvestrant treatment, no significant 
difference in the number of immune cells migrating towards MCF-7 cells following five days 
of Tamoxifen treatment was observed.  This is contradictory to literature which shows 
induction of extracellular TGF-β1 by stromal fibroblasts in human breast cancer biopsies 
following Tamoxifen treatment compared to matched controls [195]. As mentioned 
previously, the expression of this cytokine is implicated in the polarization of macrophages to 
M2 macrophage, which have been shown to suppress the inflammatory response and secrete 
factors that create a pro-tumour microenvironment [189, 190]. This is also supported by the 
observation that MCF-7 cells treated with Tamoxifen show increased activity of matrix 
metalloproteinases (MMP), which are associated with the degradation of extracellular matrix 
components and tumour cell invasion and metastasis [196, 197]. Thus, we expected to 
observe an increase in immune cell migration towards Tamoxifen treated cells, as a 
mechanism whereby these cells could continue their growth and survival in the absence of 
oestrogen.  
 
While both treatment modalities were shown to up-regulate CCL22, Fulvestrant treatment 





suggested to play an active role in supporting breast cancer development and progression, and 
has been shown to induce leukocyte directed motility to sites of inflammation [152, 153]. 
Therefore, the increase in PBMC migration in response to Fulvestrant treatment is consistent 
with the up-regulation of CCL5 we observed in the MCF-7 Fulvestrant treatment study. 
Conversely, the absence of differential CCL5 expression in Tamoxifen treated MCF-7 cells 
may contribute to the no significant difference in the number of migrating immune cells 
observed when treating with Tamoxifen.   
 
In order to directly compare the effects Tamoxifen and Fulvestrant on immune cell migration, 
the methodology was kept the same between treatment types. Thus, the three-day washout 
period performed in the MCF-7 Tamoxifen treatment study (Chapter 3), was omitted from the 
Tamoxifen treated PBMC protocol.While this protocol does better reflect the treatment of a 
patient, it is plausible that residual oestrogen in medium may have also played a role in 
dampening the effect of Tamoxifen treatment on immune cell migration in this study. The 
absence of migratory differences may also be explained by the agonist function of 
Tamoxifen, and its ability to activate non genomic signalling pathways. We propose that the 
induction of second messenger signalling events in the absence of oestrogen, including 
activation of the MAPK/ERK 1/2 pathway and PI3K signalling are able to sustain the growth 
and proliferation of ER+ breast cancer cells [198-200]. Thus, the reliance on immune 
response modulation following Tamoxifen treatment is less than cells treated with AIs and 
Fulvestrant, where these non-genomic signalling pathways are abrogated. Further 
investigation into immune cell migration following longer periods of Tamoxifen treatment 







5.5  | Conclusion  
Investigation of the number of PBMCs that migrate towards MCF-7 cells treated with anti-
oestrogens has revealed that significantly more immune cells migrate in response to the 
chemotaxic gradient elicited by Fulvestrant treated cells, compared to controls. From this, we 
suggest that Fulvestrant treated MCF-7 cells secrete chemokines which promote the spatial 
proximity of immune and malignant cells, which in turn may facilitate the creation of a pro-
tumour microenvironment. When MCF-7 cells were treated with Tamoxifen, no significant 
difference was observed in the number of migrated PBMCs between the Vehicle and 
Treatment conditions.  This is consistent with the greater number of differences in chemokine 
expression in Fulvestrant treated MCF-7 cells compared to controls, compared to chemokine 























6. Validation of in vitro chemokine expression analysis 
 
 
6.1 | Study rationale  
While a large majority of breast cancer research is conducted in vitro using established cell 
lines, inevitably these systems do not replicate all aspects of the growth of human tumours in 
vivo. [201]. Despite the clear advantages of cell line studies, including the ability to assess 
dynamic changes in gene expression and ease of use, cell line research fails to accurately 
model both the inter- and intra- tumour heterogeneity known to be present in breast tumours 
due to their clonality [202]. Additionally, cell lines studies lack the stromal and immune 
components of the local tumour microenvironment, which have been show to co-evolve with 
the tumour cells and participate in the process of tumourigenesis [101, 203].   
 
To complement the in vitro observations of chemokine expression discussed in previous 
chapters, we examined the expression of the three pro-inflammatory chemokines in two 
different in vivo systems. Firstly, a concurrent study in the Dunbier laboratory provided 
tumour tissue from a murine model of oestrogen receptor positive breast cancer. These 
tumours were developed using SSM3 cells (generated from a primary tumour in a Stat1 -/- 
mouse) injected into the mammary fat pad of immunocompetent mice. Tumours were treated 
with the aromatase inhibitor, Letrozole, in combination with a nonsteroidal anti-inflammatory 
drug, Celecoxib. Using post-treatment tumour tissue, the study aimed to investigate whether 
the inflammatory chemokines shown to be up-regulated in cell line studies following 
oestrogen deprivation (in vitro modelling of aromatase inhibitor therapy), CCL5, CCL22 and 
CXCL16, were also up-regulated following treatment with Letrozole in vivo. Additionally, we 
sought to investigate whether the use of an anti-inflammatory would reduce the expression of 






Secondly, we used publically available microarray data to perform differential gene 
expression analysis on ER+ breast cancers before and during pre-surgical treatment with 
Fulvestrant to investigate the transcriptional response of these cancers following therapy.  
Patients were treated with either 250mg/28 days or 500mg on day 0, 14, 28 and monthly 
thereafter. We hoped to elucidate the effect of dose on gene expression, and whether genes 
involved in the immune response are differentially expressed by Fulvestrant treatment.  
 
6.2  | Gene expression analysis of SSM3 tumours in 129S6/SvEv mice  
qPCR was used to compare the relative expression levels of CCL5, CCL22 and CXCL16 in 
tumours grown in 129S6/SVEV mice from injection with SSM3 cells (Figure 6.1). Once 
tumours had been established (size >49mm2), mice underwent either an ovariectomy (‘Ov’) 
or sham ovariectomy (‘Sham’) to prevent ovarian oestradiol production or to mimic the 
surgical process. Mice were then treated with: 1) Letrozole (1mg/kg/day) + Celecoxib 
(25mg/kg/day) (OvLet + CBX), 2) Letrozole (1mg/kg/day) + Celecoxib Vehicle (OvLet 
+Vgav), 3) Ethanol Vehicle + Celecoxib (25mg/kg/day) (ShamV + CBX) or 4) Ethanol 
Vehicle + Celecoxib Vehicle (Sham V + Vgav). Mice were treated for a maximum of 25 days 
or until animal welfare guidelines warranted euthanasia. Mice that were euthanised prior to 
Day 14 of treatment were excluded from this analysis. 
 
Tumour RNA was extracted from post treatment biopsies (see Section 2.10.2) and reverse 
transcribed to cDNA (see Section 2.2.8).  Quality control was performed on extracted RNA 
using the Agilent 2100 Bioanalyzer, and samples with a RIN >7 was used for qPCR. MIQE 
guidelines were adhered to in the interpretation of qPCR results. RNA transcripts were 





standard curves in Appendix 20), and the expression levels of the genes of interest (CCL5, 
CCL22 and CXCL16) were normalised to the expression of the reference genes, FKBP15 and 
PUM1, in each individual mouse. Normalised expression values can be found in Appendix 
21.  
 
Figure 6.1 illustrates the normalised expression of the three chemokines of interest; CCL5, 
CCL22 and CXCL16. Analysis was performed in RStudio (R Markdown in Appendix 22), 
using an analysis of variance (ANOVA) test. No significant difference was observed in 
expression of CCL5, CCL22 or CXCL16 between any of the conditions (p = 0.438, p = 0.145 
and p = 0.746 respectively. We do, however, observe a trend towards decreased CCL5 
expression in tumours treated with both Letrozole and Celecoxib (OvLet + CBX) compared 
to Letrozole alone (OvLet + Vgav), despite a large amount of variability in the latter. 
Additionally, expression of CCL5 is higher in mice that received a sham ovariectomy and 
were treated with Celecoxib (ShamV + CBX) compared to its vehicle counterpart (ShamV + 
Vgav). 
 
The expression of CCL22 is highly variable in mice that received a sham ovariectomy alone 
(ShamV + Vgav). The expression of this chemokine is much less variable in the three other 
conditions, and is expressed at a higher level in OvLet + CBX compared to the Celecoxib 
vehicle control. In contrast, the median of CXCL16 expression is consistent across all 
treatment groups, with a larger amount of variability observed in the OvLet +CBS and 

















































Figure 6.1: CCL5 [A], CCL22 [B] and CXCL16 [C] gene expression in tumours grown in 129S6/SvEv mice from 
injection with SSM3 cells and treated with Letrozole or Letrozole and Celecoxib in combination. Once SSM3 cell 
tumours had been established (size>49mm2) mice were treated with (1) Letrozole (1mg/kg/day) + Celecoxib (25mg/kg/day) 
(OvLet + CBX = red), (2) Letrozole (1mg/kg/day) + Celecoxib Vehicle (OvLet + Vgav = green), (3) Ethanol Vehicle + 
Celecoxib (ShamV + CBX = blue) or (4) Ethanol Vehicle + Celecoxib Vehicle (25mg/kg/day) (ShamV + Vgav = purple). 
Mice receiving Letrozole were ovariectomized (‘Ov’), while mice receiving the Letrozole vehicle (ethanol) had sham 
ovariectomies performed on them (‘Sham’). Mice were treated for a maximum of 25 days or until animal welfare guidelines 
warranted euthanasia. Post-treatment tissue was used for RNA extraction. qPCR used to compare the relative expression 
levels of CCL5, CCL22 and CXCL16, and were normalised using the reference genes FKBP15 and PUM1. Differential 




























6.3   | Differential gene expression analysis of the transcriptional response to Fulvestrant  
Using the dataset GSE71791 sourced from the Gene Expression Omnibus (GEO) database, 
differential gene expression between matched pre- and on-Fulvestrant treatment was 
calculated for ER+ breast cancer patients treated with either 250mg/ 28day or 500mg on day 
0,14,28 and monthly thereafter (see Section 2.11)  [37]. In women treated with 500mg of 
Fulvestrant, we found 7786 differentially expressed genes with a p value <0.05, and from 
those 1906 were found to have an adjusted p value <0.05 (R markdown in Appendix 23). 
When examining the lower dose, 250mg/28 days, we found 1819 genes differentially 
expressed with a p value <0. We did not, however, find any genes with an adjusted p value 
<0.05. 
 
From the list of differentially expressed genes, we extracted chemokines and chemokine 
receptors, ranked based on p value, for both 250mg and 500mg Fulvestrant treatment (Figure 
6.2). Genes listed above the grey row have a p value <0.05. We have also included our three 
chemokines of interest, CCL5, CCL22 and CXCL16, and their respective rankings 
(highlighted in blue).  We found 13 unique chemokine and chemokine receptor genes up-
regulated by treatment with 500mg of Fulvestrant. When treating at this dose, CCL5 was the 
only chemokine of interest that was altered with a p value <0.05. CCL22 and CXCL16 were 
found to be up-regulated at a non-significant cut off.  
 
In tumours from patients treated with 250mg of Fulvestrant, six unique chemokine and 
chemokine receptors were differentially expressed between pre- and on-treatment biopsies.  
Of these, five genes were found to be up-regulated, with CCR1 being the only significantly 
down-regulated chemokine receptor. All three of our chemokines of interest had a p values 


































Figure 6.2: Differentially expressed chemokine and chemokine receptors analysis.  The dataset GSE-71791 sourced from the Gene Expression Omnibus was used to perform differential 
gene expression analysis.  Matched pre-treatment and on-treatment biopsy microarray data was used to determine the log fold change (log FC) of each gene from patients with ERα+ breast 
cancer.  Genes were ranked based on p value. Chemokine and chemokine receptor genes were extracted from this list, and displayed here. Genes with a p value< 0.05 are displayed above the 
grey row. Three chemokines of interest, CCL5, CCL22 and CXCL16, are highlighted in blue, and listed below the grey row if their p value was not below the 0.05 cut off.
Fulvestrant 500mg 
    
Fulvestrant 250mg  
   Ranked ProbeID Gene logFC P.Value 
 
Ranked ProbeID Gene logFC P.Value 
455 ILMN_1803825 CXCL12 0.66992 0.00007 
 
96 ILMN_1670658 CCL15 0.08740 0.00225 
595 ILMN_1791447 CXCL12 0.89566 0.00014 
 
161 ILMN_1773245 CCL3L1 0.08799 0.00408 
2354 ILMN_1769895 CCR2 0.29490 0.00323 
 
276 ILMN_1674563 CCL4 0.05625 0.00739 
2751 ILMN_1674640 CXCR6 0.27612 0.00472 
 
439 ILMN_1801584 CXCR4 0.41570 0.01151 
2776 ILMN_1773352 CCL5 0.64746 0.00482 
 
1069 ILMN_1718552 CXCL13 0.05411 0.02927 
3159 ILMN_1740609 CCL15 0.71540 0.00662 
 
1536 ILMN_1678833 CCR1 -0.06750 0.04231 




    
3471 ILMN_1669062 CCR2 0.11303 0.00835 
 
18554 ILMN_2160476 CCL22 -0.14140 0.42592 
3724 ILMN_2320888 CXCR4 0.23985 0.00984 
 
21004 ILMN_2098126 CCL5 0.02814 0.47549 
3880 ILMN_2276996 CCR2 0.05946 0.01080 
 
33635 ILMN_1728478 CXCL16 -0.01302 0.71897 
3942 ILMN_1689111 CXCL12 0.42237 0.01116 
      4323 ILMN_1710186 CCL17 0.13143 0.01370 
      4342 ILMN_2098126 CCL5 0.56360 0.01386 
      4787 ILMN_1716276 CCL4 0.33537 0.01742 
      5110 ILMN_1764030 CCL23 0.12593 0.02007 
      5485 ILMN_1783593 CCL13 0.25705 0.02333 
      6408 ILMN_1797975 CXCR3 0.26102 0.03297 
      6510 ILMN_1801584 CXCR4 0.27209 0.03419 
      7316 ILMN_1715131 CCR7 0.35345 0.04370 




    
      16665 ILMN_1728478 CXCL16 0.17653 0.20746 
      27562 ILMN_2160476 CCL22 0.10999 0.45734 









6.4 | Discussion  
 
Despite a number of advances in the treatment of ER+ breast cancers, failure to recapitulate 
the hormonal responsiveness and biology of human ERα+ breast cancers in murine models 
has hampered efforts to develop models of tumorigenesis and response to treatment [127]. 
Using SSM3 cells transplanted into immunocompetent mice, the Dunbier laboratory has 
generated STAT1-/- tumours which have previously been shown to model ER+ breast cancer 
receptor expression and hormone dependency [90, 127]. Here, we sought to investigate the 
effect of Letrozole or Letrozole and Celecoxib in combination, following ovarian hormone 
depletion or sham-surgery, on CCL5, CCL22 and CXCL16 expression.  
 
In vitro analysis of the expression of these three chemokines following simulated AI 
treatment showed increased chemokine expression in the Treatment condition compared to 
controls. Thus, if this held true in vivo, we would expect to see increased chemokine 
expression in the OvLet + Vgav condition compared to the ShamV + Vgav condition. 
However, we found no significant difference in expression of any of the three chemokines 
between these two conditions. Compared to untreated controls (ShamV + Vgav) we do 
observe a trend towards increased CCL5 expression in mice treated with Letrozole. This 
supports in vitro observations.  
 
Several studies have implicated cyclooxygenase-2 (COX-2) expression with clinical markers 
of aggressive breast cancer, including large tumour size, higher Nottingham grade, lymph 
node metastasis and worse disease free survival [204-206].  COX-2 is largely expressed by 
cells involved in inflammation, and is up-regulated by stimulation with pro-inflammatory 
cytokines, such as IL-1 and TNF-α [207]. Pharmacological inhibition of COX-2 can impede 





metabolic products, thus exerting anti-inflammatory properties [208]. Thus, we hypothesised 
that Celecoxib, a selective COX-2 inhibitor, in combination with Letrozole would decrease 
the inflammatory response elicited in response to AI treatment. However, we found no 
significant difference in the expression of CCL5, CCL22 or CXCL16 in response to Celecoxib 
(OvLet + CBX compared to OvLet +Vgav).  We do, however see a trend towards decreased 
CCL5 expression in tumours treated with both Letrozole and Celecoxib compared to 
Letrozole alone.   
 
The lack of differential expression between treatment conditions, and large amount of 
variability, is most likely due to the limited number of samples examined. At the time of 
analysis, post treatment tissue from 36 mice was available. Ulceration was found to be a 
significant problem in the generation of these tumours, which would have confounded the 
examination of the immune response to treatment, given that inflammatory signals are 
associated with tissue injury, such as ulceration [209]. For this reason, we excluded mice that 
had been euthanized prior to Day 14 of treatment due to ulceration. This decreased our 
numbers to 23 mice. Furthermore, dissimilar to most neoadjuvant studies, the design of this 
study did not afford pre-treatment and on-treatment tumour tissue. Thus, in the absence of 
paired data, the inter-mouse variability may be hiding the effect of the treatment by adding 
biological noise. It is also possible that, despite STAT1-/- ERα mammary tumours from 
SSM3 cells reflecting the hormone dependency of human ERα positive breast cancer, the 
immune response of mice may not wholly reflect the immune response observed in humans 
[127]. Further investigation into the expression of CCL5, CCL22 and CXCL16 following 
Letrozole and Letrozole in combination with Celecoxib as the Dunbier study continues may 






An analysis of chemokine and chemokine receptor expression in response to two doses of 
Fulvestrant, either 250mg/28 days or 500mg (on days 0,14,28 and monthly thereafter), 
elucidated an overall trend of up-regulation of these genes in on-treatment biopsies, 
compared to pre-treatment controls. In women treated with 500mg of Fulvestrant, we 
observed 19 unique chemokine and chemokines receptor genes significantly up-regulated (p 
value < 0.05). Of our chemokines of interest, only CCL5 was significantly up-regulated, and 
a non-significant trend towards up-regulation of CCL22 and CXCL16 was observed. In 
women treated with 250mg of Fulvestrant, fewer chemokine and chemokine receptor genes 
differentially expressed between pre- and on-treatment biopsies. At this dose, five genes were 
significantly up-regulated following treatment, and one gene, CCR1, was significantly down-
regulated. CCR1 encodes for the cognate receptor of chemokines CCL3, CCL5, CCL7 and 
CCL23, which are involved in the recruitment of T cells to inflammatory sites [210, 211]. In 
agreement, we also found down-regulation of CCL5, though not at a statistically significant 
level. In vitro work investigating mi-RNA-mediated gene regulation in Fulvestrant resistant 
ER+ breast cancer elucidated the expression of miRNA-221 and miRNA-222 were found to 
be significantly upregulated in MCF-7FR (Fulvestrant resistant) cells [212]. Ectopic 
expression of these miRNAs in MCF-7 cells was found to increase proliferation independent 
of oestrogen and upregulate CCL5 expression, suggesting that this chemokine is modulated in 
the acquisition of Fulvestrant resistance [212]. Thus, the differences in gene expression may 
be due to the absence of Fulvestrant resistance during the four-week time course undertaken 
in this data set [37].  No significant modulation of our three chemokines of interest was 
observed between pre- and on-treatment biopsies. 
 
The difference in the number of chemokine and chemokine receptors modulated by 





two doses on patient outcome was analysed in the CONFIRM Phase III Trial, in post-
menopausal women with ER+ advanced breast cancer who had experienced progression after 
prior endocrine therapy [213]. Compared to women treated with 250mg of Fulvestrant every 
28 days, women treated with 500mg on days 14 and 28 (and every 28 days thereafter) were 
found to have significantly longer progression-free survival, as well as increased clinical 
benefit, duration of clinical benefit and overall survival [213]. Thus, 500mg was deemed to 
have a clinically meaningful improvement in patient outcome in contrast to 250mg of 
Fulvestrant [213]. This may support our hypothesis, as increased dependence on immune cell 
recruitment for growth and proliferation is hypothesized to be associated with poor response 
to therapy. Further investigation is warranted to draw meaningful conclusions. 
 
While we found up-regulation of CCL5 in response to Fulvestrant treatment, the absence of 
statistical significance in differential gene expression of our other two chemokines of interest, 
CCL22 and CXCL16, may be due to a relatively small sample size. In comparison to 
microarray data that elucidated the up-regulation of these three chemokines in AI treated ER+ 
breast cancer, which consisted of 81 matched samples, the sample size of this dataset is much 
smaller [53]. Instead, the Fulvestrant treated cancers contained 22 matched samples for 
patients treated with 500mg, and 16 matched samples for patients with 250mg of Fulvestrant. 
Furthermore, inter-patient variability as a by-product of tumour heterogeneity may also 
dampen this analysis. Thus, a larger dataset may elucidate a greater trend of chemokines and 
chemokine receptors modulated by Fulvestrant treatment.  
 
 
6.5 | Conclusions 
 
In vivo analysis of the expression of CCL5, CCL22 and CXCL16 in the presence of an 





as well as investigating the effect of anti-inflammatory drugs on the inflammatory response in 
an ER positive murine model setting. While currently, no significant difference between 
treatment types has been observed, this study is ongoing and we hope to see a trend develop 
with additional tumour samples.  
 
When investigating differential gene expression in response to Fulvestrant treatment, we 
observed increased unique chemokine and chemokine receptor gene expression in ER+ breast 
cancers treated with 500mg of Fulvestrant compared to 250mg. This suggests that drug dose 
affects chemokine expression. With regards to our chemokines of interest, CCL5, CCL22 and 
CXCL16, we observed a general trend of up-regulation in response to treatment, however 
CCL5 in patients treated with 500mg was the only chemokine to reach statistical significance.  
We propose that increased sample size may help to further investigate the effect of 




















7. GENERAL DISCUSSION  
 
 
The development of oestrogen independent growth is a significant hindrance in our ability to 
treat women with oestrogen receptor positive breast cancer [78, 79]. Response and resistance 
to endocrine therapy in ER+ breast cancer is poorly understood, and despite significant initial 
response rates, 20-40% of patients’ malignancy reoccurs within 10 years [77-79]. As the most 
common cancer diagnosed in women worldwide, an understanding of the mechanisms of 
resistance to current therapeutics has the potential to improve the treatment and outcome for a 
large number of women [1]. 
 
The recently recognised dual role of the immune response in carcinogenesis, and the role of 
the tumour microenvironment in supporting tumour progression, has led to investigation of 
the co-evolution of malignant cells, tumour vasculature, the extracellular matrix and immune 
cells, in cancerogenesis [100, 101]. Consequently, the distribution of immune cell infiltration 
has been shown to be an independent predictor of poor prognosis in a number of 
malignancies [107, 108]. Secretion of pro-inflammatory cytokines is a method whereby the 
innate immune system can act to enhance tumour progression and growth by promoting 
spatial proximity of immune and stromal cells, which secrete pro-tumour factors [105]. It is 
suggested that this secretion of pro-inflammatory cytokines facilitates co-evolution and 
pushes tumorigenic cells from the equilibrium to escape phase in the absence of oestrogen 
[105]. This is supported by a higher baseline expression of an inflammatory signature 
associated with poor response to aromatase inhibitor treatment in patients with ER+ breasts 






Thus, this project sought to investigate the modulation of pro-inflammatory chemokine 
expression following treatment with Tamoxifen and Fulvestrant. Both these drugs act to 
selectively modulate and/or degrade the oestrogen receptor and the inhibit the expression 
oestrogen responsive genes, however, the effect of these modalities on chemokine expression 
is unknown. Furthermore, it is unknown whether the underlying differences in mechanism of 
action of Tamoxifen and Fulvestrant elicit dissimilar expression patterns. We examined the 
effect of anti-oestrogen treatment on chemokine expression was examined in vitro and in 
vivo, and investigated immune cell recruitment in response to treatment. Additionally we 
performed gene set enrichment analysis on microarray data from ER+ breast cancers before 
and during pre-surgical treatment with Fulvestrant.  
 
7.1    | Expression of pro-inflammatory chemokines in response to Tamoxifen and …...  
xxxxxFulvestrant in MCF-7 cells  
Here we have shown that the expression of pro-inflammatory chemokines by ERα+ breast 
cancer cells in response to anti-oestrogen therapies is both treatment and cell line specific. 
Following the observation that the expression of three pro-inflammatory chemokines, CCL5, 
CCL22 and CXCL16 was increased in response to oestrogen deprivation (in vitro modelling 
of aromatase inhibitor therapy) in MCF-7 cells, we examined the expression of these 
chemokines in response to both Tamoxifen and Fulvestrant in this cell line [126]. Our results 
are summarised in Table 7.1. We showed that expression of CCL22 was the only chemokine 
to be modulated in the same manner across all three treatment modalities. Following 
Tamoxifen treatment, no difference in the expression of CCL5 and CXCL16 was observed 
between the Treatment and Vehicle. CCL5 expression was up-regulated following 
Fulvestrant treatment, however, no difference between expression of CXCL16 expression was 





Table 7.1: Summarised chemokine expression from in vitro and in vivo analyses. Red arrows indicate significant (p <  
0.05) differential expression of the chemokine in the Treatment compared to control. Black arrows indicate a trend in 
expression. Up arrows indicate up-regulation of the chemokine in the Treatment compared to control, whereas down arrows 
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From the three anti-oestrogens of interest, classical oestrogen signalling is most significantly 
impacted by the effects of the pure oestrogen antagonist, Fulvestrant, due to its multifaceted 
mechanism of action [214].  In contrast to the 2.5% affinity for the ER elicited by Tamoxifen, 
the affinity for Fulvestrant is 89% that of oestrogen, and thus acts to inhibit the transcriptional 
activity of the ER more efficiently than Tamoxifen [67, 68, 170]. Its additional effects on 
receptor localisation and degradation means that oestrogen signalling in its classical sense 
should be most completely inhibited by treatment with Fulvestrant [66, 68]. This was shown 
by microarray analysis, where oestrogen-regulated gene expression was completely abolished 
by Fulvestrant, in contrast to Tamoxifen treatment, where some genes remained 
transcriptionally responsive to oestrogen [215]. Similarly, treatment with AIs inhibits the 
synthesis of oestrogen, a vital requirement for oestrogen signalling [60]. Thus, persistent 
populations of breast cancer cells following treatment with these modalities must express 
genes involved in cell growth and proliferation in the absence of oestrogen and the oestrogen 
receptor [216].  
 
Increasing evidence suggests that, in addition to the classical ER signalling pathway, the ER 
may also regulate gene expression via the activation of other receptors [217, 218]. 
Endogenous membrane ERs have been shown to cross-talk with EGF, ErbB2 and IGF-I 
receptors in ERα+ breast cancer [219, 220]. This results in the activation of downstream 
signalling cascades involving ERK MAPK and PI3K/AKT kinases, which are associated with 
the up-regulation of the transcriptional activity and stability of the ER, and phosphorylate 
discrete residues of the nuclear ER in response to soluble stromal factors, such as growth 
factors, stress and various chemokines [199, 221-223]. Therefore, increased chemokine 





pathways that drive cell cycle progression and survival in the absence of oestrogen signalling 
[224]. 
 
 Phosphorylation of serine-305 of ERα has been associated with the induction of agonist 
effects associated with Tamoxifen [225].  Activation of protein kinase A (PKA) and 
subsequent phosphorylation of the ER was found to cause conformational arrest of the 
receptor, whereby Tamoxifen is able to bind to the receptor, but does not induce the 
conformational changes associated with inactive ER [225]. Thus, PKA activity induces ERα- 
dependent transactivation and switches the antagonistic effects of Tamoxifen to agonistic 
[225]. Consequently, in the absence of oestrogen binding, such as treatment with Tamoxifen, 
oestrogen responsive genes are able to remain transcriptionally active.  
 
Furthermore, the transcriptional activity of activator protein-1 (AP-1), a dimeric transcription 
factor involved in cell proliferation, transformation and death, is primarily regulated by the 
JNK and p38 MAPK phosphorylation cascades [216, 226]. Differentially induced by cellular 
location of the ER, the ligand-binding of 17β-oestradiol in the cytoplasm has been shown to 
activate AP-1-dependent transcription and support proliferation and growth [217, 227]. 
Furthermore, Tamoxifen was shown to induce the activation of AP-1, at a comparable level 
to 17β-oestradiol, when ERα is present in the cytoplasm [217]. However, when treated with 
Fulvestrant, the non-genomic actions of the ER were inhibited [217].  
 
The number of mechanisms by which cells treated with Tamoxifen can facilitate growth in 
the absence of classical oestrogen signalling, in addition to the agonist effects of this drug, 
suggest that the reliance in immune response modulation by cells treated with this therapy is 





oestrogen signalling [66, 68, 216]. We propose that cells treated with Fulvestrant are more 
reliant upon the interaction of the stroma, malignant cells and immune response to facilitate 
growth and proliferation than cells treated with Tamoxifen. However, the chemokines 
examined in this study represent a small subset of the number of chemokines involved in 
immune cell recruitment. Consequently, it is possible that a more extensive examination of 
additional chemokines and immune signalling molecules could reveal additional pathways of 
response to oestrogen signalling blockade. Therefore, assessing the immune-dependence on 
these three chemokines has limited application.  
 
The expression of immune related genes in response to Fulvestrant has been investigated in 
vivo and will be discussed further in Section 7.5. A similar investigation and direct 
comparison with Tamoxifen treated biopsies may provide a more holistic picture of the 
immune landscape in response to anti-oestrogen therapies. 
 
7.2          | Comparison of pro-inflammatory chemokine expression in two ER+ breast 
xxxxx.xxxcancer cell lines  
While a vast majority of breast cancers are termed ER+, the individual differences in cell 
lines are marked [176]. Despite the umbrella term of ER+ breast cancers, the transcriptional 
response of different cells lines to treatment modalities has been shown to differ in both 
number of genes regulated and composition [176]. For this reason, we investigated the effect 
on pro-inflammatory chemokine expression in two ER+ cell lines, to examine whether 
patterns observed in MCF-7 could be generalised to a greater number of ER+ cell lines. 
Instead, we found that, especially with regards to Tamoxifen, expression of CCL5, CCL22 






The notion that the molecular mechanisms underlying the non-genomic actions of oestrogens 
is cell type specific has been proposed in a number of other studies [228, 229]. An example 
of cell line specific non-genomic action is the differential involvement of ERα and ERβ in the 
recruitment of steroid receptor coactivator-1 (SRC-1) [230]. While members of the SRC 
family have been shown to weakly interact with the N-terminal region of ERα, 
phosphorylation of the AF-1 domain of ERβ  has been shown to recruit SRC-1 in vitro [230, 
231]. SRC-1 interacts with other general transcription factors, such as TFIIB and TBP, and 
co-activators, which suggests that it plays an important role in combining interactions of 
receptor activation functions with transcriptional machinery to facilitate transactivation [34, 
231, 232]. Compared to MCF-7 cells, the ERα/ERβ ratio in T47D cells is much lower [162]. 
It is, therefore, conceivable that this difference in receptor ratio impacts recruitment of 
coactivators and thus, transcriptional activity of the oestrogen receptors between these two 
cell lines [162, 230].  
 
Further investigation into pro-inflammatory chemokine expression following anti-oestrogen 
therapy would, therefore, benefit from the use of an increased number of ER+ breast cancer 
cell lines to elucidate whether generalisability is appropriate over a larger number of ER+ 
breast cancers.  
 
7.3          | Immune cell recruitment following Tamoxifen and Fulvestrant treatment 
Here, we examined the expression of three pro-inflammatory chemokines, CCL5, CCL22 and 
CXCL16 in response to Tamoxifen and Fulvestrant treatment. Immune cell recruitment is, 
however, facilitated by a large number of chemokines and their cognate receptors [233, 234]. 
Therefore, although we do observe more modulation of the expression of these chemokines in 





treated cells (up-regulation of CCL22), this is a small subset of chemokines responsible for 
immune cell migration and is consequently not solely responsible for increased immune cell 
migration [234].  
 
Consistent with MCF-7 cells treated with AIs, we observed significantly more immune cells 
migrate towards cancer cells treated with Fulvestrant than the control. This supports our 
hypothesis that the immune landscape in Fulvestrant treated MCF-7 cells facilitates spatial 
proximity of immune cells and cancerous cells in vitro, and may promote interaction with the 
stroma in vivo. The correlation between increased cell migration towards AI treated MCF-7 
cells, in conjunction with poor response to this modality in post-menopausal women with 
ER+ breast cancers, is suggestive that increased cell migration towards Fulvestrant treated 
MCF-7 cells may have an association with clinical outcome in these cancers [53, 126]. This 
will be further discussed in Section 7.5. In contrast, no difference in immune cell migration 
was observed towards MCF-7 cells treated with Tamoxifen compared to controls. 
 
The methodology used to examine PBMC migration following AI, Tamoxifen and 
Fulvestrant treatment differed slightly. In the AI treatment study by Hazlett et al., MCF-7 
cells underwent a three-day period of oestrogen deprivation prior to treatment with AIs [126]. 
This was done to remove residual oestrogen from culture in order to directly compare the 
effects of oestrogen deprivation and physiological levels of oestrogen on immune cell 
migration [126].  Therefore, the observed effects are a result of eight days of oestrogen 
deprivation. Due to the effect of Fulvestrant on cell number, we changed the methodology to 
accommodate five days of treatment when completing the study on chemokine expression 





Fulvestrant treatment on immune cell recruitment may have been even stronger after eight 
days of treatment.  
 
For consistency, we designed the PBMC migration studies to incorporate this new 
methodology, and thus, the time course associated with the qPCR Tamoxifen treatment study 
and the PBMC migration in response to Tamoxifen study differ. While the difference in cell 
number between Treatment and Vehicle in the Tamoxifen treatment study meant we were 
unable to treat cells for more than three days, we were able to treat the MCF-7 cells for five 
days when looking at PBMC migration. As discussed in Chapter 3, the metabolism of 
Tamoxifen to its active metabolites, Endoxifen and 4-OH-Tam, may contribute to clinical 
variability observed in vivo [168, 169]. Due to increased anti-oestrogenic effects, the use of 
these metabolites may elicit a stronger dependence of MCF-7 cells on the expression of pro-
inflammatory chemokines and immune cell migration to facilitate growth and proliferation. 
Further investigation using a more comparable time course would facilitate direct comparison 
between chemokine expression and immune cell recruitment following treatment with 
Tamoxifen. Additionally, examining these effects following treatment with active metabolites 
may reveal an effect on immune cell migration.   
 
7.4         | In vivo expression of pro-inflammatory chemokines 
An ongoing study in the Dunbier laboratory examining the effect of the aromatase inhibitor, 
Letrozole, and Letrozole in combination with Celecoxib in a murine model of ERα breast 
cancer facilitated the examination of the expression of CCL5, CCL22 and CXCL16 in vivo. 
Although these three genes were found to be up-regulated in post-menopausal women treated 
with AIs, we were unable to recapitulate this observation in this model at this current stage 





towards up-regulation of CCL5 in Letrozole treated tumours, compared to the untreated mice 
(ShamV + Vgav). Additionally, expression of this chemokine was decreased in mice treated 
with Letrozole and Celecoxib in combination compared to Letrozole alone. A large amount 
of variability in CCL22 expression was observed in untreated mice, and expression was found 
to be higher in the OvLet + CBX condition compared to Letrozole or Celecoxib alone. The 
expression of CXCL16 was highly variable in both the untreated mice and OvLet + CBX 
condition, while the median expression level was relatively similar across all conditions.  
 
It is important to acknowledge tumour heterogeneity and its role in response to treatment. 
Differences between the same sub-type of breast cancers, or inter-tumour heterogeneity, have 
long been accepted as a considerable challenge in cancer therapy [235]. For example, in the 
clinical setting, oestrogen-receptor positive status is assigned to tumours in which the number 
of cells exhibiting this receptor exceed a 1% threshold [11]. This low threshold value implies 
that in a number of cases, the majority of cells present in a tumour display molecular features 
inconsistent with the overall status appointed [11]. Thus, the genetic make-up of tumours in 
two patients, whom were both assigned ER+ breast cancer as their clinical diagnosis, may be 
vastly different [11, 236].  
 
Furthermore, it is now accepted that the topography of a tumour is both dynamic and varied, 
even within the same lesion [101, 237, 238]. Intra-tumour heterogeneity is a term which 
denotes the existence of sub-populations of cells, within a given tumour, which can differ in 
genotypic, phenotypic and behavioural characteristics [236, 237].  Therefore, biopsies of a 
lesion may not provide an accurate representation of the heterogeneous cell types within a 
single tumour [237, 239].  As we are sampling a small section of a tumour, it is possible that 





the design of this study did not afford paired data, inter-mouse variability may have created 
biological noise which may hide the effect of the treatment.  
Consequently, when examining responses to treatment modalities in vitro, the effect may be 
found to be stronger in this homogenous populations compared to the heterogeneous 
population of cells in a tumour mass [202]. While cell lines are a convenient way of assessing 
dynamic changes in gene expression at numerous time points, the true level of complexity of 
cancer is much higher than examination of homogenous cell population can model [202, 
203]. Furthermore, they are not representative of the local tumour microenvironment found in 
patients, as therapeutic response and resistance are reliant on the interaction of neoplastic 
cells with the extracellular matrix and immune cells [101, 202, 235]. Thus, the ability to 
utilise murine models and human biopsies to examine chemokine expression in vivo has the 
potential to strengthen in vitro work from our laboratory.   
 
7.5        | Bioinformatics 
Microarray analysis has shown that the overall transcriptional response to Fulvestrant has 
much in common with oestrogen deprivation [37]. Focussing on chemokine and chemokine 
receptor expression, we examined the regulation of these genes in ER+ breast cancers who 
had previously progressed on endocrine therapy [37]. While our three chemokines of interest, 
CCL5, CCL22 and CXCL16 were found to be up-regulated in response to AI therapy, we 
observed that CCL5 alone, following high dose Fulvestrant, was the only one of these three 
chemokines to be significantly up-regulated by treatment.  
 
When comparing our in vitro observations to publically available microarray data, we found 
that CCL5 was up-regulated in both Fulvestrant treated MCF-7 cells and tumours treated with 





with 250mg was increased, it was not at a significant level. Furthermore, we did not observe 
any difference in expression of CCL5 between the Treatment and Vehicle in vitro. While the 
expression of our other two chemokines of interest, CCL22 and CXCL16, were increased in 
the on-treatment biopsies compared to pre-treatment with 500mg Fulvestrant, it did not meet 
significance thresholds. In our in vitro work, we found up-regulation of CCL22 in both MCF-
7 and T47D cell lines, and no difference in the expression of CXCL16 between Treatment and 
Vehicle conditions.  
 
Compared to our in vitro work, which examined homogenous cell populations, the 
microarray differential gene expression analysis is influenced by both inter-and intra-patient 
variability. Using matched pre-treatment and on-treatment biopsies, we looked for genes that 
were differentially expressed between these two time points, and significantly regulated 
within the whole cohort. Thus, by the nature of inter-patient variability, the expression of 
some chemokines or chemokine receptors in some patients may have dampened the overall 
effect of treatment on expression. Furthermore, spatial and temporal heterogeneity within a 
single lesion, combined with the influence of tumour microenvironment may have 
contributed to differences between the pre- and on-treatment biopsies, independently of 
treatment [101, 236].  Despite these acknowledged limitations, microarray studies in the 
neoadjuvant setting are a valuable tool to examine the dynamic clinical and molecular 
response to treatment in a heterogeneous environment representative of the tumour micro-
environment [202].  
 
7.6        | Clinical implications and future directions  
While anti-oestrogen therapeutic modalities have improved the prognosis and quality of life 





significant problem from 20-40% of patients [77-79]. Therefore, elucidating the molecular 
mechanism underlying resistance to current therapeutics has the potential to aid a large 
number of women [46]. 
 
The growing body of evidence toward the dual role of the immune response in 
tumourigenesis, and the role of the tumour microenvironment in supporting equilibrium to 
escape transition phase has shifted the focus of therapeutics from the cancer cell itself 
towards the hosts immune system and tumour microenvironment [100, 240]. The association 
between increased expression of an inflammatory signature, increased lymphocytic 
infiltration, and poor response to AI treatment in post-menopausal women with ER+ breast 
cancer has driven this investigation into chemokine expression and immune cell migration in 
ER+ cell lines in response to two other anti-oestrogen therapies, Tamoxifen and Fulvestrant 
[53]. We observed differential expression of three chemokines from the inflammatory 
signature, dependent on treatment. Consistent with AI treated MCF-7 cells, cells treated with 
Fulvestrant were found to recruit significantly more immune cells towards the cancerous 
cells, compared to controls. In comparison, treatment with Tamoxifen had no significant 
effect on immune cell migration.   
 
Future investigation would aim to strengthen our observation that chemokine expression is 
cell line specific. By utilising a number of other ER+ cell lines, we would be able to elucidate 
whether the regulation of these chemokines representative of a larger number of ER positive 
cell lines, or whether our observation, that the expression of CCL5, CCL22 and CXCL16 







Given the significant migration of immune cells towards MCF-7 cells treated with 
Fulvestrant, an investigation into the type of immune cells which migrate in response to this 
treatment will further our understanding of the interactions in the local tumour 
microenvironment. This could be achieved using fluorescence-activated cell sorting (FACS) 
for T cell, B cell and NK cell cell surface markers including CD3, CD4, CD8, CD19 and 
CD45 [241]. 
 
Furthermore, we could probe the mechanisms by which chemokine production is modulated 
following Tamoxifen and Fulvestrant by investigating COX-2 expression in response to these 
modalities. Due to the association of COX-2 expression and poor clinical outcome, and its 
role in inflammation and cell proliferation, up-regulation of this enzyme may be a mechanism 
whereby cell proliferation is potentiated in the absence of classical oestrogen signalling [204-
206].  By using qPCR and western blot, we may elucidate a target for improved treatment of 
















8. GENERAL CONCLUSIONS  
 
 
Overall, this study has shown that the expression of pro-inflammatory chemokines by ERα+ 
breast cancer cells in response to anti-oestrogen therapies is both treatment and cell line 
specific. We have illustrated that chemokine expression in response to both Tamoxifen and 
Fulvestrant differs between two ER+ cell lines, MCF-7 and T47D.  
 
Furthermore, we demonstrated that immune cell recruitment is affected by treatment with 
Fulvestrant, in that significantly more immune cells were found to migrate towards MCF-7 
cells treated with Fulvestrant compared to controls. With Tamoxifen treatment, we found no 
difference in the number of migrating immune cells between the Treatment and Vehicle.   
 
The murine model of oestrogen receptor positive breast cancer is yet to show any significant 
modulation of our three pro-inflammatory chemokines of interest in response to Letrozole or 
Letrozole and Celecoxib in combination. However, the lack of paired tissue samples from 
these tumours limits our interpretation of these data. The ongoing study may reveal a trend 
with increased number of samples.  
 
Bioinformatic analysis of the transcriptional response of ER+ breast cancers to Fulvestrant 
has illustrated the differences between observations in vitro and in vivo, and highlights the 
importance of considering the interactions between neoplastic cells, the immune response and 
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Appendix 1: Representative photos of MCF-7 cells treated with either 10µM of Tamoxifen or 0.05% DMSO in MCF-7 
washout media at seeding densities of 60,000, 80,000 and 100,000 after five days of treatment. MCF-7 cells were grown for three 
days in phenol-red free rpmI [+] 2-Glutamine media supplemented with 10% DCC-FBS and 1nM of oestrogen. Cells were then 
seeded at three different densities: 60,000, 80,000 and 100,000 cells per well. 24 hours post seeding, media was removed and cells 
were either treated with either 10µM of Tamoxifen or 0.05% DMSO in MCF-7 Washout Media. Media was replaced on Day 3 post 
seeding, and photographs were taken on Day 5 using an Olympus IX71 microscope and Olympus DP71 camera at 4X magnification. 
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10μM of Tamoxifen 
in MCF-7 washout media 
 
0.05% DMSO 

























































































































Appendix 2: Cell counts of three biological replicates of the MCF-7 Tamoxifen treatment study. MCF-7 cells were grown for 
three days in phenol-red free RPMI [+] 2-Glutamine media supplemented with 10% DCC-FBS and 1nM of oestrogen. Cells were 
then seeded at 80,000 cells per well in 6-well plates. 24 hours later, cells were treated with either 10μM of Tamoxifen or a 0.05% 
DMSO control for 3 days. Cell counts were performed on the haemocytometer at Day 0, 1 and 3. Each point represents the average of 
three cell counts with error bars displaying the standard error of the mean. Cell counts that are significantly different between the 
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Appendix 3: Representative standard curves for the chemokines of interest CCL5, CCL22 and CXCL16, and the 
reference genes FKBP15 and PUM1 in MCF-7 cells treated with 10µM Tamoxifen or 0.05% DMSO.  An equimolar 
mixture of Day 3 Tamoxifen treated and DMSO vehicle samples were used to make standard cDNA.  Dilutions of known 
concentration were used in triplicate to create a standard curve. Samples with a Cq value of >35 were not included.
 


































Appendix 4: CCL5, CCL22 and CXCL16 gene expression in MCF-7 cells exposed to Tamoxifen treatment or DMSO vehicle. Following a three-day washout period (DCC media 
supplemented with 1nM of oestrogen), MCF-7 cells were seeded in 6-well plates and treated with either 10μM of Tamoxifen or a 0.05% DMSO control for three days. Each point 
represents the average of three replicates. Values were Normalised using the reference genes FKBP15 and PUM1. Error bars are given are the standard error of the mean. Differential 
expression between the two groups was analyses using an unpaired t test, assuming both populations have the same standard deviation. Expression values for the treatment group 


































Appendix 5: Representative photos of T47D cells treated with either 5μM of Tamoxifen or 0.025% DMSO in T47D 
washout media at seeding densities of 100,000, 150,000 and 200,000 cells per well. T47D cells were grown for three 
days in phenol-red free rpmI [+] 2-Glutamine media supplemented with 10% DCC-FBS, 0.02% insulin and 1nM of 
oestrogen. Cells were then seeded at three different densities: 100,000, 150,000 or 200,000 cells per well. 24 hours post 
seeding, media was changed and cells were either treated with 5μM of Tamoxifen or 0.025% DMSO in T47D washout 
media. Media was replaced 72 hours post seeding, and photographs were taken 120 hours post seeding. Photographs were 
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Appendix 6: Cell counts of three biological replicates of the T47D Tamoxifen treatment study. T47D cells were 
grown for three days in phenol-red free RPMI [+] 2-Glutamine media supplemented with 10% DCC-FBS and 1nM of 
oestrogen. Cells were then seeded at 80,000 cells per well in 6-well plates. 24 hours later, cells were treated with either 
5μM of Tamoxifen or a 0.025% DMSO control for five days. Media was changed on Day 3. Cell counts were performed on 
the haemocytometer at Day 0, 1, 3 and 5. Each point represents the average of three cell counts with error bars displaying 
the standard error of the mean. Cell counts that are significantly different between the Treatment and Vehicle conditions are 
indicated on the graph with summarized P values: ** <0.005 and **** <0.0001. 
 














































Appendix 7: Representative standard curves for the chemokines of interest CCL5, CCL22 and CXCL16, and 
the reference genes FKBP15 and PUM1 in T47D cells treated with 10µM Tamoxifen or 0.05% DMSO.  An 
equimolar mixture of Day 5 Tamoxifen treated and DMSO vehicle samples were used to make standard cDNA.  
Dilutions of known concentration were used in triplicate to create a standard curve. Samples with a Cq value of 






Appendix 8: CCL5, CCL22 and CXCL16 gene expression in T47D cells exposed to Tamoxifen treatment or DMSO vehicle. Following a three-day washout period (DCC 
media supplemented with 1nM of oestrogen), MCF-7 cells were seeded in 6-well plates and treated with either 5μM of Tamoxifen or a 0.025% DMSO control for five days. 
Each point represents the average of three replicates. Values were Normalised using the reference genes FKBP15 and PUM1. Error bars are given are the standard error of the 
mean. Differential expression between the two groups was analyses using an unpaired t test, assuming both populations have the same standard deviation. Expression values 

































Appendix 9: Representative photos of MCF-7 cells treated with either 0.1μM of Fulvestrant or 0.0005% DMSO in 
MCF-7 complete media at seeding densities of 60,000, 80,000 and 100,000 cells per well: MCF-7 cells were grown for 
until confluency in MCF-7 complete medium. Cells were then seeded at three different densities: 60,000, 80,000 or 
100,000 cells per well. 24 hours post seeding, media was changed and cells were either treated with 0.1μM of Fulvestrant 
or 0.0005% DMSO in MCF-7 complete media. Media was replaced 72 hours post seeding, and photographs were taken 120 
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Appendix 10: Representative photos of MCF-7 cells treated with either 0.1μM of Fulvestrant or 0.0005% 
DMSO in MCF-7 complete media for five days. At ~80% confluency, MCF-7 cells were split into 75cm2 cell 
culture flasks. 24 hours later, 75cm2 flasks were treated with either 0.1μM of Fulvestrant or a 0.0005% DMSO 
control. On Day 2, treated 75cm2 flasks were used to seed 6-well plates at 80,000 cells per well. Photographs were 
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Appendix 11: Cell counts from three biological replicates of the MCF-7 Fulvestrant treatment study. At 
~80% confluency, MCF-7 cells were seeded at 80,000 cells per well in 6-well plates (Day 0 and Day 2 counts), in 
addition to 75cm2 cell culture flasks. 24 hours later, 6-well plates and 75cm2 were treated with either 0.1µM of 
Fulvestrant or a 0.0005% DMSO control. On Day 2, treated 75cm2 flasks were used to seed 6-well plates at 80,000 
cells per well for Day 3, 4 and 5 counts (indicated by black arrow). Cell counts were performed on the 
haemocytometer at Day 0, 2, 3, 4 and 5. Each data point represents the average of three cell counts, with error bars 
displaying the standard error of the mean. Cell counts that are significantly different between the Treatment and 
Vehicle conditions are indicated on the graph with summarized P values: ** <0.005, *** <0.0005 and **** 
<0.0001. 
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Appendix 12: Representative standard curves for the chemokines of interest CCL5, CCL22 and CXCL16, 
and the reference genes FKBP15 and PUM1 in MCF-7 cells treated with 0.1µM Fulvestrant or 0.0005% 
DMSO.  An equimolar mixture of Day 5 Fulvestrant treated and DMSO vehicle samples were used to make 
standard cDNA.  Dilutions of known concentration were used in triplicate to create a standard curve. Samples with 






Appendix 13: CCL5, CCL22 and CXCL16 gene expression in MCF-7 cells treated with 0.1µM Fulvestrant treatment or 0.0005% DMSO control. At ~80% confluency, MCF-7 cells were 
seeded at 80,000 cells per well in 6-well plates (Day 0 and Day 2 counts), in addition to 75cm2 cell culture flasks. 24 hours later, 6-well plates and 75cm2 flasks were treated with either 0.1µM 
of Fulvestrant or a 0.0005% DMSO control. On Day 2, treated 75cm2 flasks were used to seed 6-well plates at 80,000 cells per well for Day 3, 4 and 5 RNA harvest. Each data point represents 
the average of three replicates. Values from each biological replicate were Normalised using the reference genes FKBP15 and PUM1. Error bars are given are the standard error of the mean. 
Differential expression between the two groups was analysed using an unpaired t test, assuming both populations have the same standard deviation, and were plotted with error bars indicating 
the standard error of the mean. Expression values for the treatment group significantly different to the vehicle are indicated on the graph with summarized P values: * <0.05, ** <0.005, *** 


































Appendix 14: Representative photos of T47D cells treated with either 0.01μM of Fulvestrant or 0.00005% 
DMSO in MCF-7 complete media for five days. At ~80% confluency, T47D cells were split into 75cm2 cell 
culture flasks. 24 hours later, 75cm2 flasks were treated with either 0.01μM of Fulvestrant or a 0.00005% DMSO 
control. On Day 2, treated 75cm2 flasks were used to seed 6-well plates at 80,000, 100,000 and 120,000 cells per 
well. Photographs were taken 120 hours post re-seeding, using an Olympus IX7I microscope and Olympus DP71 
camera at 4X magnification. 
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Appendix 15: Cell counts from three biological replicates of the T47D Fulvestrant treatment study. At ~80% 
confluency, T47D cells were seeded at 120,000 cells per well in 6-well plates (Day 0 and Day 2 counts), in 
addition to 75cm2 cell culture flasks. 24 hours later, 6-well plates and 75cm2 were treated with either 0.01µM of 
Fulvestrant or a 0.00005% DMSO control. On Day 2, treated 75cm2 flasks were used to seed 6-well plates at 
120,000 cells per well for Day 3, 4 and 5 counts (indicated by black arrow). Cell counts were performed on the 
haemocytometer at Day 0, 2, 3, 4 and 5. Each data point represents the average of three cell counts, with error bars 
displaying the standard error of the mean. Cell counts that are significantly different between the Treatment and 
Vehicle conditions are indicated on the graph with summarized P values: * < 0.05, ** <0.005, *** <0.0005 and 
**** <0.0001. 
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Appendix 16: Representative standard curves for the chemokines of interest CCL5, CCL22 and CXCL16, 
and the reference genes FKBP15 and PUM1 in T47D cells treated with 0.01µM Fulvestrant or 0.00005% 
DMSO.  An equimolar mixture of Day 5 Fulvestrant treated and DMSO vehicle samples were used to make 
standard cDNA.  Dilutions of known concentration were used in triplicate to create a standard curve. Samples with 
a Cq value of >35 were not included.
 

































Appendix 17: CCL5, CCL22 and CXCL16 gene expression in T47D cells treated with 0.01µM Fulvestrant treatment or 0.00005% DMSO control. At ~80% confluency, T47D cells were seeded at 
120,000 cells per well in 6-well plates (Day 0 and Day 2 counts), in addition to 75cm2 cell culture flasks. 24 hours later, 6-well plates and 75cm2 flasks were treated with either 0.01µM of Fulvestrant or a 
0.00005% DMSO control. On Day 2, treated 75cm2 flasks were used to seed 6-well plates at 80,000 cells per well for Day 3, 4 and 5 RNA harvest. Each data point represents the average of three 
replicates. Values from each biological replicate were Normalised using the reference genes FKBP15 and PUM1. Error bars are given are the standard error of the mean. Differential expression between 
the two groups was analysed using an unpaired t test, assuming both populations have the same standard deviation, and were plotted with error bars indicating the standard error of the mean. Expression 


























































































Appendix 18: Three biological replicates of the Tamoxifen PBMC migration assay. At ~80% confluency, 
MCF-7 cells were split into 75cm2 cell culture flasks. 24 hours later, 75cm2 flasks were treated with either 10μM 
of Tamoxifen or a 0.05% DMSO control. On Day 2, treated 75cm2 flasks were used to seed 6-well plates at 80,000 
cells per well in respective treatment medias. Cells were then cultured for an additional three days. On Day 5, 
media was removed from the cells and the Transwell inserts were placed over the cells. 106 PBMCs were added to 
each insert, and corresponding media was added to each well. Cells were then incubated for four hours at 37°C and 
5% CO2. The number of migrated PBMCs was then determined using a haemocytometer. Each condition has three 
technical replicates. Differences in the number of migrated PBMCs between the Treatment and Vehicle groups 
was analysed using an unpaired t test, assuming both populations have the same standard deviations, and were 
plotted with error bars indicating the standard error of the mean. 
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Appendix 19: Three biological replicates of the Fulvestrant PBMC migration assay. At ~80% confluency, 
MCF-7 cells were split into 75cm2 cell culture flasks. 24 hours later, 75cm2 flasks were treated with either 0.1μM 
of Fulvestrant or a 0.0005% DMSO control. On Day 2, treated 75cm2 flasks were used to seed 6-well plates at 
80,000 cells per well in respective treatment medias. Cells were then cultured for an additional three days. On Day 
5, media was removed from the cells and the Transwell inserts were placed over the cells. 106 PBMCs were added 
to each insert, and corresponding media was added to each well. Cells were then incubated for four hours at 37°C 
and 5% CO2. The number of migrated PBMCs was then determined using a haemocytometer. Each condition has 
three technical replicates. Differences in the number of migrated PBMCs between the Treatment and Vehicle 
groups was analysed using an unpaired t test, assuming both populations have the same standard deviations, and 
were plotted with error bars indicating the standard error of the mean. The number of migrated cells in the 
Treatment group found to be significantly different to the Vehicle are indicated on the graph with summarized P 
values: ** <0.005. 
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Appendix 20: Representative standard curves for the chemokines of interest CCL5, CCL22 and CXCL16, and the 
reference genes FKBP15 and PUM1 in tumours grown in 129S6/SVEV mice from injection with SSM3 cells, following 
treatment with Letrozole or Letrozole and Celecoxib in combination.  SSM3 cells, NIH/3T3 cells and tumour tissue was 
used to make standard cDNA.  Dilutions of known concentration were used in triplicate to create a standard curve. Samples 









































   
    Normalised Chemokine Expression 
    Treatment  CCL5 CCL22 CXCL16 
Mouse  30 OvLet + Vgav 0.686334 1.634302 23.440752 
ID 41 OvLet + Vgav 7.009688 4.982443 1.073203 
  77 OvLet + Vgav 34.065696 12.827407 4.712172 
  88 OvLet + Vgav 6.112035 7.149675 1.344583 
  15 OvLet + CBX 1.264526 0.974300 12.498468 
  16 OvLet + CBX 1.082917 58.574944 90.981051 
  24 OvLet + CBX 3.826441 4.129862 6.542892 
  25 OvLet + CBX 0.674393 UD 66.526194 
  42 OvLet + CBX 10.588473 11.002493 1.770636 
  48 OvLet + CBX 7.673099 10.783362 0.918779 
  65 OvLet + CBX 4.441093 5.622089 1.325223 
  95 OvLet + CBX 11.680367 14.226395 1.514197 
  27 ShamV + Vgav 1.168475 48.794655 52.799199 
  31 ShamV + Vgav 3.757849 79.998173 7.539539 
  53 ShamV + Vgav 4.791889 9.427391 1.458265 
  67 ShamV + Vgav 1.673708 1.312463 0.203730 
  21 ShamV + CBX 8.062375 5.363687 3.396139 
  22 ShamV + CBX 0.420088 UD 52.924362 
  23 ShamV + CBX 1.446573 3.648563 8.276051 
  44 ShamV + CBX 8.900476 4.650754 1.369037 
  51 ShamV + CBX 4.232973 3.132270 0.404035 
  64 ShamV + CBX 29.803995 13.478233 3.049049 
  93 ShamV + CBX 6.508596 5.535355 2.287655 
 
 
Appendix 21: Normalised CCL5, CCL22 and CXCL16 gene expression in tumours grown in 129S6/SVEV 
mice from injection with SSM3 cells and treated with Letrozole or Letrozole and Celecoxib in combination. 
Once SSM3 cell tumours had been established (size>49mm2) mice were treated with (1) Letrozole (1mg/kg/day) + 
Celecoxib (25mg/kg/day) (OvLet + CBX = red), (2) Letrozole (1mg/kg/day) + Celecoxib Vehicle (OvLet + Vgav 
= green), (3) Ethanol Vehicle + Celecoxib (ShamV + CBX = blue) or (4) Ethanol Vehicle + Celecoxib Vehicle 
(25mg/kg/day) (ShamV + Vgav = purple). Mice receiving Letrozole were ovariectomized (‘Ov’), while mice 
receiving the Letrozole vehicle (ethanol) had sham ovariectomies performed on them (‘Sham’). Mice were treated 
for a maximum of 25 days or until ethical reasons warranted euthanasia. Post-treatment tissue was used for RNA 
extraction. qPCR used to compare the relative expression levels of CCL5, CCL22 and CXCL16, and were 
normalised using the reference genes FKBP15 and PUM1. Samples with a Cq value of >35 are defined as 


















data <- read.csv('mouseTumours.csv',na.strings="UD") 
View(data) 
names(data) 
## [1] "ID"        "Treatment" "CCL5"      "CXCL16"    "CCL22" 
 
## Removing mice < 14days Treatment  
dataX <- data[!(data$ID%in%c(11,19,20,38,39,45,50,55,56,59,60,63,80)),] 
 
## Make Boxplot of CCL5 Expression 
boxplot(dataX$CCL5 ~ dataX$Treatment, las=3, cex.axis=0.6, col=rainbow(4), ylab="CCL5 Expression") 
## ANOVA CCL5 Expression 
summary(aov(CCL5 ~ Treatment, data=dataX)) 
##                    Df   Sum Sq   Mean Sq   F value   Pr(>F) 
## Treatment    3    210.3       70.09        0.946      0.438 
## Residuals   19    1407.2     74.06 
## Make Boxplot of CCL22 Expression 
boxplot(dataX$CCL22 ~ dataX$Treatment, las=3, cex.axis=0.6, col=rainbow(4),ylab="CCL22 Expression") 
## ANOVA CCL22 Expression 
summary(aov(CCL22 ~ Treatment, data=dataX)) 
##                    Df   Sum Sq   Mean Sq   F value   Pr(>F) 
## Treatment    3     2347        782.3        2.053    0.145 
## Residuals   17     6478         381.1                
## 2 observations deleted due to missingness 
## Make Boxplot of CXCL16 Expression 
boxplot(dataX$CXCL16 ~ dataX$Treatment, las=3, cex.axis=0.6, col=rainbow(4),ylab="CXCL16 Expression") 
## ANOVA CXCL16 Expression 
summary(aov(CXCL16 ~ Treatment, data=dataX)) 
##                   Df   Sum Sq   Mean Sq   F value   Pr(>F) 
## Treatment    3      857         285.8       0.413    0.746 
## Residuals   19     13156      692.4 
 
Appendix 22: R Markdown for preparation of box plots for in vivo expression analysis of CCL5, CCL22 and 
CXCL16. Normalised expression for the three chemokines of interest were used to make box plots in R Studio. 
























sym <- as.list(illuminaHumanv3SYMBOLREANNOTATED) 
geneNames <- sym[match(rawDat$PROBE_ID,names(sym))] 
plot(density(newDat[,1])) 
for(i in 2:ncol(geneData)) lines(density(newDat[,i])) 




for(i in 2:ncol(geneData)) lines(density(normDat[,i])) 







## Stratifying Clinical Data 
## ful500 is 500mg Fulvestrant  
ful500=clinData[clinData$DOSE=="Faslodex 500mg",] 
##ful250 is 250mg Fulvestrant 
ful250=clinData[clinData$DOSE=="Faslodex 250mg",] 
 
###Differential Expression Analysis of Fulvestrant 500mg 
geneData500=geneData[,match(ful500[,1], colnames(geneData))] 
geneData500[,ful500$TRT=="pre-treatment"] 
patID <- factor(ful500$PATID) 
## treat <- factor(ful500$TRT, levels=c("on-treatment","pre-treatment")) 
treat <- factor(ifelse(ful500$TRT=="on-treatment","O","P"), levels=c("O","P")) 
design <- model.matrix(~patID+treat) 
fit <- lmFit(geneData500, design) 
fit <- eBayes(fit) 
## All significant genes 





                  Gene=unlist(geneNames)[rn], 
                  tt) 
write.table(ttOut,file="toptable-500-20160520.csv",sep=',',row.names=F) 
 
####Differential Expression Analysis of Fulvestrant 250mg 
geneData250=geneData[,match(ful250[,1], colnames(geneData))] 
geneData250[,ful250$TRT=="pre-treatment"] 
patID <- factor(ful250$PATID) 
## treat <- factor(ful250$TRT, levels=c("on-treatment","pre-treatment")) 
treat <- factor(ifelse(ful250$TRT=="on-treatment","O","P"), levels=c("O","P")) 
design <- model.matrix(~patID+treat) 
fit <- lmFit(geneData250, design) 
fit <- eBayes(fit) 
## All significant genes 
sig <- as.numeric(rownames(tt)[tt$adj.P.Val<0.05]) 
cat(as.vector(unlist(geneNames[sig]))) 
## All significant genes (raw p.values) 





                  Gene=unlist(geneNames)[rn], 
                  tt) 
write.table(ttOut,file="toptable-250-20160520.csv",sep=',',row.names=F) 
 
Appendix 23: R Markdown of differential gene expression analysis.  Publically available data was used to 
analyse differentially expressed genes in post-menopausal women with oestrogen receptor positive breast cancer 
treated with either 250mg/28 days or 500mg (day 0,14, 28 and monthly thereafter) of Fulvestrant. Genes 
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